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2ABSTRACT
A vaccination coverage survey was carried out in the Colombian Amazon, a former high
endemic area for hepatitis B, involving 3573 children less than II years old. It was carried
out in Leticia, Puerto Narifio, and Araracuara, both urban and rural areas. Children were
selected using a one stage cluster sampling, randomly selecting clusters in urban and rural
areas where all children under 11 were surveyed. At the same time blood samples were taken
from all children with known vaccination status (n=1603), and from their mother, when she
was available (n=8l2). These samples were processed for hepatitis B surface antigen
(HBsAg), antibodies to hepatitis B core antigen (Anti-HBc) and antibodies to HBsAg (Anti-
HBs). A sample of children without vaccination data available was also bled to compare
their results with those of children with vaccination data.
Full vaccination coverage was found to range between 39% and 69% among different areas
while hepatitis B vaccination ranged between 73% and 95%. Factors which improve the
likelihood of being fully vaccinated in this study were: Age above one year, living in Leticia,
being. affiliated to the social security, mother's years of schooling. Health worker's
knowledge on vaccine contraindications and perceptions of logistical barriers against
vaccination or importance of hepatitis B as a public health problem were also related to full
vaccine coverage.
Prevalence of hepatitis B infection reached 5% among those who were bled (8211603) while
HBsAg positive status was 1.6% (26/1603). Since the introduction of the vaccine prevalence
of hepatitis B infection has fallen from 40%, an 85% reduction, while carrier prevalence has
fallen from 5%, a 68% reduction. Age above 7 years, living in a rural area, birth delivery
supervised by other than a MD or nurse, and being born from an Anti-HBc+ mother were the
most important general factors related to being infected with HBV. Having an incomplete
schedule for hepatitis B vaccine was associated with an increase in the risk of being Anti-
HBc or HBsAg+. However, some characteristics of the vaccination process were related to
being HBsAg+/Anti-HBc+. Delays in receiving the first dose of hepatitis B after birth and
delays to receiving the second dose after the first dose were associated with an increased risk
of being HBsAg+/Anti-HBc+. None of these characteristics were related to being Anti-Hlic+
alone.
3In conclusion, the introduction of a recombinant Cuban manufactured hepatitis B vaccine has
produced a marked decline in the high infection prevalence of children in the Colombian
Amazon area. A higher coverage has been achieved from the beginning of the program
though intervals from birth to first dose and between doses are too long leading to new
infections that could have been avoided.
There is still room to make improvements in the control program, including the
implementation of a surveillance system of the HBV serological status for pregnant women,
in order to ensure better vaccination schemes for those born to infected or HBsAg+ mothers.
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Chapter 1: Introduction
Hepatitis B virus can lead to acute and chronic infection. Infection is transmitted by blood
exposure, sexual intercourse, perinatally from mother to child and horizontally during early
childhood. It is estimated that more than 300 million people are chronically infected with
hepatitis B virus (HBV) around the world. Asia and Africa contain most of the carriers but
there are also places in South America where highly endemic transmission occurs. (Hadler S
and Margolis H 1993; Hall A 1994; Kane M 1995)
Despite a great number of studies the available data on prevalence of hepatitis B virus
infection in Latin America are still incomplete. It is estimated that there are 6 million chronic
carriers of whom 20% will die as a direct result of HBV infection consequences. In addition
400,000 new HBV infections occur in Latin America each year of which 10-25% could end
in hepatocellular carcinoma. Between 25 to 67% of the infections in Latin America become
chronic hepatitis, and it is thought that 440-1000 cases of fulminant hepatitis each year are
caused by HBV (Tanaka J 2000; Fay 0 et al 1990; Silveira T et al 1999).
In Colombia there are 5 well-delimited areas where more than 70% of the population have
been infected with HBV. These places are located on the Caribbean Coast, the Pacific Coast,
the Amazon basin and the Catatumbo River on the border with Venezuela. A serological
study made in 1980 using a representative sample covering about 60% of the population
found that HBsAg positivity ranged from 3 to 8% through all age groups. Based on these
findings there are 600.000 HBV carriers and at least 4.000.000 people that have been
infected with hepatitis B virus in Colombia. Co infection and super infection with hepatitis
Delta virus (HDV) are common in HBV carriers living in these highly endemic areas (Gast
Galvis A 1955;Buitrago Bet al 1986; Buitrago B et al 1986; Martinez M 1991; Ljungreen K
et al 1985; Juliao 01991).
The Amazon department in Colombia has one of the highest rates of hepatitis B infection in
the world. More than eighty percent of people living in some rural areas are infected with
HBV and more than 8% carry HBsAg. Prevalence of infection in urban areas is less well
known. Infection with HDV was also common in this region (Martinez M 1991; De la Hoz F
et al. 1992; Gayotto LC 1991; Buitrago B et al 1991)
Despite the availability since the early 1980' s of a highly efficacious vaccine against HBV
virus, control of this infectious disease remains a serious public health problem in many
developing and developed countries around the world. In 1992 WHO recommended that
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hepatitis B vaccination should be integrated into national immunization programs (EPI) in all
countries by 1997. However many barriers have been found to the global application of this
vaccine. The relatively high cost of the biological is one of the most important impediments
to its universal implementation. (Kane M 1995; Kane M 1993; Hilleman M 1993).
Colombia started a vaccination program against hepatitis B in the Amazon basin in 1992.
Children under five years of age and new-barns were targeted to receive three doses of a
Cuban recombinant hepatitis B vaccine using a 0, 1,2 months schedule (MINSALUD-INS
1992). The objectives of this program were to decrease the prevalence and incidence of
hepatitis B infection in the Amazon and to reach and maintain coverage above 90% in
children under five years old. No comprehensive evaluation of the vaccination process has
been done since implementation of this measure. Small coverage studies have found lower
coverage with hepatitis B vaccine than with other EPI vaccines but factors influencing
vaccine coverage have not yet been explored (Revelo D 1995; MINSALUD-INS 1996).
These studies were carried out in places where hepatitis B is not recognised as a public
health problem.
The Colombian control program does not include Hepatitis B Immunoglobulin (HBIG) at
birth for several reasons. One is that Colombia does not have a program of HBsAg screening
during pregnancy so the prevalence of HBeAg in childbearing age women is unknown.
Another more important reason is that in developing countries inclusion of HBIG would
make the control program too expensive to be supported by local funds. This absence of
HBIG might reduce the effectiveness of the program in preventing the HBsAg carrier state.
Conflicting results have come from studies evaluating the efficacy of hepatitis B vaccine
alone to prevent the development of HBsAg carrier status in children born to HBeAg
positive mothers. Efficacy using plasma derived vaccine ranged between 60-70% while one
study with recombinant vaccine has shown an efficacy of more than 90%. It is important to
evaluate in children born to HBsAg positive mothers whether vaccination given under field
conditions in Colombia has an acceptable impact on HBsAg carrier rates. Previous studies
have been done using controlled conditions to deliver vaccine and most used plasma
vaccines. No studies have evaluated the effectiveness of recombinant hepatitis B vaccines
against perinatal transmission under field conditions. (Chen H et al 1996; Lee Ch et al 1997;
Lee P et al 1995; Lee P et al 1995; Wong V et al 1984; Whittle H et al 1991; Greenberg D
1993). If an approach without HBIG is adequate to control perinatal transmission in a normal
EPI program it would encourage development of other control programs in the world without
HBIG.
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Evaluation is critical for all health promotion and control programs. There are two main
reasons for evaluating a vaccination program: to improve it and to determine its
effectiveness. Additional reasons are: to demonstrate the worth of a program, to compare
different types of programs, to meet the requirements of the funding source, and to provide
information about the program. One of the major tasks of an evaluation is to judge a
program's merit. A meritorious program has worthy goals, achieves its standard of
effectiveness, provides benefits to its participants, fully informs its participants of the
potential risks of participation and does no harm. We want to evaluate the hepatitis B
vaccination control program in Colombia in all of these terms. (Fink A 1993)
The high costs of hepatitis B vaccine compared with other EPI vaccines has been one of the
most important barriers to its implementation in developing countries. This raises the issue
that whenever this vaccine is implemented in a national EPI it should be evaluated at least in
two aspects, impact and process. The impact of vaccine introduction is generally measured
through the evaluation of changes in disease trends. The process should be evaluated
studying the patterns of vaccine delivery, by measuring coverage, its trends and whether
recommendations from national or local health authorities are followed in the vaccination
program. Process evaluation is a very important component of program evaluation since
effectiveness of an intervention really depends on how the intervention is implemented and
how wide is the coverage in the target population.
The evaluation of a program tries to provide data on the extent to which a program's
objectives are achieved. It also answers questions about a program's activities and offers
insight into a program's implementation and management. Evaluation generally uses one of
two sets of evaluation terms. Some authors use the terms process, impact, and outcome to
identify types of evaluation used to determine the value of a program. Others authors use the
terms formative and summative evaluation to describe the evaluation that occurs during
the program and after the program, respectively. Process evaluation provides
documentation during program implementation to make adjustments for improvements of
the program. There are no published studies on vaccine coverage with hepatitis B in other
Latin American countries despite Cuba, Brazil and Peru having introduced the vaccine in
their Expanded Program of Immunisation. Even around the world studies on vaccination
coverage are limited and most have been done in developed countries where prevalence of
infection is low (Freed G et al 1994; Dobson S et al 1995; Walter E et al 1994; Wong Wand
Tsang K 1994). Studies of vaccination coverage in Colombia have found that hepatitis B
coverage ranges between 20-80% in different populations. Some studies have found a lower
coverage against hepatitis B compared to other EPI vaccines (Revelo 0 1997; Minsalud
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1992). Factors influencing this specific lower coverage with hepatitis B vaccines have not
been explored in Colombia. A study from Taiwan reported that coverage against hepatitis B
was higher at the beginning of the program but has decreased by 30% due to unknown
factors (Chen H 1996). Also in Indonesia coverage with three doses of hepatitis B vaccine is
under 60% for unknown reasons. (Milne A 1993).
Impact evaluation assesses the overall effectiveness of a program in producing favourable
knowledge, attitudes, behaviour, and health status. Many studies around the world have
found that hepatitis B vaccine has very high efficacy, high immunogenicity and is relatively
safe. Both experimental and observational epidemiological studies have been used in the
evaluation of the vaccine. Most observational approaches used in hepatitis B vaccine
evaluations consist of follow up studies where cohorts of vaccinated children and adults have
been followed for up to twelve years. These studies have demonstrated that the protective
levels of antibodies (> 10 IV/ml) remain for more than 7 years in a high proportion of
children (more than 60%). Also it has been shown that high protective efficacy against
infection and the HBsAg carrier status last for 10 years or more. (Fortuin M et al 1993;
Marion S et al 1994; Mahoney F et al 1993; Chen Het al 1996; Chotard J et al 1992; Lee Ch
et al 1997; Wainwright R et al 1997; Lee P et al 1995 page 1685; Lee P et al 1995 page 716;
Hadler S et al 1986; Wainwright R 1989; Stevens C et al 1992; Wong V et al 1984;
Coursaget Pet al 1986; Whittle H et al 1991; Greenberg D 1993).
Despite these encouraging findings, more evaluations are needed. Some questions anse
around the efficacy of this vaccine. One of the most important is how long the protection
lasts and when a booster is needed. Another important point is whether incomplete schedules
provide any protection against infection or the HBsAg carrier status or if delays in dose
delivery can affect the effectiveness against these outcomes (Me Mahon B et al 1993;
Hibberd P et al 1993). This last aspect is particularly important considering that under field
conditions vaccines are delivered when children come to the vaccination clinics and not
when indicated by the vaccination program. Some studies have evaluated immunogenicity of
hepatitis B vaccine under different schedules found in the field. They have found that
immunogenicity is not affected by delays in vaccine application, however one study in
Indonesia showed that delays to receive the first dose after birth can increase the risk of
being HBsAg+ (Inskip H et al 1991 page 765; Hadler Set al 1989; Inskip P et al 1991 page
770; Ruff T et al 1995).
Outcome evaluation determines whether the program met the stated long-term goals and
objectives, such as reduction in morbidity or mortality rates of the target population. Most
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studies on effectiveness of hepatitis B are based on children who have received a full course
of hepatitis B vaccine. There are few, if any studies of the effectiveness of the incomplete
schedules that are frequently found when evaluations of vaccination coverage (proportion of
vaccinated people in a population) are done in developing countries (Cutts F et al 1989;
Revelo D 1997). This point is very important since in many developing countries many
children do not complete the vaccination schedule. If hepatitis B vaccine provides significant
protection against the carrier state even if the schedule is not completed, the likelihood of
effective control of the spread of the HBV is increased. On the other hand, if only complete
schedules are able to protect against carriage then local health services should make greater
efforts to ensure adequate coverage with complete schedules. Cohort studies, one of the most
common designs found in hepatitis B evaluation, are very expensive and are threatened by
loss of a significant amount of people when the length of follow up is long. Many developing
countries are unable to undertake this kind of study to evaluate vaccination programs.
Therefore alternatives methods are needed for evaluating effectiveness of hepatitis B
vaccine. Case control studies, which have been used to evaluate effectiveness in other
vaccines, are an inexpensive and rapid method for continuous evaluation of hepatitis B
vaccine. In this particular disease no case control study has been done until now. (Smith Pet
al 1984; Rodriguez L and Kirkwood B 1990; Comstock G 1994) One problem in designing
case control studies to evaluate hepatitis B vaccine effectiveness in children is that cases of
infection will be detected mostly by serological methods since in most infections there is no
clinical manifestation. Therefore only cumulative incidence ratios (Risk Ratios), not
incidence density ratios (lDR), would be estimated from the OR's. However since the
expected prevalence of surface antigen is very low the OR closely estimates both measures.
Formative evaluation provides immediate feedback during program planning and
implementation to improve and refine the program. It is more comprehensive than process
evaluation, since information is collected from a variety of sources. Summative evaluation
is conducted at the end of the program. It determines if outcomes or aims of the program
were met. Outcome and impact evaluation are considered forms of summative evaluation.
Our evaluation of the Colombian hepatitis B vaccination involved process, impact and
outcomes thus being summative and formative. (McKenzie J. and Smeltzer J. 1997; Fink A
1993)
One important neglected issue in evaluating hepatitis B vaccine in the field is the absence of
information regarding children's exposure to hepatitis B in most post licensure studies. Only
a few studies have considered the mother's serological status in the design and just one has
considered other variables such as time at first dose, country of birth, the mother's age at
21
child's birth and other socio-economic variables. Many of these factors have been associated
with hepatitis B infection in the pre vaccine era studies (Marion S et al 1994; Hadler Sand
Margolis H 1993).
In order to evaluate the vaccination process in the Amazon department we designed a
coverage survey in rural and urban areas aimed at measuring vaccine coverage with hepatitis
B vaccine and other EPI vaccines such as measles, yellow fever and DPT. In addition to
coverage we wanted to evaluate if the vaccination process was following the
recommendations issued by the Ministry of Health. We also collected data on factors thought
to influence vaccine coverage from parents and health workers. I will compare coverage with
hepatitis B vaccine with that of other EPI vaccines and try to identify barriers against timely,
complete vaccination with hepatitis B.
In addition a sero-epidemiological survey in children less than 10 years old living in areas
endemic for HBV was done. This study measured prevalence of infection with HBV and
prevalence of HBsAg positives in children and their mother allowing us to stratify the
vaccine's effectiveness by serological status of mothers. Factors related to being HBV
infected or HBsAg+ were also assessed. These variables included vaccination, individual,
and mothers characteristics.
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Chapter 2: Literature review.
I. Hepatitis B vaccines.
1.1. Vaccine development: In 1971, Krugman reported that a crude HBV - containing serum
that had been diluted 1:10 and heated at 98 degrees for one minute induced measurable
antibody in a majority of human recipients following one or more injections of the
preparation. Additionally challenge studies showed that 59% of children previously
vaccinated with inactivated serum were completely protected against infection after having
been challenged with infectious unheated serum. This was the first step in the development
of plasma derived hepatitis B vaccines and the most important development after
Blumberg's discovery of the "Australian Antigen." (Hilleman M 1993)
A short time after Krugman's experiment it was possible to develop a standardized technique
of purification to produce plasma-derived vaccine on an industrial scale. Hepatitis B vaccine
should contain only purified subunits of the HBV surface envelope. However, since the
plasma of persons with chronic HBV infection contains both virulent HBV particles and
non-infective HBsAg particles, protocols were developed to eliminate HBV or any other
virus during the purification of HBsAg. The plasma-derived vaccine was produced by
ultracentrifugation of sera from HBsAg carriers. The ultracentrifugation concentrated the 22
nanometre (nm) HBsAg particles, which consist of excess, non-infectious surface antigen
protein. The particles were then heated and treated with one or more chemicals including 5M
urea, pepsin at low pH, and formalin to inactivate any infectious material in the preparation ..
Aluminium hydroxide is added as an adjuvant. (Mac Mahon B and Wainwright R 1993)
In 1975 the vaccine was considered sufficiently well developed to justify first trials in
humans. The first clinical efficacy trial was initiated in 1978 by Szmuness et al. in a study
conducted among male homosexuals in New York. A second study was performed by
Francis et al. from the CDC also in homosexual males using a multi-centre design.
(Szmuness W et al 1981; Francis D et al 1981; West D 1993)
Although the production process for this vaccine was state-of-the-art and unique to any
vaccine then, the acceptance of the vaccine was very slow, partly because the biological
source material was highly infectious for hepatitis B. In addition there were many concerns
about the availability of sufficient suitable HBsAg donors. The production process was time
consuming and the manufacturing cycle was as long as one year. It was recognized that a
second generation of hepatitis B vaccines were needed. There were unsuccessful attempts to
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produce enough hepatitis B surface antigen from E. coli. In 1981 it was possible to transfer
the portion of the HBV genome coding for HBsAg to an appropriate plasmid that is then
inserted in Saccharomyces cerevisiae, the common baker's yeast. In 1986 a recombinant
DNA (rONA) vaccine was licensed for human use even though plasma derived vaccine
remained available around the world. Most licensed recombinant vaccines consist of the 226
aminoacid S gene product (major surface protein) of HBV. (Sitrin Ret al 1993).
Although the HBsAg in both types of vaccine consist of 20 to 22 nm subvirion particles
composed of 226 aminoacid there are subtle differences between the plasma derived and
recombinant vaccines: I) the type of lipids present in the HBsAg differ; and 2)
approximately 25% of the plasma derived HBsAg is glycosylated whereas the recombinant
HBsAg is non-glycosylated. The HBsAg in both vaccines is adsorbed to aluminium
hydroxide, and thimerosal is added as a preservative. Both kinds of vaccine have been
demonstrated to be safe and immunogenic even though plasma derived vaccines produce
higher geometric levels of anti-HBs. (Greenberg 0 1993; Dandalos E et al 1985; Hilleman A
1987; Papaevangelou Get al 1985; Mc Aleer Wet al 1984).
The decision to select yeast rather than mammalian cells as the target system in which to
produce HBsAg was prompted by several important considerations. The yeast cell is
considered a less fastidious and expensive medium requirement. Indeed, yeast can be grown
in completely synthetic media, thereby offering greater advantages with vaccine purity since
no product of biological origin need be employed during the production process. The use of
yeast cell technology results in higher productivity and operating cost as compared with
mammalian cell systems. Moreover animal cell cultures are more prone to contamination
than yeast cultures and require more stringent operating procedures. Finally, the yeast system
can be easily scaled up to several cubic metres such that the yield of HBsAg antigen per litre
of fermentation broth is greater by a factor of 10 than that achieved in well-established
mammalian cell lines. (Stephanne J 1990)
The Colombian EPI uses a Cuban recombinant hepatitis B vaccine that is also produced in
yeast cells. The vaccine is manufactured in the Centro de Ingenieria Genetica y
Biotecnologia de la Havana (Cuba). Before being introduced in Colombia the vaccine was
tested for immunogenicity and safety using workers from hospitals and the Colombian
Ministry of Health. In these studies (open clinical trials) it was demonstrated that the Cuban
vaccine was as safe and immunogenic as a Belgian manufactured recombinant HBV vaccine
(Hoyos A et al 1991; Juliao 0 et al 1991)
24
1.2. Efficacy and safety of hepatitis B vaccines: In 1975 the first efficacy study was carry
out in a haemodialysis centre. Three doses of vaccine were administered monthly to 46
haemodialysis staff. 66% developed anti-HBs after the complete course of vaccination and
none developed hepatitis B. Then 217 people were vaccinated and followed to evaluate
efficacy. 5% were infected among the vaccinated while among an unvaccinated control
group more than 50% become infected with HBY. p<O.OOI(Tuoisi C et al 1993).
In 1978 Szmuness conducted the first large-scale study on efficacy of hepatitis B vaccine. A
randomised placebo controlled double blind trial was done among homosexuals males. A 40
ug dose was administered intramuscularly at 0, I, 6 months to 549 individuals. A similar
group received only placebo. After 26 months of follow up 158 episodes of HBY infection
were recorded. 80% of them occurred in the placebo group and most cases among the
vaccinated occurred before day 105 after randomisation, indicating that their infection
probably had taken place near the time of initial vaccination.(p<O.OOI) (Szmuness W et al
1981).
CDC conducted another randomised double blind trial in homosexual males (n=1400) but
using a reduced dose of vaccine (20ug). Efficacy results were similar to those obtained by
Szmuness et al. After 15 months 2% of the vaccinated (n=712) had evidence of infection
compared to II % of the placebo group (n=688) (p<O.OOI). In other high risk subgroups of
the population studies showed a similar high efficacy. In haemodialysis patients and staff,
Guesry, Szmuness and Stevens found high seroconversion rates, more than 90%, while
efficacy ranged from 53-85%. (Szmuness W et al 1982; Dienstag J et al 1984; Desmyter J et
al 1983; Coutinho Ret al 1983; Stevens C et al 1984). Table 2.1 shows a summary of results
in studies of hepatitis B vaccination in adults.
In 1983 Beasley and co-workers randomised 243 infants to receive one of three schedules
using HBIG and plasma derived HB vaccines or placebo. Only 5.7% of children receiving
both vaccine and HBIG developed the carrier state while among controls 88% became
HBsAg carrier. In 1984 a randomised placebo controlled trial involving 189 infants of
HBsAglHBeAg positive mothers was made in Hong Kong. The randomised groups were
allocated to receive plasma derived vaccine + HBIG, or plasma derived vaccine alone, and
placebo. Protective efficacy was 90.7% in the combined group that received only one dose of
HBIG, 96% in those who received 7 doses of HBIG and 71.3% among those who receive
vaccine alone. (p<0.005.) (Beasley R et al 1983; Tuoisi C et al 1993). Table 2.2 displays a
summary of results in some studies on efficacy of hepatitis B vaccine in children.
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Other studies using only vaccine have shown a protective efficacy ranging from 45.5% to
75.3% indicating that protection from vaccine is lower than protection afforded when HBIG
is used together with vaccine. However these studies have been done in countries where the
amounts of HBV DNA amongst carrier mothers vary leading to different probabilities for
perinatal transmission. Therefore generalizations from these results could lead to erroneous
interpretations. (How H et al 1980; Xu Z et al 1985; Poovorawan Y et al 1989; Stevens C et
al 1987).
There are relatively few studies on infants of HBsAg + and HBeAg negative mothers. In a
study from China, 193 children born to HBsAg + mothers were randomly allocated to
receive 20 ug of two brands of plasma vaccine. One of them was made in the Beijing
Institute of Vaccines and Serum (BIVS) and the other at the National Institute of Allergy and
Infectious Disease (NIAID). Two groups received just vaccine while another received
vaccine + HBIG and the last one placebo. In the group of HBeAg + mothers, 20% of
children developed chronic carrier status among those who received vaccine alone compared
with 6% among those who received vaccine + HBIG. Sixty six percent become HBsAg
positive among those who received placebo. In the groups of HBeAg negative mothers there
were no differences in the proportion of children who became carriers. Five percent
developed the carrier status among those receiving vaccine alone, 15% among those
receiving vaccine plus HBIG and 6% among the placebo group.(p>0.05.) Poovorawan et al.
in Thailand found that just 4% of children born to HBeAg+ mothers developed the chronic
carrier state after receiving 10 ug recombinant plasma vaccine alone. Poovorawan used four
doses given at birth, I, 2 and 12 months while in China three doses were used at birth, 1 and
6 months of age. More studies comparing schedules at birth are needed on this point.
(Poovorawan Y et al 1990; Tong M et al 1984; Schalm S et al 1989; Xu Z et al 1995).
Long-term studies on the effectiveness of hepatitis B vaccines have been done in infants who
were vaccinated under one year. Most of them show high protection against the carrier status
even after a follow up of between five and ten years. In Senegal 143 children were followed
for 6 years after vaccination and 4 children were HBsAg positive among vaccinees. In Hong
Kong 183 infants were followed for 5 years and only one became HBsAg positive after one
year of age. In The Gambia after three years of follow up, less than 1% of children
vaccinated before one year had become carriers and just 5% were infected. The main
predictor of infection was the serological status of the mother. The probability of being
infected was higher among those whose mothers were HBeAg positive. After nine years of
follow up in The Gambia, 8% of vaccinated children have developed infection measured by
positivity for anti-HBc, and 1% have become carriers. Compared to a control group taken
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from non vaccinated villages in The Gambia, HBV vaccine has a cumulative protective
efficacy of 75% against infection and 90% against carriage (Hall A et al 2000; Yeoh E et al
1988; Delage G et al 1988; Lo K et al 1988; Whittle H et al 1991).
The peak of hepatitis B antibody reached after the first course of vaccme is strongly
correlated to protection. In The Gambia, Jack et al. have found that there is a significant
linear trend relationship between the peak after three doses of plasma derived vaccine and
protection against infection. Those who reached titres between 10 and 99 mIUlml have
almost three times less risk of becoming core antibody positive than children with less than
10 IV after primary vaccination. Those with titres 100 to 999 mIU/ml had 10 times less
chance to becoming infected and those with titres above 1000 mIV/ml had 20 times less
probability of infection. An interesting finding from this study is that children with titres of
anti-HBs above 1000 mIV/ml can become infected but most of them lost the marker of
infection. This study also shows that there is no absolute protection for any titre of antibody.
(Jack A et al 1998)
Studies in infants suggest that while HB vaccine provides excellent long term protection for
4-6 years, HBsAg positive breakthrough infections in vaccine responders may have
occurred. Most of these studies show that most children who became HBsAg + during follow
up did not respond adequately to the vaccine. It is unknown how many of these HBsAg
breakthrough infections are due to mutants strains of the virus and what is the potential
transmissibility of these mutants in the vaccinated population. (Hall A 1994; Chotard J et al
1992; Coursaget P et al 1986).
In addition to its high efficacy the plasma-derived vaccine was well tolerated. In most
healthy adults vaccinated the most common reaction was mild transient discomfort at the
injection site. With the emergence of AIDS there was concern that hepatitis B vaccines
might be contaminated with HIV. This concern was quickly discarded since several follow
up studies in homosexual and health care workers showed no evidence of HIV sero-
conversion among vaccine recipients. In a surveillance system created by CDC to monitor
rare neurological events associated with the vaccine the occurrence of Guillian Barre
Syndrome was slightly more frequent than expected ( 9 cases observed vs 4 expected.
p=O.OI using Poisson distribution). However this association was not consistent throughout
the analysis and there was no conclusive evidence for a causal role for the vaccine. Two
reports link hepatitis B vaccination with anaphylaxis and there is a case report linking the
recombinant vaccine to Multiple Evanescent White Dot Syndrome, a rare retinal condition.
However benefits from hepatitis B vaccination overwhelmed potential dangerous side
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effects. (West D 1993; Shaw F et al 1988; CDC 1996; Stratton K et al 1994; Me Mahon B et
al 1992; Baglino E et al 1996).
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1.3.Dose Schedule:
The standard adult regimen for plasma derived hepatitis B vaccine is 20 ug (40 ug for dialysis
patients) administered by intramuscular injection at intervals of 0, 1,6 months. For healthy
neonates it is 10 ug given in the first seven days after delivery followed by two doses at the
second and sixth months. Also schedules using 0, 1,2 months as intervals have become widely
used in endemic areas or among high-risk groups where a rapid protection is needed. In the
latter scheme titres of antibodies are lower than in the first one and a booster at 12 months has
been recommended. However recommendations on the need of booster are not widely accepted
because the role of immune memory. (Safary A and Andre F 2000;West D 1993; Me Lean A
1986; Prozesky 0 et al 1983).
One important question with hepatitis B vaccine is whether time between doses could affect the
effectiveness of the vaccine. Data available from field studies in The Gambia and Venezuela
show that variations in vaccination schedule do not influence the protective level of antibodies.
(lnskip H et al 1991; Hadler S et al 1989). However these studies were done focusing on
antibody level and not on effectiveness against infection or carriage status.
Studies of other vaccines such as DPT show that efficacy depends on the vaccination scheme
used. DPT efficacy is lower when only I or two doses are applied instead of the three
recommended doses. Also the interval between doses has been demonstrated to influence the
quality of the immune response to this vaccine. (Fine P and Clarkson J 1987; Halsey Nand
Galazka A 1985)
After 5-7 years of follow up in most studies, 50-80% of the vaccinated had titres above 10
lUlL .. After nine years of follow up, 75% of vaccinated children in Gambia still have antibodies
above 10 lUlL and the GMT was 19 lUlL. It is possible to calculate the mean duration of
antibodies in a vaccinated population using these data from Gambia. In the first year after
vaccination the GMT reached 2068 lUlL and 98% of children had titres above 10 lUlL. Using
exponential models it is possible to predict that after 15 years of the primary vaccination less
than 50% of children will have titres above 10 lUlL and GMT will fall to less than 5 lUlL after
13 years of being completed the scheme. Given this assumption it is necessary to keep an
ongoing system of monitoring HBV vaccine efficacy to assess if protection remains when most
people in the population have lost their antibodies. Since the age when these individuals lose
their antibodies is probably above 15 years the chance of clinical illness with HBV infection
increases and those studies that attempt to monitor the vaccine efficacy should include this
effect in their main outcomes. (Viviani S et al 2000). However most of these studies have been
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done on plasma derived vaccine and there are few data above five years for recombinant
vaccine, which induces a lower response after the primary course of vaccination. Also a large
loss of people to follow up has been observed in homosexuals and population based studies
A booster dose of the vaccine clearly induces antibody response in 90-100% of healthy adults
and children who received a primary vaccine series several years earlier. Even those whose
titres have decayed below to mIU/ml when the booster was given respond adequately. However
titres reached after this booster, are not higher than those reached with the preliminary scheme.
(Krugman S and Davidson M 1987; Moyes C et al 1990).
There is no agreement about the need for providing a booster dose 5-10 years after the primary
course of vaccination in those who reach titres above 100 mIU/m!.. The first indication for a
booster is to augment an inadequate or non-response to the basic immunization series. Clemens
et at. used boosters of 20 ug of a recombinant vaccine every two months in 79 low responders
and 83 non-responders to a previous complete course of hepatitis B vaccine. All of them
produced serological titres of anti-HBs above 100 mIU/ml after the second and third booster.
Goldwater compared the effectiveness of two doses 40 and 20 ug used as booster in previous
non-responders to a complete scheme of HBV vaccine. He found that there were no differences
between the two doses and after a second booster half of the people in each group had titres
above 10 mIU/ml but the rate of non-responsiveness was high. So, evidence about benefits of
more doses in non-responders is inconclusive. Other authors considered that "non-responders"
are actually "slow-responders" with different kinetics of humoral response and that most of
them do not need boosters. (Clemens R et al 1997; Goldwater P 1997; Safary A and Andre F
2000; Weissman Yet al 1988)
Most discussion concerns the question whether a booster is needed to raise declining anti-HBs
levels after an adequate response to the vaccine has been achieved. Since immunological
response differs by age and other characteristics, this question should be addressed looking at
the particular risk group concerned. There are enough data showing that the at risk population
will be protected against clinical infection by a natural anamnestic response even if their
antibodies decline to less than to mIU/m!. Resti et al. compare the response to a booster after to
years following the primary vaccination in two groups of children born to HBsAg + mothers.
One group had received a booster at 5 years of age and the other did not. Serological response
after the 10-year booster was similar between the two groups suggesting that boosters do not
enhance immunological memory before 10 years of age. More studies are needed to determine
whether and when to give a booster (Davidson M and Krugman S 1986; Resti M et al 1997;
Stevens C et al 1992; Wainwright R et al 1997).
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Low doses of hepatitis B vaccine have been proposed as a means to reduce costs of hepatitis B
control programs in endemic countries. In some studies schedules using reduced doses were
successfully delivered. Goldfarb et al. carried out two studies in healthy infants and children
from 0 to 6 years comparing the immunogenicity of 10 ug of a recombinant vaccine against 5 ug
of the same vaccine. They used an interval of 0-1-6 months between doses for children above 2
years and a scheme of 2-4-6 months among newborns. They found that GMTs for those
receiving 10 ug were 8062 among children from 2-6 years old and 1641 among the newborn.
Children who receive 5 ug had the same proportion with more than 10 lUlL (98%) as those
receiving 10 lUlL but GMTs were significant lower (3732 and 880 lUlL). (Goldfarb Jet al 1996
page 768; Goldfarb Jet al 1996 page 764). In other studies low doses also elicit lower titres of
antibodies and although it is accepted that more than 10 IUlml are protective, breakthrough
infections are associated in some studies with lower titres. In other words higher titres could
reduce the chance of breakthrough infections. However breakthrough infections are not
necessarily an important outcome to measure in hepatitis B vaccine effectiveness since the most
important outcome of infection is the carrier status. Since lower doses are an attractive
alternative to a high cost vaccine it is very useful to study the protection conferred by low doses
against carriage in groups such as IVD users, new-borns to HBeAg + mothers and health
workers. (Moyes C et al 1987; Milne A et al 1989).
1.4. Vaccine types: It has been demonstrated that the proportion of people who reach protective
titres after using recombinant vaccine is similar to the proportion when plasma vaccines are
used. They are also as safe as plasma-derived vaccines. (Andre F 1989; West 0 1989; Zajac B
et al 1986)
Most studies done with recombinant vaccines have had an open design, since high efficacy of
the vaccine makes it unethical to use placebo control groups. Based on the well-controlled
studies of plasma derived hepatitis B vaccines plus the studies of yeast derived vaccines using
historical controls, the induction of anti-HBs titres is now generally viewed as an acceptable
surrogate measure of efficacy for s antigen vaccines.
A study in Army recruits in 1984 confirmed that recombinant vaccine was safe and
immunogenic even though low titres were reached with recombinant vaccine than with plasma
derived vaccine. (Wiederman G et al 1987)
Research on improved immunogenicity of hepatitis B vaccines is focusing on the pre S products
of the S gene. It is thought that a vaccine containing both pre Sand S antigen might provide a
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broader base of protection against hepatitis B infection. Since available hepatitis B vaccines
have a high protective efficacy, it is unlikely that vaccines containing pre S antigen could
demonstrate a higher efficacy. Probably its role would be limited to those who do not respond
well to traditional vaccines containing only S antigen. Leroux Roels et al. compared the effect
of a preS I and preS2 vaccine and a recombinant one in poor responders to a previous course of
three doses with a recombinant vaccine. No differences were observed in the proportion with
sero-protection nor in GMT. (Leroux Roels G et al 1997).
Some open trials have been done in newborns of HBsAg +/HBeAg + mothers comparmg
plasma derived vaccines and recombinant vaccines. No statistical differences have been found
between these regarding efficacy.
1.5. Immunogenicity: Factors that influence immunogenicity include factors related to the
vaccine such as dosage, number and timing of inoculations, storage of the vaccine and the use of
adjuvants. The most important host factors are weight, age, antecedent smoking, and presence
or absence of chronic diseases such as diabetes, renal failure, HIV, and others.
When different dosages have been compared, those people receiving 40 ugs have shown the
highest antibody titres. After 6 months these differences compared to those who received 20
ugs disappeared, and no differences were seen between dosage groups utilising the same
schedule. (Hollinger F et al 1981).
Sites of inoculation other than intramuscular in the deltoid region showed inconsistent data.
Intradermal inoculation with plasma or recombinant vaccine is safe but has not led to equivalent
levels of Anti-HBs titres in most studies. Gluteal administration induces poor response and it is
not used. (Bryan J et al 1990; Fessard C et al 1988).
Regarding duration of protection it has been widely demonstrated that antibody levels wane
after vaccination. The rate of decline is independent of initial post vaccination titre, but
vaccinees with a high starting titre will remain above some bench mark level (e.g., 10 mIU/ml)
longer than those with a lower titter.Protection against clinical hepatitis B or antigenaemia lasts
longer than do antibody titres. This long protection has been observed in studies on homosexual
men as well as in new-borns. However more studies are necessary to determine accurately how
long the immunological memory lasts.
There are few studies of efficacy using Cuban recombinant vaccine. In Colombia two studies of
immunogenicity were done before licensure. The first was an open trial comparing Cuban and
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Belgian recombinant vaccines. Participants were selected from healthy adults working in the
Colombian Ministry of Health or the Colombian National Institute of Health. Two hundred and
fifty-seven people agreed to participate in the study and were randomly allocated to receive one
of the two vaccines. There were two schemes to deliver the vaccine. Those allocated to the first
received Cuban or Belgian vaccines in a 0-1-2 months scheme while those in the second scheme
were vaccinated at 0-1-6 months. After three doses 100% of individuals vaccinated with the
Cuban vaccine had anti-HBs titres above 10 mIV/ml compared with 84% among those receiving
the Belgian vaccine. Ninety-eight percent of recipients of Cuban vaccine had titres above 100
mIV/ml compared with 70% among recipes of the Belgian vaccine. There were no statistically
significant differences between different schedules with respect to the amount of antibodies
elicited. No important side reactions were detected among the vaccinated. (Juliao 0 et al 1991)
In the other study 32 health workers from a hospital in Bogota received one dose of the Cuban
vaccine. All of them had received full schemes of another brand of HBY vaccine before but
were unable to mount an appropriate antibody response. After receiving 20 ug of the Cuban
vaccine 75% reached titres above 10 IV. (Hoyos A et al 1991)
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1.6 Perspectives: There are concerns about the feasibility of eradicating hepatitis B despite the
availability of this highly efficacious vaccine. Some authors have stated that eradication is not
possible since there is a large mass of carriers and the existence of non-responders to the
vaccine. Intrauterine infection is another barrier to eradication as a possible goal. Lack of
knowledge about how long protection remains when given by a complete schedule of hepatitis
B is another important barrier for control. However recent analysis of dynamics of hepatitis B
infection using mathematical deterministic models has shown that eradication is theoretically
conceivable (Edmunds W et al 1996; Anderson R and May R 1991; Anderson R and May R
1990; Anderson R 1992). Even using less complicated models we can assume that vaccine
coverage above 70% could eradicate hepatitis B if coverage levels are preserved for sufficient
time. See Table2.4.
Table 2.4. Ro values for hepatitis B in Colombia and proportion of people to be vaccinated
to reach eradication.
L (y) A (y) D (y) Ra po
65 40 0.8 1.65 30%
55 25 0.8 2.27 50%
45 15 0.8 3.16 70%
45 10 0.8 4.9 80%
L= Average life expectancy
A= Average age of infection
D= Duration of maternal antibody
Ro= Basic Reproductive Number= UA-D
po= Proportion to be vaccinated = I-IlRo
Edmunds et al. developed a dynamic transmission model of HBV to investigate some of the
implications of losing vaccine-induced immunity on effectiveness of mass HBV vaccination in
high endemicity countries. After running the model for 150 years of continuing vaccination, the
prevalence of carriers falls to less than 2% even if the effect of vaccine lasts for only 3 years.
However the paper does not state how long it will take to reach 0 prevalence of carriers if
vaccine last for longer periods of time. The model also analyses the effect of vaccination on
prevalence of acute disease. An increase in prevalence of acute disease, in the long term,
appears unlikely regardless of coverage of vaccination or duration of vaccine induced-
protection. In the short term, some assumptions in the model such as a low coverage «60%)
and non-permanent protection yielded an increase in the prevalence of acute disease. They
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compare a control program that gives a booster 5 years after the primary vaccination against one
in which no booster is given. The proportion of carrier projected for 80 years decrease in the
same proportion in both programs. Just a little marginal difference is observed in the program
that used booster. (Edmunds W et al 1996)
In the Colombian program only recombinant vaccine is being used by the EPI. Other programs
in Africa use hepatitis B vaccine without HBIG and they have reported high effectiveness in
control of HBV in the first year after delivery even though vaccine is not applied at birth. The
impact of a program using vaccine alone depends on whether the prevalence of HBeAg/HBsAg
positive mothers is high or not in the general population and this data is unknown in Colombia.
Also we do not know if field workers are delivering the vaccine soon after birth. If perinatal
transmission is important in the Colombian Amazon and vaccine is applied late after birth it is
unlikely to prevent as many HBsAg carriers as we would expect.
In children from endemic countries in Asia and Africa horizontal transmission of HBV is more
frequent than perinatal. Epidemiological studies in the prevaccination era showed that at least
50% of persons who became chronic carriers are infected after birth. In Senegal 50% of children
infected under the age of 2 years become chronic carrier before vaccine was available. In Alaska
about 30% of those infected under five years become HBsAg carriers. (Coursaget P et al 1987;
Mac Mahon B et al 1985; Beasley R et al 1982; Maupas P et al 1981)
Hepatitis B vaccine can be administered in conjunction with other EPI vaccines, except measles.
In fact one of the strategies used to improve vaccination coverage is to combine it with other
vaccines such as DTP and Haemophilus influenzae b (Safary A 2000).
1.7 Barriers against hepatitis B vaccination: Extensive studies on barriers to completion of
vaccine schedules have been carried out in developing and developed countries, especially on
measles, oral polio and DPT vaccines. Cutts et al. (Cutts F et al 1992), have grouped the causes
for low immunisation coverage in the USA in those associated with consumer demand and the
supply of immunisation services.
Consumer demand for immunisation services is affected by the following factors:
- Health beliefs: This has four components, "perceived susceptibility, "perceived
severity, "perceived benefits" and, "perceived barriers". The last component has the most
important impact on the acceptance of vaccines.
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- Socio-economic status: Economic and demographic measures of socio-economic
status (parental education. income. family size and race) have been found repeatedly to be
strong predictors of vaccine coverage.
The supply of immunisation services is affected by barriers to utilisation of immunisation
services. the frequency of missed immunisation opportunities. and the existence of follow up
systems.
Multiple methods have been used to assess performance of immunisation program around the
world. These evaluation techniques include qualitative and quantitative approaches such as key
informants, focus groups and cluster surveys. It is concluded that no one study methodology is
ideal and it is recommended that evaluation methods should be combined to obtain more
reliable results. Qualitative methods have the general advantage that they are quicker and
simpler and frequently yield the same information as more complicated quantitative methods.
Qualitative methods are specially suited for evaluating knowledge, attitudes and practices.
Quantitative methods such as cluster surveys have the advantage that they allow a better control
of sampling errors for those outputs where this is important such as coverage by vaccination.
(Cutts F et al 1990 page 769; Cutts F et al 1990 page 199; Cutts F et al 1991; Cutts F et al 1989)
There are few studies concerning how the vaccine has been integrated into the EP!. Most of
these studies have been done in Africa and Taiwan. They showed that integration of the vaccine
is possible but in other countries this integration has been less successful due to unknown
factors. (Schoub B et al 1991). Some evaluations made at the beginning of the program showed
that coverage with hepatitis B vaccines were as high as those reached with other EPI
biologicals. However in countries such as Taiwan coverage with hepatitis B vaccine has
decreased from 83% to 67%. Factors associated in Taiwan with poor compliance to hepatitis B
vaccine schedules were: younger age and lower education and career of the parents. The order
of the children in the family was also an indicator of vaccination status and the higher order was
linked to lower rates of full immunisation schedule. Children born in winter or autumn also have
lower coverage than those born in spring or summer and more urbanised families had lower
coverage. Parents' attitudes and knowledge about vaccines were also related with achieving full
immunisation. Attitudes and knowledge about hepatitis B infection did not influence uptake of
HBV vaccine while many missed opportunities were found. (Wong Wand Tsang K 1994).
In other countries such as Indonesia, coverage with three doses of HBV vaccine was lower at
60%. In South Africa an assessment in 1991 showed that coverage with hepatitis B was only
39% while coverage with poliomyelitis vaccine was above 90% (Schoub B et al 1991). Reasons
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invoked for this include a separate system for HBV vaccine distribution that resulted in a
shortage of vaccine in vaccination points. Also there were complaints from mothers and health
workers about the need for extra injections for hepatitis B. However no efforts were made to
understand specific reasons for the sharp drop in coverage. Also in some high and low endemic
areas in Colombia. coverage with hepatitis B vaccine is lower than with the other standard EPI
vaccines (Revelo D 1997; Minsalud 1996). An evaluation is necessary to determine the factors
leading to this dissimilarity between hepatitis B vaccine and the others.
In developed countries coverage with HBV also varies widely. In British Columbia a universal
school based hepatitis B vaccination program shows high coverage with three doses of vaccine.
above 90%. However school based programs are not very useful in highly endemic countries
were heavy transmission occurs before children go to the school. Studies from USA show that
following recommendations from CDC about universal immunisation coverage increased from
I% in 1989 to 32% in 1993. Despite this significant increase universal immunisation has been
not achieved in the USA. (Dobson S et al 1995; Woodruff Bet al 1996).
Some evaluations of vaccination barriers have been done in other developed countries (mainly
USA). These studies focused on attitudes and beliefs of paediatricians and family doctors about
the need to implement universal vaccination against HBV. It has been shown that paediatricians
and family doctors have an aversion to multiple injections that is reflected in a low coverage
with hepatitis B vaccine in children attending their clinical practice. In one of these studies only
53% of paediatricians and less than 30% of family physicians had adopted universal
immunisation into practice. Fragmentation of health care provision has also been identified as a
major barrier in developed countries where the first dose of vaccine is applied by hospital teams
and following doses are delivered by others. Other barriers identified are related to infant's
health conditions. age and education of the mother. patient failure to return for second and third
dose and parental refuse of immunisation. (Freed G et al 1994; Walter E et al 1994; Woodruff B
et al 1996; Bertolino J 1996)
II. Epidemiological aspects of hepatitis B virus infection in Colombia.
Colombia has some recognised zones where transmission of hepatitis B virus is highly endemic.
These areas have been identified through serological and histopathological studies and are
located in different geographical areas of the country. The main characteristics of these places
are described below.
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11.1. North part of the country (Zone bananera de Santa Marta): around the Sierra Nevada
de Santa Marta and close to the Caribbean Sea, outbreaks of fulminant hepatitis due to
coinfection by delta virus and HBV have been identified as early as in 1920. These coinfections
were diagnosed in 1985 using a large collection of liver specimens collected by Doctor Augusto
Gast Galvis, a former pathologist from the CNIH. People who live in these areas are a mixture
of black, Indian and Spanish people. (De la Hoz F et al 1991; De la Hoz F et al 1996; Bauer J
and Kerr J 1933; Aguilera A et al 1987; Gast Galvis A 1955; Buitrago B et al 1986; Buitrago B
et al 1986; Ljungreen K et al 1985)
11.2. Serrania de los Motilones: close to the Catatumbo river, in an area shared with Venezuela
delta and hepatitis B viruses has been detected through serological studies conducted together
by Colombian, Venezuelan and CDC scientists. The most affected people in the area are
Motilones and Yucpas, two of the most important Indian families in Colombia. At the beginning
it was supposed that only aboriginal people were being affected by these viruses in the area,
however serological studies in zones around the Indian reserve have shown a high prevalence of
hepatitis B virus infection in people living there who are not Indians. Chronologically this
endemic focus has been recognised later than the first described above. Oral history from the
oldest people in the tribes estimated the first epidemic of fulminant hepatitis around the mid
years of 1960. (Buitrago B 1991; Hadler S et al 1991)
11.3.The central region of the country: in the heart of the department of Antioquia where gold
mining activity was carried out at the beginning of this century. Fulminant hepatitis was
discovered at the same time as in the Sierra Nevada de Santa Marta. This focus has decreased its
activity for unknown reasons, but probably because this department has improved its economic
development since the early 1950' s with an important development in public services such as
running water, excreta disposal, etc. Most people living here are descendants from Hispanic
people. (Buitrago B 1991)
11.4. The Amazon Basin: in the border area with Peru and Brazil outbreaks of fulminant
hepatitis have been detected here since around the 1950's. Most outbreaks in Colombia have
occurred on the banks of the Putumayo River, a tributary of the Amazon river and the most
affected people have been those from Tucanos, an aboriginal ethnic group in the area. (De la
Hoz F et al 1992; Gayotto L 1991)
11.5. The Uraba Gulf: Is an area placed near to the border with Panama, on the Atlantic Ocean.
This area is shared by departments of Choco and Antioquia and mainly black people live here.
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The first reports of high endemic transmission of hepatitis B in this area were produced around
1980. (Buitrago B 1991; Padilla J 1993; Arboleda N 1987).
Figure 2. I shows the location of these areas.
Figure 2.1. Hepatitis B endemicity by geographical area
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Figure 2.2. Geographical position of Colombia in the Americas.
11.6. Epidemiological studies in the Zone Bananera de Santa Marta: As early as 1906
sporadic outbreaks of fulminant hepatitis had been reported in the Zone bananera de Santa
Marta, most of them with a familial pattern of occurrence and with a high case fatality rate.
Between 1975 and 198264 cases of fulminant hepatitis were reported and 35 of them died. This
yields a cumulative incidence of 30/ 10.000 per year. A higher incidence and mortality was
observed among males under 30 years. Co infection and super infection with hepatitis D among
carriers of surface antigen of hepatitis B virus has been largely identified as the cause of these
outbreaks. (Bauer J and Kerr J 1933; Aguilera A et al 1987; Buitrago B 1991; Gayotto L 1991;
Gast Galvis A 1955; Buitrago B et al 1986 page 1292; Buitrago B et al 1986 page 1285;
Ljungreen K et al 1985)
In 1988 seroepidemiological studies for hepatitis B markers were done in four of the most
endemic villages of the zone (Varela, Santa Rosalia, Cerro Azul y Julio Zawady). After this a
vaccination campaign was started in order to immunise all people who were susceptible to
hepatitis B virus infection. All people living in these villages and who agreed to participate in
the study were bled and serum samples were examined for HBsAg, anti-HBc and anti-HBs.
Antibodies against delta antigen were tested in those people who were carriers of HBsAg.
(Buitrago Bet al 1991 page 115; De la Hoz F et al 1996)
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About 70% of the population living in these areas agreed to participate In the study. A
prevalence of HBV infection of 55% (Cl 95%: 53-57%) was found among 2332 people
participating in the study. Prevalence ratios did not differ among villages except for Varela that
showed the lowest prevalence of infection 29% (Cl 95% 25.5-32.5%). For the whole population
a prevalence of surface antigen of 7.6% was found and it varied from 2.2% in Varela to 10.5%
in Cerro Azul. Prevalence of delta antibodies among HBV carriers was as high as 30% in Cerro
Azul while in Varela no carriers were positive for this marker. (De la Hoz F et al 1991; De la
Hoz F et al 1996)
A study of risk factors for infection was done in Varela and Cerro Azul. In Varela factors
associated with infection were age above 15 years, a history of jaundice, a history of a relative
dying of a cause related to hepatitis B, a history of blood transfusion in the local hospital and a
history of more than 4 parenteral injections (for medical reasons) during the last year. None of
the measures of sexual activity was associated with HBV infection. (De la Hoz F et al 1991)
In Cerro Azul, HBV infection was statistically associated with living in a house with poor
sanitation and a history of a relative dying of a cause related to hepatitis B. (De la Hoz F et al
1991 )
Cumulative incidence of infection with HBV between the first and second dose of vaccine was
recorded for 167 peoples. Thirty-eight (23%) became seropositive for anticore in this period.
Incidence was highest for those older than 22 years (55%) and lowest for those under 10 years
(7%) No differences were observed by gender.
Over four years 124 carriers of HBsAg were followed for sera-conversion to Anti-HBs. Only 10
became anti-HBs positive (8% CI95% 3-13%) and 3 died from causes related to their carrier
state. Causes of death in carriers were hepatocellular carcinoma, cirrhosis and fulminant
hepatitis. The incidence of hepatocellular carcinoma in these people was 20 times higher that in
the general population. (De la Hoz F et al 1996)
In 1997 a serological study was done in 154 children less than 15 years in Julio Zawady. All of
them were fully vaccinated and had lived in the area for more than one year. A prevalence of
infection of 10% was observed among them while prevalence of infection in 1988 in a similar
age group was 60% (Vaccine efficacy: 83% IC 73-89%). None of the children surveyed in 1997
were found HBsAg positive but in 1987 10% in a similar age were found HBsAg positive
(31/296) p< 0.001. A large reduction in the number of people with clinical jaundice seeking
medical care has been observed in all health centres in the area. This decrease coincided with
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the year when mass vaccination of people under 10 was initiated in this area in 1989. Between
1987 and 1989 more than 60 people with jaundice sought medical care in local health centres
per year while between 1990 and 1994 this number has been reduced to less than 20 people per
year. No other measure that could reduce the incidence of hepatitis A or B has been undertaken
in the area, e.g., increase of coverage in running water or excreta's disposal or a decrease of
levels of poverty in the area. Instead they have become poorer since an increase in political
violence has been observed in the last few years causing migration people from other areas. (De
la Hoz F et al 1991; Gamboa M et al 1997)
11.7. Epidemiological studies in the Colombian Amazon Basin: Most studies in Colombia
have been carried out on the banks of the Putumayo River, one of the larger tributaries of the
Amazon River in Colombia. Despite early reports of Labrea Hepatitis or "Black fever" made by
Dr Jorge Boshell, a former Colombian epidemiologist around 1960, there was no published
serological studies on HBV infection, in the Colombian Amazon basin before 1990. In 1989 an
outbreak of fulminant hepatitis killed 5 children aged 7 to 15 years attending a remote primary
school in the Amazons department on the Caraparana River a tributary of the Putumayo. A
serological study was done in 404 people, between I and 20 years, attending the school. A
blood sample was obtained from both staff and students and sera were processed for anticore
(anti-HBc), surface antigen (HBsAg) and antibody against surface antigen (anti-HBs) using
Abbott ELISA methods. Only 119 were found to be sero-negative for all markers (34%) and
66% were found infected by HBV. Prevalence of HBsAg positives was 27% while 12% showed
serological signs of early infection. It was not possible to study these samples for delta antigen
or antibody. A similar or higher prevalence of HBV infection was found in other people living
in 5 villages around this area. (Gayotto L 1991; De la Hoz F et al 1992; Martinez M et al 1991)
These high endemic patterns of HBV transmission have been observed in others parts of the
Colombian Amazon such as in the departments of Putumayo, Vaupes, Vichada, and Caqueta
where more than 1000.000 people could be at risk for hepatocellular carcinoma and fulminant
hepatitis. (Buitrago Bet al1991 page 115)
Eighteen months later, in 1991, a vaccination program was started in this area using plasma-
derived vaccines. Before delivering the first dose serological tests were done in those people
new to the area and those found to be sero-negative in 1989. Incidence was measured in 45
children who were sero-negative in 1989. Thirty of them were found to be infected so the
cumulative incidence was 67% (53-81 %). We estimate a risk of 7% of developing fulminant
hepatitis in those positive for HBsAg, and a global incidence of 12/1000 of fulminant hepatitis
for all people living in the school (Martinez M et al 1991). Factors found to be associated with
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positivity for HBV markers were age above 12 years, living with a relative with a history of
jaundice and previous skin lesions. (De la Hoz F 1992)
In 1996 serum samples were obtained from 75 people who were vaccinated against hepatitis B
in 1991 and 1992. They were known to be sera-negative for HBV markers at the start of the
vaccination campaign. They were aged between 1 and 35 years while 39 (52%) were males.
HBV infection was found in 11 of them (14.8%) while 4 people were HBsAg positive (5%).
Anti-delta was found in two children less than JO years (2.7%). Geometric mean titres of anti-
HBs were 512 lUlL (CI95% 331-776) among those uninfected. Most people, 53 (85,5%), had
titres above 100 lUlL while 32% had titres above 1000 lUlL. Only 4.8% had less than 10 lUlL.
There was high variability of dose intervals while the length of the interval between first and
third dose was related to serological response. The GMTs of anti-HBs by time between first
and third dose were: 3162 lUlL among those with less than 92 days, 537 lUlL in those with
interval between 92-314 days and less than 400 lUlL in those with more than 314 days.
(P=0.02.) Prevalence of infection among those with less than 315 days between first and third
dose was 4% (1/23) while in those with more than 314 days it was 20% (PR= 0.21 Cl 95% 0.03-
1.54).
These vaccinated people had a reduction of 78% in prevalence of HBV infection compared with
the prevalence observed in those of a similar age group before vaccination was introduced (PR=
0.22 C195% 0.12-0.37). HBsAg prevalence had been reduced by 67% (PR=0.33 C195% 0.12-
0.82). (De la Hoz F, et al. Unpublished data)
II.S. Epidemiological studies in health workers: Vaccination against hepatitis B among health
workers became available in Colombia in 1992 when the Ministry of Health started a campaign
to vaccinate all the staff at risk in public hospitals. At least 70% of people targeted for this
intervention received one dose of a Cuban recombinant hepatitis B vaccine. However results of
this initiative have not yet been evaluated therefore the proportion of people who received a
complete schedule of immunisation is unknown.
Some serological studies have been carried out in Colombia in health workers. Seven have been
carried out before 1990 and 8 have been done in that year or after. Prevalence of HBV infection
in these studies varied between 7.6% and 44.3%. Prevalence of HBsAg varied from 0.4% to
2.1%. Infection rates vary across cities probably reflecting differences in HBV prevalence in the
general population. Studies in health workers in high endemic populations (Amazonas y
Magdalena) have shown that health workers born in these areas have similar prevalence to the
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general population (above 50%) while those who came from less endemic areas have prevalence
under 10%. It is unknown if these differences are explained by occupational factors or by the
same factors that account for infection in the general population. Age above 25 years, more than
10 years working in a hospital, and not being vaccinated against HBV have been found as
factors associated with an increased likelihood of infection. (De la Hoz F et al 1996; Fajardo H
and Gomez A 1994; Arroyave A et al 1994; Arroyave M 1985; Juliao 0 et al 1991; Plata G
1992; Urbina D 1987)
A slight decrease in prevalence of infection is observed between studies made before 1990 and
those made after that year. Overall prevalence in studies before 1990 is 16% (630/3972 Cl 95%
14.9-17.1%) while it is 14% (Cl 95% 13.6-14.4%) in those made in the 1990s. Prevalence of
HBsAg has diminished from 2.7% (Cl 2.2-3.2%) before 1990 to 1.04% (Cl 95% 0.88-1.16) in
the 1990. These differences could be due to differences in methodology of the studies such as
different range of age, sex and percentage of people in each job category, e.g., nurses, doctors,
etc. This reduction also coincides with the start of the vaccination campaign and could be an
effect of it. A recent study in more than 2000 health workers in 9 cities has found that blood
exposure through percutaneous injuries is frequent. Furthermore, among those health workers
who suffered exposure to blood there is a poor understanding of the need for close surveillance
and treatment. While more than 50% of people included in one study suffered a needle injury,
less than 10% of them reported the accident to the occupational health office that is in charge of
the management of these injuries. (De la Hoz F et al 1996)
11.9. Other epidemiological studies of "BV infection: Studies in different populations in
Colombia have shown a wide range of prevalence. On the Caribbean coast there are some high
endemic populations as described before. Studies in other departments of the same area have
shown prevalence of infection from 15% to 58% while prevalence of HBsAg ranged from 3 to
1 I% (excluding studies in aboriginals). In 268 patients with acute jaundice and hepatitis studied
in Barranquilla, the largest city in this area, prevalence of markers for HBV was 9% in children
and 21% in adults. (Falsl Borda 0 et al 1986)
Prevalence of HBV infection in the Andes has been found to be lower than those on the
Caribbean Coast. From 3 to 58% of people have been infected with HBV and prevalence of
HBsAg ranged from 0 to 9.5%. In 53 patients with acute hepatitis, prevalence of markers for
HBV was 26% and 19% were HBsAg positive. (Ochoa L 1989; Botero R 1991; De la Hoz F et
al 1995)
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On the Pacific Coast prevalence of markers for HBV infection ranked from 35% to 83% and
prevalence of HBsAg has been found between 0.6 and 17%. (Buitrago B et al 1991; Padilla J
1993; Buitrago B 1991 page 5)
In women of childbearing age prevalence of HBV infection has been between 3 and 34%. Most
of these studies have been carried out in areas where HBV is not endemic. Prevalence of
HBsAg in these studies ranged from 0 to 5%. In areas with high endemicity for HBV women
have a prevalence of 15% or more. No study for HBeAg prevalence in women has been carried
out in Colombia. Some factors have been associated with HBV infection in these studies namely
having more than two previous sex partners; tattoos and a history of a relative with an HBV
related chronic disease. (Velandia M et al 1997; Sierra F 1988)
In 1980 a nation wide serological study on hepatitis B was carried out in the framework of a
National Health Study, using multistage random sampling. ELISA was used for the first time in
Colombia to examine the prevalence of HBsAg. Only three geographical areas were included
(Central, East and Pacific). Territories in the rain forest as well as the Caribbean coast were
excluded from the sample. Researchers investigated a sample of 10,968 people from 0 to 70
years. Overall prevalence for surface antigen was 6% for those 0-9 years, 5.4 % in those 10-14
years, and 4.7% among those above 15 years. Prevalence was higher in the central region (8%)
than in the Oriental (3%) or Pacific (3.5%). (Juliao 01991 page 56)
No study has been done in Colombia on hepatocellular carcinoma and HBV or HDV.
11.10. Needs for more evaluation on effectiveness of hepatitis B vaccine: Considering these
findings and based on the WHO guidelines, most areas in Colombia would have a medium
endemicity level of HBsAg (2-5% of carriers) and some areas a high endemicity level (>5% of
carriers). Considering this the Ministry of Health has started a universal program of
immunisation against HBV using the Cuban recombinant hepatitis B vaccine. This program was
implemented across the country in 1992. People targeted for the program are new-borns and
children less than 5 years. The Colombian EPI recommends that the first dose of hepatitis B
vaccine should be administered at birth together with BCG. Second and third doses should be
administered at 2 and 6 months with DPT. No boosters have been recommended by the EPI.
More than 10 millions'dollars have been expended by the Ministry in acquiring the vaccine.
Some surveys on vaccine coverage have found that in highly endemic area's coverage is above
70% while in lower endemic areas coverage is under 50% despite availability of the vaccine
(Revelo D 1997; Minsalud 1996; Minsalud 1992)
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Although many studies on prevalence of hepatitis B have been carried out in Colombia in
different areas of the country, there are some aspects of the epidemiology of HBV that remain
unknown. One of the most important is the role of perinatal transmission in the observed
prevalence of carriage. It is unknown what the prevalence of HBeAg in women of childbearing
age is. Vaccination policies against hepatitis B in Colombia have not taken into account this
aspect of the epidemiology of the virus. In endemic zones, it is supposed that children are
vaccinated shortly after delivery but it is unknown if this is done systematically. Ignoring this
factor could lead to an important shortfall in vaccination objectives especially if women have a
high prevalence of HBeAg. In Lombok (Indonesia), those children vaccinated more than 7 days
after the birth had a prevalence of 3% of HBsAg compared with 1.4% in children vaccinated in
the first 7 days from the birth (p<O.OOI) (Ruff T et al 1995).
Another point of concern is persistence of antibodies and its relationship with protective
effectiveness of vaccine. This aspect has not been extensively studied in populations under
conditions of heavy transmission. It is known that a high proportion of children are protected for
ten years or more but the duration of protection could depend on the force on infection in each
place. A study in The Gambia shows that protection could be lower in those places where
horizontal transmission is predominant. Also little is known about the characteristics of those
children who were infected before ten years. Most villages in the Amazon Basin are in remote
areas where accessibility is difficult and hepatitis B transmission is frequent. These access
barriers could lead to very long intervals between doses that could reduce the effectiveness of
HBV vaccine.
One study in the Amazon Basin found an association between antibody response to the vaccine
and number of days between the first and third dose. This finding is against previous evidence
from studies in other countries where dose interval was not associated with significant
differences in dose response. Further evaluation using larger sample sizes in these areas is
needed to resolve the question if large intervals between first and third doses adversely affects
vaccine effectiveness. It would be necessary to study factors which lead to difficult access to
local health services and possible solutions that guarantee an adequate vaccination schedule to
children in high endemic areas.
In addition to the geographical barrier it is possible that social, cultural and economical
characteristics of target populations could hamper coverage with hepatitis B vaccine. Also
health worker attitudes may provide obstacles to delivery of HBV vaccine. This is a relatively
new vaccine and the disease is relatively infrequent among children as many cases are clinically
silent. Therefore local health workers could see the utilisation of this vaccine as a less important
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measure and/or as an additional work. Barriers arising from health workers need to be assessed
quickly as they could be removed by retraining.
A study in China has found difference in antibody titres among people of different ethnic groups
(Hsu Let al 1996). Colombia has a rich diversity in ethnic groups and some of them have been
affected by HBV and HOV infection. It is important to evaluate if response to vaccine varies
among them. If it does then some populations may need different dose schedules. A trial could
be implemented in two or three populations with different ethnic composition and assess if titres
in new-boms reach the same geometric mean.
Also hepatitis delta has been shown to occur in some vaccinated children but it is unknown if
this infection has clinical consequences for children since most of them are not carriers of
HBsAg. A follow up using serological markers of HBV and HOV as well as tests for hepatic
function would be useful to determine the real probability of being infected with HOV after
HBV vaccination. Risk factors and the clinical meaning of these infections also need to be
determined.
The Colombian Ministry of Health carried out a vaccination among health workers 4 years ago.
This measure also needs evaluation since an important amount of resources were invested in the
vaccination process. Studies in health workers are not conclusive about what factors affect
inmunologic response to the HBV vaccine. In endemic countries this is very important as health
workers are exposed to a larger number of carriers than in developed countries. Booster effect
in high risk health workers also remains to be fully studied. Most studies on occupational
exposure among health workers have been done in low endemic countries (Europe and USA).
Few have been done and published on HBV exposure and consequences among health workers
in developing countries where the general population has higher rates of HBV infection.
Therefore exposure to infectious blood is likely to be greater and management of these accidents
in Colombia is inadequate in most hospitals. A surveillance system for occupational injuries and
management of exposures to HBV in hospitals of developing countries could improve our
understanding of occupational risk for hepatitis B infection in our country. Vaccine
effectiveness in health workers has been studied using prevalence studies and there are no
conclusive findings on infection in those with low antibody response when exposed. Studies in
Colombia show that prevalence of HBsAg in pregnant women seeking care at general hospitals
could be as high as 10%.
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Studies on effectiveness of smaller doses of hepatitis B vaccines are always welcome in
countries with scarce resources. This could be implemented in new-borns and in high-risk adults
such as health workers.
Although other countries in Latin America have a similar pattern of hepatitis B epidemiology to
Colombia few have ongoing vaccination program against this disease. In a recent search on
hepatitis B reports from Latin American countries few articles on vaccination results were
found. Most of these studies were done using small sample sizes in high-risk adult populations
such as health workers. They focused on antibody response rather than effectiveness against
infection. Therefore evaluation of the Colombian experience could be useful for other countries
that have implemented hepatitis B vaccination or are about to implement it.
III. Methodological issues in postlicensure evaluation of hepatitis B vaccine effectiveness:
Post licensure evaluation of vaccines is a very important task in delivering health services for
populations. Although vaccines are extensively evaluated before release to the public, most
evaluations are conducted under conditions that do not permit policy makers to take decisions
about its introduction into public health programs. In the specific case of hepatitis B vaccine
many evaluations were done using controlled trials to assess efficacy and immunogenicity. Very
few have been done on effectiveness under normal conditions in the EPI programs and most of
them have focused only on fully and timely vaccinated people. In most vaccination program,
children are immunised when they are able to go to the point of delivery of the vaccine and not
when they are supposed to receive it. This aspect has not been assessed in trials and in most post
licensure studies. Also pre-licensure trials do not look for the effect of incomplete schedules or
poor vaccine storage practices on the efficacy of the vaccine. All these aspects need to be
considered in post licensure studies to show the real impact of the vaccine under normal field
conditions. (Clemens Jet al 1996; Hall A and Aaby P 1990).
Different approaches have been used in evaluating hepatitis B vaccines in the field. However
some of them are inappropriate to the main question concerning the true direct and indirect
impact of vaccination against hepatitis B spread. Most studies have assessed both direct and
indirect effects of vaccination since they have compared prevalence of infection between
vaccinated and historical controls. To clarify the approaches that could be used for evaluating
hepatitis B vaccines in the field we have reviewed those used to evaluate other vaccines.
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In evaluating field effectiveness of hepatitis B vaccine it is important to take into account the
following aspects: What is the main outcome to be evaluated, and what are the most suitable
methods for these outcomes.
111.1. Outcomes: The following outcomes could be used to evaluate hepatitis B vaccme
effecti veness:
Clinical illness: The earliest studies in hepatitis B vaccine, using clinical controlled
trials, demonstrated a high efficacy of HBV vaccine against severe or moderate clinical illness.
However most of these studies were carried out in adults where hepatitis B infection frequently
results in clinical illness. Conversely most studies in the post licensure era of hepatitis B
vaccines have focused on the protective effect of the vaccine among children where clinical
illness is rare. This biological characteristic of the HBV makes it difficult to select clinical
illness as an endpoint to evaluate HBV vaccine effective, particularly in young populations.
Another point that makes clinical illness unattractive for HBV vaccine evaluation is that it
probably does not represent an important step towards chronic disease. Clinical illness could be
considered as an aspect to evaluate just in those countries where universal immunisation against
hepatitis B has been implemented more than 15 years ago. At this stage the first cohort of
vaccinated people have reached adolescence where sexual risk factors could increase rates of
HBV infection and a higher proportion of infected may have clinical symptoms.
Chronic carriage: This is the most suitable end point to be evaluated as effectiveness
of hepatitis B vaccine. This status represents an early step in the development of cirrhosis and
hepatocellular carcinoma. So if vaccine could prevent it, the later complications of HBV
infection could be avoided. Studies using this as outcome should be cautious in the case
definition since people positive for surface antigen should be retested in six months.
Fulminant hepatitis: This is an outcome of particular interest in those populations
where co infection with HDV is frequent among carriers of HBsAg. Fulminant hepatitis often
has a high fatality rate especially in these isolated populations where it is frequent in South
America. There is no large evaluation of HBV vaccines using this result as end point probably
because it is not a frequent event in Asia or Africa where most evaluations have been carried
out. However populations of intravenous drug users and aborigines' populations in Latin
America could be used to monitor the impact of HBV vaccine on this syndrome.
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Table 2.5. Serological results of different Hepatitis B surveys done in Colombia by region.
Region Sample size Prevalence of infection Carrier prevalence
Atlantica
Guajira
General population 1045 4.4%
Indigens 170 1.2% 0%
B/quilla
Patients with jaundice 268 21.7% adults. 9% child. 3%
Risk groups 434 31.7% 7.8%
Healthy adults 486 14.6% 5.5%
Cesar
Indigens 864 21.1% 2.8%
Healthy adults 133 58% 11%
Cundinamarca
General population 264 0.3%
Pregnant women 68 4.4%
Pregnant women 200 1%
Pregnant women 175 9.5%
Pregnant women 1000 3.1% 0.1%
Patients with jaundice 53 26% 19%
Healthy individuals 366 7.1% 1.6%
Antioquia
Uraba 492 83% 17%
Sn Vicente 129 17.4% 10%
Occidente (women) 1690 8.5% 1.1%
Indigens (women) 830 34.3% 4.2%
Manzanares 197 58.4% 2.5%
Pacifico 254 82.3% 9.4%
Indigens Jardin 61 9.8%
Pacific
Tumaco- Imbili 3500 35%
Choco-Riosucio 912 76%
Tolima
Pregnant women 246 13% 4%
Prisoners 103 39% 22%
Prison staff 31 12% 0%
Guaviare
General population 59 45.7% 8%
Guainia
Indigens 105 67%
Valle
Blood donors 20458 0.55%
Infection: Since infection does not itself represent a risk for hepatocellular cancer it has
been little considered in post licensure studies of HBV vaccine. However this should be
considered when an effectiveness study is done, because those who are infected by hepatitis B
virus could contribute, even for a short time, to the spread of infection.
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Cancer hepatocellular and cirrhosis: Controlling hepatocellular cancer is the most
important aim in most countries where a hepatitis B vaccination program has been implemented.
However since the induction time between infection and cancer development is so long it may
be difficult to gather information about vaccination status if a case control study is used for
evaluation. If a cohort study were done instead. there would be a potential for biased estimates
of efficacy due to losses during the follow up. Evaluations using cancer as an end point should
be supported by the availability of large databases containing the vaccination status of the
population. A recent study from Taiwan has shown that the incidence of hepatocellular
carcinoma is decreasing among children 6 to 14 years of age. Investigators collected data from
the Taiwan' s National Cancer Registry from 198 I to 1994. They observed that annual
incidence of hepatocarcinoma has declined from 0.7/100.000 children in 1981 to 0.361100.000
in 1990- I994. After controlling by date of birth, those born among 1984 and 1986 had an
incidence of O. I 31 100.000 compared with 0.52 among those born among 1974 and 1984.
Surprisingly all cases of hepatocarcinoma occurred among children who have received 3 doses
of hepatitis B vaccine. This fact supports the hypothesis that those who fail to respond to the
vaccine are still at risk of hepatocarcinoma. (Chang M et al 1997)
111.2.Methods for post licensure vaccine evaluation: Different methods are available for
evaluating post licensure vaccine effectiveness (Orenstein W et al 1985; Orenstein W et al
1988).
Screening Method: This simple method allows us to estimate quickly if vaccine
effectiveness is within expected limits. It uses the following formula:
rev = _P_P_V_-_C.;_P_P_V_*_V_E....:_)
1- (PPV *VE)
Where,
PPV= proportion of population vaccinated
pev= proportion of cases vaccinated
VE=vaccine efficacy
Cases are identified through regular surveillance, their state of vaccination is ascertained and
vaccine coverage in the population where cases come from is obtained from local statistics from
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the public health authorities. Probably this is not a suitable method for hepatitis B in childhood
when most cases are asymptomatic.
Outbreak investigation: It has been proposed that this is probably the best situation to
evaluate vaccine effectiveness. Unfortunately clusters of hepatitis B infections are rarely
detected, as it does not result in clinical illness. This approach could be useful for hepatitis B
vaccine in some special settings such as haemodialysis units where closed monitoring of
patients and staff could lead to a detection of these outbreaks.
Secondary attack rates in families: This approach has been suggested to avoid biased
estimates of vaccine efficacy arising from differences in exposure between vaccinated and
unvaccinated participants. In them secondary attack rates are compared between those groups.
However as discussed before, secondary attack rates for hepatitis B are very hard to estimate
because few people develop clinical illness.
Serological studies: These studies are useful if there is a serological correlate for
clinical infection. This approach has been used extensively in hepatitis B vaccine evaluations
since it has been found that titres above 10 IU/ml are protective against carrier status. However
the answers we can obtain from serology are limited. We can solve questions about how long
this level of antibody lasts but we cannot obtain direct or indirect estimates of effectiveness with
cases prevented for example.
Most studies have looked for infection and carrier status in vaccinees and doing so have failed
to estimate indirect effects of vaccination. This is a very important point in disease control and
design of studies that permit estimations of indirect effect of vaccine are still needed. Most
effectiveness studies on hepatitis B vaccine compared the prevalence among vaccinees against it
in historical controls. This is not particularly wrong but it does not allow evaluation of changes
in the dynamic of the infection produced by herd immunity effects.
Cohort studies: These studies have been carried out in some countries such as The
Gambia, Senegal, Alaska and Taiwan. They have focused mainly on the long effectiveness of
HBV vaccine. Most of them have observed just a cohort of vaccinated people and results have
been compared with historical levels of prevalence. This approach does not allow estimation of
direct effects of vaccination, it estimates the combined impact of direct and indirect effects of
vaccine (Struchiner C 1990). Loss of participants could bias the results.
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Case-Control Studies: In the last few years case control studies have been widely used
in evaluating vaccine effectiveness for different infectious diseases. Most have been done in
BCG, Haemophilus intluenzae and measles (Smith P 1987). There are no published studies on
effectiveness of HBV vaccine using case control methods. Most discussions on assessment of
vaccine effectiveness using case control methods have focused on diseases that result in clinical
manifestations. There are few if any which discuss an infection without a distinctive clinical
picture such as hepatitis B.
Many advantages have been attributed to cases controls studies in this field. One of the most
important is that they save money and time. Also evaluation using the case control approach is
more realistic since controlled trials usually are conducted under ideal field conditions and this
is not found frequently in public health services like EPI. Ethical considerations can also be a
barrier for designing controlled trials when beliefs about high efficacy of an intervention are
strong.
Other additional advantage of case control studies is that we can perform evaluation of
effectiveness for subgroups of patients not included in randomised trials and for different
schemes of treatment or dose delivery. This is a particularly important aspect in hepatitis B
since most field evaluations have focused on children who had a complete scheme of
vaccination. However effectiveness of incomplete schemes remains unevaluated. For example
most endemic areas in Colombia are placed in remote settlements where incomplete schedules
of vaccination are common.
Critical points in case control studies on hepatitis B vaccines are:
Case definition: As we discussed before the most useful end points in hepatitis Bare
hepatocellular carcinoma and the carrier status. Cases of hepatocellular carcinoma must be
selected only from those who have a well documented disease including the use of ultrasound
and biochemical markers of hepatocellular cancer. Carrier status could be ascertained using less
complicated technology and is the outcome of election in most studies.
Case finding: Cases can be detected from a hospital or health centre or from
community based surveys. Cases from health facilities are easier to obtain if clinical illness is
the outcome of interest. When the main outcome is carrier status, they could be obtained from
community based serological surveys. These have some methodological advantages. One of the
most important is that we can select controls at random from the population, avoiding one of the
most important sources of bias in case control study that is that cases and controls could be
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different in many ways aside exposure factor. In that way areas with high and non-high risk
could be included in the sample. Another approach to avoid this confounding effect is to restrict
the study to those zones with high endemicity where vaccine should have been delivered in a
better way. The main disadvantage for community-based surveys is a poor rate of participation.
Carriers also can be selected using hospital-based methods.
Control selection: It is well known that odds ratios obtained from a case control study
could estimate different parameters of association (incidence rates, risk ratios, or odds)
depending on the frequency of disease but also on the way controls are selected. It has been
proposed that for vaccine evaluation using the case control method controls should be selected
based on the proposed model of action of the vaccine. Smith (Smith Pet al 1984) proposed two
models of action for vaccines. Vaccines under model 1 are supposed to produce an overall
decrease in the incidence of the disease, however its effects tend to become weak when time
pass. Under model 2 vaccines would yield a protection of "all or nothing." Hepatitis B vaccine
could be classified as having a model 2 action since most people, especially children, are
completely protected for at least ten years after vaccination.
For this kind of assumption Smith and Rodriguez (Smith P et al 1984; Rodrigues Land
Kirkwood B 1990) proposed a scheme of control sampling selecting people from the population
regardless of their disease status. As they have demonstrated theoretically this sampling method
leads to an estimation of the relative risk that is an unbiased estimator of the effectiveness of the
vaccine. In hepatitis B we use serological tools to determine if anybody has been exposed to
hepatitis B before, and including seropositive controls in the study could reduce the estimated
effectiveness of the vaccine. On the other hand, as authors have remarked, a traditional
approach to select controls could overestimate vaccine effectiveness. An intermediate solution
would be selecting two groups of controls and compare the effectiveness in each assessment.
Another approach would be restricting cases to those with recent infection and selecting
controls from all the population if proportion of recent infectious would be very low. In this
case most people selected as controls would be either sera-negative or sero-positive with an old
infection. Since the sample size for case control study is low this approach could have many
methodological advantages. An additional advantage of HBV infection is that it could have low
rates of infection after mass campaigns of vaccination, so both methods of selecting controls
could yield similar results.
Table 2.6 showed the effect of these assumptions on evaluating HBV vaccine effectiveness. For
this exercise we assume that incidence of disease is 0.04 per person/year.
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Table 2.6. Expected effectiveness of HBV vaccine against carrier status under model 2 of
efficacy.
Year NI Cl YI NO CO YO VEf VEr VEorl VEor2
1000 40 980 1000 8 996 0.80 0.80 0.81 0.80
2 960 37 940 992 7 987 0.82 0.80 0.82 0.80
3 922 36 903 984 7 982 0.82 0.80 0.82 0.80
4 885 35 868 979 7 974 0.82 0.80 0.83 0.80
5 850 34 833 971 7 968 0.83 0.80 0.83 0.80
6 816 32 800 965 6 961 0.83 0.80 0.84 0.80
7 784 31 768 958 6 955 0.84 0.80 0.84 0.80
8 753 30 738 952 6 950 0.85 0.80 0.85 0.80
NI= Number unvaccinated. NO=Number vaccinated. CI= Number of cases among unvaccinated.
CO=Number of cases among vaccinated. Yl= Number of persons years at risk among unvaccinated
at the end of every year. YO=Number of persons years at risk among vaccinated at the end of every
year. VEf= Vaccine efficacy measured using incidence rate of disease. VEr= Vaccine efficacy using
risk ratios. VEorl= Vaccine efficacy using odds ratios calculated by selecting as controls those who
remain negative at the end of each period. Veor2= Vaccine efficacy using odds ratios calculated by
selecting as controls all at the start of the study (regardless serological status)
As we can see above, Veor2 and Ver yield an unbiased estimate of the vaccine effectiveness
across the years of follow up. However, differences between the different approaches are
narrow probably because yearly incidence of carrier status is low.
Vaccination status ascertainment. One potential source of bias in case-control studies
is "recall bias." It can be avoided by determining vaccination status before performing any
serological assessment. Since in hepatitis B it is possible to use serological tests to classify cases
and potential controls, previous knowledge about vaccination status cannot influence diagnosis
of infection. Also all vaccination status should be confirmed by reviewing vaccination cards or
records from the local health workers. This will make it unlikely that knowledge about infection
of the subject under study could influence classification of vaccination status.
Comparability of vaccinees and non-vaccinees. The principal disadvantage of the
case control approach is that the likelihood of being vaccinated is never truly random in a non-
experimental situations since 'confounding by indication can arise when vaccine is being
delivered in the field. This confounding is unavoidable in the moment of vaccine application but
it could be avoided in designing a case control study if cases and controls are randomly
selected from the population.
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Factors associated with the development of disease should be similar for cases and controls.
Perinatal and horizontal transmission of hepatitis B account for most infections in endemic
areas. Most cases of horizontal transmission occur among those who have siblings or parents
infected with hepatitis B. This potential source of bias could be controlled by performing
serological tests on relatives of both cases and controls. Then in the analysis we will stratify
association between vaccination and presence of HBV marker in study's subjects by presence or
absence of active or past infection in the family. Using this approach we can detect any effect of
modification or control any confounding bias introducing by serological status of the family. A
problem in this method is that prevalence of mother and siblings could not be assumed as
independent since prevalence in siblings could also be explained by mothers' infection. Another
approach is assuming that random selection of people under study from the population would
lead to these potential confounders being distributed equally among cases and controls.
Using community based surveys to detect those infected means they are prevalent cases that
could differ from incident cases in several ways. One of the most important aspects is severity
of disease. If prevalent cases have had a less severe disease than acute cases we will be unable
to assess vaccine impact against a severe form of disease.
Comstock (Comstock G 1994) discusses infections that are called by him "inapparent infections
with subsequent immunity" and "inapparent infections with subsequent disease risk." However
none of these categories is suitable for hepatitis B. It is true that hepatitis B produces subclinical
and inapparent infection in most cases but clinical efficacy of hepatitis B vaccine may be better
than efficacy against infection.
Comstok assumes that if infected people are included in vaccinated and unvaccinated groups in
the same proportion the overall protective effect will estimate true efficacy adequately if
infected survivors have zero risk of subsequent disease. This is similar to evaluations of
effectiveness in hepatitis B, since those infected with hepatitis B have no risk of re-infection.
Table 2.7 shows the expected effects of including in the study people who were infected before
vaccine was available in the population selected for the study. We can see that if coverage of
vaccination is about 50% and proportion of prevalent cases is similar (2%), VEor2 yields the
closest estimate of the true YE. However if previous prevalence of infection increases, VEorl
become a better estimator of TVE. Even if the coverage of vaccination increase, Veor I remains
as a better estimator of TVE. These results support the idea that two groups of controls would
help researchers to estimate the range of TVE.
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Table 2.7. Effect on vaccine efficacy of different assumptions about prevalent cases before
vaccine implementation.
NO CPO CO NI CPI Cl ORI VEorl OR2 VEor2 TVE
1000 20 167 1000 20 510 0.20 0.80 0.33 0.67 0.70
1000 80 218 1000 80 540 0.24 0.76 OAO 0.60 0.70
1000 80 126 1000 80 460 0.15 0.85 0.24 0.76 0.90
1400 112 176 600 48 324 0.12 0.88 0.23 0.77 0.90
Nl= Number unvaccinated. NO=Number vaccinated. CI= Number of cases among unvaccinated.
CO= Total number of cases among vaccinated. CPl= Prevalent cases among vaccinated before
vaccine was available. CPO= Prevalent cases among non vaccinated before vaccine was available.
VEorl= Vaccine efficacy using odds ratios calculated by selecting as controls those who remain
negative at the end of each period. Veor2= Vaccine efficacy using odds ratios calculated by selecting
as controls all at the start of the study (regardless serological status). TVE= true vaccine efficacy
111.3. Variables: Most effectiveness studies have focused just on vaccination as the exposure
of interest. It has been forgotten that there are other variables that are closely related with the
risk of infection and carrier status. The most useful of these variables are those related with
socio-economic status and in most studies in Colombia they were found associated with
infection. Those people living in poor conditions are more likely to be affected by HB.
Availability of excreta disposal, crowding, infected people in the same household, antecedent
jaundice in relatives, serological status of the mother, among others; have been found
consistently associated with infection. However, they have been omitted in most observational
studies of hepatitis B vaccine. We propose that all of them should be included in any
observational study of HBY vaccine, especially when cross sectional and case control
approaches are used. They can help investigators to control the effectiveness of vaccines by the
probability of exposure to HBY. Just two observational studies, one in Canada and other in The
Gambia, looked for relationship between infection and some socio-economic variables apart
from the vaccination status of children. However Canada is a developed country, and the main
source of infection for these children was a carrier mother. Horizontal transmission of hepatitis
B is low in households with adequate conditions of sanitation while in developing countries this
risk is as high as the risk of perinatal transmission. Therefore these kinds of variables are more
useful in studies of vaccine effectiveness in developing countries with high endemicity levels of
HBY infection.
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Chapter 3: Methods.
3.1. Proposed Study:
I) To assess the effectiveness under field conditions of a Cuban recombinant hepatitis B
vaccine used in Colombia by the EPI for individual protection against HBY infection and
carriage.
2) To evaluate barriers to adequate delivery of hepatitis B vaccine in high endemicity areas
in Colombia.
3.2. Objectives:
I) To measure coverage with hepatitis B vaccine among a random sample of Colombian
children living in highly endemic areas.
2) To compare the prevalence of infection with hepatitis B and proportion of HBsAg carriers
among those children receiving a full course of hepatitis B vaccine against prevalence in
those unvaccinated or with an incomplete schedule of hepatitis B vaccine, in highly endemic
areas of Colombia.
3) To examine the influence of dose interval (vaccine scheme) on protective efficacy of a
recombinant hepatitis B vaccine.
4) To compare prevalence of infection among those who have received hepatitis B vaccine
and whose mother are HBsAg negative against prevalence among those vaccinated or
unvaccinated whose mother is HBsAg positive.
Objectives 3, 4, and 5 will permit us to evaluate effectiveness, under field conditions, of the
recombinant Cuban manufactured hepatitis B vaccine used in Colombia by the EPI
programme.
5) To measure factors and barriers related to incomplete vaccination with hepatitis B
vaccine.
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6) To compare the prevalence of complete coverage with hepatitis B vaccine against
coverage reached by other vaccines of the EPI programme. This will allow us to evaluate if
there are specific constraints to delivery of hepatitis B vaccine.
3.3. Type of study: A cross sectional survey using one stage cluster sampling was carried
out in the rural and urban population of Leticia, Puerto Narifio, Puerto Santander, and
Araracuara. The first two areas were included in the study because they are the most
populated areas of the department while the latter two had been identified in previous studies
as having the highest prevalence of HBV infection in the department (Cristancho LM 1991).
Data were analysed as a case control study with cumulative sampling for the main results of
the study: vaccination status and factors related with it as well as serological status (HBsAg
prevalence) and its relationship with vaccination and other characteristics believed to be
important.
3.4 Localisation of the study: Leticia is placed on the left bank of the Amazon River and is
the most southern town in Colombia sharing borders with Brazil and Peru. It has a
population of 22400 inhabitants, 15400 are urban in urban Leticia and around 7000 live in
rural settlements along the Amazon River. It is the capital of the Amazon department. In
urban areas about half of its population have an ethnic origin from aboriginal tribes such as
the Ticunas and Huitotos. Socio-economic level in the urban area is low. Access to running
water is estimated at 85% by the municipal planning office while piped domestic sewage
disposal would hardly reach 50% of the urban population.
In rural settlements of Leticia most people live below the poverty line. There is no running
water available and most people collect it directly from the Amazon River. Excreta disposal
is mostly by latrines or pits. The main economic activities are fishing and vegetable
cultivation (cassava, maize. etc.)
Puerto Narifio is also located on the Amazon River to the west of Leticia and shares borders
with Peru. It has a population of 3800 inhabitants, 1400 urban in the settlement called Puerto
Nanfio and 2400 scattered in small villages along the Amazon and Loretoyaco rivers. In
Puerto Narifio most people have running water but the water is not treated and goes directly
from the river to the houses. There is no municipal sewage disposal system and most people
have latrines or pits to dispose of excreta. In rural settlements conditions are similar to those
in Leticia's rural areas. Most people in both the urban and scattered areas belong to the
Ticunas tribe, one of the two most important ethnic groups in the Amazon.
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Araracuara and Puerto Santander are villages located on the banks of the Caqueta River.
Combined they have around 1400 inhabitants. Socio-economic conditions are similar to rural
areas in Leticia and Puerto Narifio and most of its habitants belong to the Huitotos tribe, the
second most important ethnic group in the department.
Tables 3.2 and 3.3 show the population distribution in rural and urban areas in Leticia and
Puerto Narifio. Table 3.4 shows the population distribution in urban Leticia by
neighbourhood.
3.5 Target population: Children above 1 year old and less than 12 years living in Leticia,
Puerto Narifio, Araracuara and Puerto Santander.
3.6 Sample size and selection: We estimated that a sample of 1088 children between one
and eleven year old would be required to estimate a prevalence of vaccine coverage of 85%
with intervals between 82 and 88% which was similar to the coverage reported by the
Amazon EPI in the year before the start of the study. This estimate was calculated with a
95% confidence level and a design effect of 2.0. To calculate this sample size we used the
formula provided by Kish & Leslie 1965, which is available in EPIINFO 6.04 c (Dean et al
1994):
Where;
Sample size = nI(1-(nlpopulation».
N=Z*Z(P( I-P»/(D*D)
However since we had to estimate from the same survey other measures such as the
prevalence of infection with hepatitis B virus (HBV), the prevalence of surface antigen
carriage (HBsAg), and risk factors for infection we needed a larger sample size due to the
low frequency of carriage expected in vaccinated children. Therefore we estimate that a
sample of 2239 children would be needed to fulfil the different objectives of the study. See
Table 3.4.
This sample was selected proportional to population size. Thus in Leticia we planned to
survey 1350 children (59% of the sample), in rural Leticia 407 children (18%) and in Puerto
Narifio 538 children (23%). In Araracuara and Puerto Santander, given the small size of the
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population but the undoubted importance of including them for the study, it was decided to
recruit all children less than 12 years old living in the main settlements
In urban Leticia we selected 60 clusters (blocks) for the study. To select them we divided the
city into 163 clusters (blocks) and every cluster was numbered. Then at random we chose 60
numbers.
In rural Leticia villages were listed and numbered. As before a random number list was
generated in EPIINFO and villages were arranged and visited in the same order provided by
the list. We stopped visiting villages when the sample size for rural Leticia was completed. A
similar procedure was used to fill the sample size in rural Puerto Narifio.
In the urban area of Puerto Narifio we divided the population into 22 clusters (blocks) and
we surveyed every one because there were a large number of children without accurate
vaccination status. A similar procedure was done in Puerto Santander and Araracuara where
every household was visited.
3.7 Population survey and logistical aspects: A team of two health promoter was
assembled to visit households in rural and urban areas. They were trained by the principal
investigator concerning the procedures to carry out the census, taking blood in the field,
obtaining parental consent, and applying the mother's questionnaire. Direct observation and
assistance in the field was provided by the main investigator and a field co-ordinator, a very
skilled field epidemiologist nurse who is in charge of the control of communicable diseases
in the local health department. They reviewed the forms filled every day in order to detect
missing values or mistakes. They also reviewed blood samples to ensure that they were
handled in an appropriate way and that they were correctly identified. Some of the study'S
villages, especially those located on the Loretoyaco river, were accessible only by river and
for a few months of the year, so the trip schedule had to be adjusted to those periods when
the Loretoyaco river had sufficient water enough to ensure access. Those located on the
Amazon river were accessible by boat all the year and therefore they were visited first.
In every selected cluster or village this team visited every household. First they filled a
household census form where we asked the number of people living in the household,
number of children less than II years and the socio-economic conditions of the family
(crowding, running water, social security). We recorded the names and ages of every person
living in the house. If at least one child less than one was found living in the household the
interviewer asked the child's parents for the vaccination card. If it was available the
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interviewer recorded the number of doses of hepatitis B, OPT, BCG, measles or MMR and
dates when every dose was given. After that the field workers obtained informed consent to
obtain a blood sample from every children living in the household and from their mothers.
They also questioned the mothers about general risk factors for hepatitis B infection such as
antecedent clinical hepatitis in the household, antecedent death by fulminant hepatitis in the
family. and a family history of cirrhosis or hepatocarcinoma. This questionnaire (see
appendix 2) also recorded parents' level of education, breastfeeding, mother's age at first
birth, mother's age at birth of the child, child's number of siblings, ethnic group, and the site
where the child was born.
3.8 Definitions for vaccination status: We defined as a fully vaccinated children any
one aged between one and eleven years old who, at the moment of the survey, had received
at least the following vaccination scheme:
Three doses of hepatitis B.
Three doses of OPT.
Three doses of polio.
One dose of yellow fever.
One dose of measles or MMR.
One dose of BCG
Those failing to fulfil these criteria were defined as not fully vaccinated and were used as
the control group for the fully vaccinated when risk factors for vaccination were explored.
Only children holding a vaccination card were included in these definitions. We did not
consider in the analysis those doses or vaccines that were reported by mothers without
written support.
Table 3.1 below show the vaccination schedule recommended by the Ministry of Health and
the Amazon Health Service.
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Table 3.1. Vaccination schedules recommended by the Colombian Ministry of Health
and by the Amazon.
Vaccine Number Age
of doses
Interval Booster
BCG At birth
Polio 4 Birth, 2,4, 6 months. Four weeks 18 months and 5
years.
Hepatitis B 3 Birth. 2. 6 months. Four weeks -
DPT 3 2, 4, 6 months. Four weeks 18 months and 5 years
Measles. I year old 10 years
Yellow I year old Every 10 years.
fever
As we can see children should receive at birth one dose of BCG, one dose of polio and the
first dose of hepatitis B. Then at two months of life they should receive the second dose of
hepatitis B, the first dose of OPT and polio. Second doses of polio and OPT should be
applied at four month of life. At six month children should have completed the basic scheme
for OPT, polio and Hepatitis B (three doses) and at the age of twelve they should receive
yellow fever and measles or MMR vaccines.
We considered as completely vaccinated against hepatitis B those aged between one
and II years who had received three doses of hepatitis B vaccine. Those who failed to fulfil
these criteria were considered as not completely vaccinated against hepatitis B. As
before, I only considered in the analysis those children with a vaccination card. Those
without written evidence of vaccination were excluded.
3.9 Blood sample collection and handling: Participants were bled usmg a disposable
syringe and needle preferably from the left arm. We tried to obtain ten centilitres from
mothers and children above 5 years, while five centilitres were drawn from children under
five. A code was assigned to every children participating in the study and was written on the
syringe using non-erasable ink. This code was formed by adding the number of the cluster,
number of the household, and the number of the child in the household. For mother's
sample we used the same code of the first of their children who was bled adding a letter M.
Sera was obtained from blood samples by centrifugation in the field and kept refrigerated
until they were sent to the National Virology Laboratory in the Colombian National Institute
of Health in Bogota. There, samples were stored frozen until the moment that they were
analysed for hepatitis B virus markers.
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Photo 1. Field workers in Araracuara
Photo 2. Field workers travelling by boat to Puerto Santander on the Caqueta River
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3.10 Serological markers: Children's sera were processed in the CNIH's Virology lab for
the following markers:
Hepatitis B surface antigen (HBsAg).
Antibody to core antigen total (Anti-HBc).
Antibody against core antigen IgM (IgM Anti-HBc).
Antibodies against surface antigen (Anti-HBs).
Delta virus antibody (lgG).
All sera were processed initially for HBsAg and anti-HBc. Those who were found positive
for HBsAg were then tested for Delta antibody and IgM anti-HBc while those anti-HBc
positive but HBsAg negative were processed only for IgM anti-HBc. A sample of those who
were negative for HBsAg and anti-HBc were processed for measuring quantitative titres of
anti-HBs.
Mother's sera were processed for:
Hepatitis B surface antigen (HBsAg).
Antibody against core antigen total (Anti-HBc).
Antibody against core antigen IgM (IgM Anti-HBc).
Hepatitis B "e" Antigen (HBeAg).
Delta virus antibody (lgG).
First mother's samples were processed for HBsAg and anti-HBc. Samples from mothers
found positive for HBsAg were also processed for HbeAg, Delta antibody and IgM anti-
HBc.
Initial testing was done using ELISA. Samples positives for HBsAg or anti-HBc were
confirmed using neutralization methods. For delta virus we repeated all those who tested
positive in order to confirm them.
3.11 Definitions for serological study: Children were divided in the following categories
regarding their status for hepatitis B infection:
Infected children were any children aged between one and eleven years who was positive
for anti-HBc or HBsAg.
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HBsAg positive children were any children aged between one and eleven years who was
positive for HBsAg and anti-HBc, both by ELISA and neutralisation techniques.
Seronegative children were all those aged between one and eleven years who were
negative for both HBsAg and anti-HBc .
For the quantitative analysis of anti-HBs titres we divided children in two categories:
Children with more than to IU were classified as protected while those with titres under
that level were classified as negative for anti-HBs.
Mothers were classified as follows:
Infected mothers were those positive for HBsAg or anti-HBc.
HBsAg positive were those who were repeatedly positive for HBsAg, both by ELISA and
neutralization techniques.
Highly infective mothers were those who were positive for HBsAg and HBeAg.
Low infective mothers were those who were positive for HBsAg but negative for HBeAg.
Seronegative mothers were those who were negative for HBsAg and Anti-HBc
All serological markers were processed using ELISA techniques and commercial available
kits (ABBOTI). These kits have in general more than 99% of sensitivity and more than 99%
of specificity. However, we carried out some additional procedures to ensure the quality of
the results. First, we used a high absorbance ratio (observed absorbance/cut-off point), to
classify samples as positives for HBsAg or Anti-HBc. The selected value for the absorbance
ratio was 2.0. Second, all positives samples for HBsAg were tested twice using the same
technique and those repeatedly positive were confirmed by neutralization. Samples positives
for Anti-HBc were processed twice with the same technique and only those found repeatedly
positive were included in the analysis as positive. Third, we only included as HBsAg + those
who tested positive for both HBsAg and Anti-HBc, which reduced even further the
likelihood of having included negative children as positives. No attempts were done to retest
negative samples given the high costs that it had imposed on the study budget. However
given a prevalence of 5% and a test sensitivity of 99% we should expect only a maximum of
2 false negatives over 2000 samples processed. Therefore the impact of false negatives on
our estimates, odds ratios (OR) and prevalence, should not be important.
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3.12 Data collection from health workers on vaccination knowledge and practices: We
interviewed 24 health workers in 19 towns in the Amazon department. We used a
questionnaire combining structured and open questions to measure their knowledge in the
following areas: name of the vaccine preventable diseases, contraindications for the vaccine
most commonly used in the EPI (polio, DPT and hepatitis B), site of application of hepatitis
B vaccine, age when a child should have completed the basic vaccine schedule, and
vaccination coverage in the area where they worked. We also collected information on
administrative aspects and operational characteristics of each health centre included in the
study e.g. the number of health workers, the number of medical doctors, daily working hours
in the centre, availability of physical structure to carry out vaccination activities (freezer and
cold chain). We tried to assess the attitudes of these health workers towards children who do
not attend the vaccination centre and the reasons (logistical, administrative, cultural or health
worker related) some children are not vaccinated according to the government schedule.
For the interview we selected only health workers directly involved in vaccination activities
(administrative and operational) in the area, regardless of their time in the job or their
professional level. We found that health workers in three professional categories: nurses,
auxiliary nurses and health promoters were involved in vaccination. According to Colombian
regulations nurses spend 6 years in a university in order to get their degree, auxiliary nurses
should have a technical training of 2 years in a non-university institution and health
promoters should be trained for one year in the same kind of institutions as auxiliary nurses.
Most auxiliary nurses and health promoters have not completed the basic school scheme
available in Colombia. Since the interviews were carried out some weeks after the
vaccination coverage survey not all the health centres in the area could be included, because
in rural areas a few health workers were not available at the time the interview was done.
One trained auxiliary nurse applied the questionnaires in rural and urban health centres. He
was trained over two days by the principal investigator in Leticia. We performed a pilot
interview on three health workers at the departmental level who were formerly involved in
vaccination activities. First the principal investigator showed the questionnaire to the
interviewer teaching him the correct manner to ask the questions and to record the answers
and encouraging him to make suggestions concerning the phrases used in the questionnaire,
or to ask questions if anything was unclear for him. Then he carried out one interview in the
presence of the auxiliary nurse that was followed by doing one interview in the presence of
the principal investigator. After these initial procedures the interviewer performed two other
interviews alone that were reviewed by the principal investigator in order to ensure that no
question was left blank due to mistakes or misunderstanding. Special emphasis was made
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concerning open questions where the interviewer was instructed to write down all the ideas
given by the interviewee.
3.13 Data handling and analysis:
The census and questionnaires were entered in several databases using EPIINFO 6.04. One
had data concerning child's vaccination status, the second one environmental and socio-
economic characteristics of the household, the third general risk factors for hepatitis B
infection, a fourth mother's serological status, and the last vaccination knowledge and
practices. Files containing data about children and mothers shared a common identification
number that was constructed from the cluster household numbers.
3.13.1. Analysis of health worker data:
Variables obtained from health workers were divided in four broad categories: general
characteristics of health centre, general knowledge on vaccines, general knowledge on
hepatitis B vaccine, and health worker's perception of barriers for adequate vaccination
coverage. The last category was divided into subcategories: logistical barriers, parent related
barriers, geographical barriers and health worker related barriers.
First we describe the frequency of every variable using percentages for nominal and median
for continuous variables. Then we performed an ecological analysis aiming to identify those
health worker or health centre characteristics related statistically with higher or lower levels
of fully vaccination coverage and hepatitis B vaccine coverage. The ecological unit of
analysis was every village or town. The dependent variable was the proportion of children
fully vaccinated or completely immunised against hepatitis B treated as continuous variables.
The bivariate approach in the ecological analysis was done comparing the median of
vaccination coverage between categories of the independent variables and median
differences were tested using the Kruskall Wallis test.
Variables found to be associated with vaccination (p<O.2 or differences in coverage above
15%) were included in multi variable models. We also included some health worker or health
centre characteristics believed to be theoretically important even if in the bivariate analysis
they were not strongly related to vaccination. Models were built using linear regression to
assess which variables were more important for the determination of vaccination coverage,
as well as to assess the presence of confounding. We ran models using the option "robust"
and as analytical weights the number of children under 10 years in every village. Vaccination
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coverage was included in different models both in its original scale as a proportion and using
a base 10 logarithmic transformation. But we found that log transformation did not improve
the fit of the model so we decided to use coverage in its original scale. The "robust" options
in Stata use the HuberIWhite/sandwich estimator of variance instead of the traditional
calculation that allowed us to calculate linear regression coefficients even if linear
assumptions were not completely filled. (Stata 1999).
To select the best set of predictors for vaccination coverage and the most parsimonious
model we used a stepwise procedure (backward). The decision whether to keep a determined
variable in the model or not was taken on the basis of the partial F test (Fisher L and Van
Belle G 1993) comparing the square sum of regression of the model without the independent
variable under study to the square sum of residuals of the complete model. To detect
correlation between independent variables and to avoid its effects on coefficients and
standard errors we built a correlation matrix including independent variables. Those
variables that were correlated at more than 0.5 were not included together in the same model.
3.13.2. Cross sectional survey data:
A) Analysis of vaccination status and related factors: As dependent variables in the
analysis we considered several outcomes: I) being fully vaccinated and 2) being
completely vaccinated against hepatitis B.
Vaccination coverage was described by categories of place, person and time variables.
Percents of fully vaccinated children and its 95% confidence intervals were calculated for
rural and urban areas stratified by age. The number and proportions of vaccinated children
were calculated taking into account the complex design of the sample and using the
following formulae provided by Stata:
Where Y is the number of children vaccinated in the total population, y is the number of
children (j) vaccinated in the h.. strata (L= total number of strata) and i ... primary sampling
unit, and Whij are the user-specified sampling weights. Y might also be another measure such
as a proportion or a mean.
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The estimate of the variance for Y is obtained as follow:
Where,
mhl
Zyhi =LWhijYhij
j=1
and
1 nil
Zyh =-I Zyhi
nh i=1
and (l-fh) is the finite population correction.
To calculate confidence intervals the design effect (deff) was taken in account therefore they
are more conservative than those that might be obtained using a simple random sampling
approach as seen in the following formula:
deff = V(B)
V.\T.n1.'Or (Osr,,' )
Where V(e) is the design- based variance for a parameter e, and Vsrswor(esrs) is an estimate of
the variance for an estimator esrs that would be obtained from a similar hypothetical survey
conducted using simple random sampling (srs) without replacement (war) with the same
number of sample elements as in the actual survey. (Stata 1999, volume 4:68-70)
We also described the lag of time before starting hepatitis B vaccination, to complete
hepatitis B vaccination and to complete the full vaccination scheme. To carry out this we
calculated medians of the number of days between doses or between date of birth and doses
then I described differences by area and age. Bar graphs and line graphs were used to
visualise differences.
Independent variables considered in the analysis were divided in two broad categories: I)
individual variables which were also divided in individual factors related to children,
related to parents and related to socioeconomic conditions. 2) Ecological variables
which were also divided in those describing general conditions of health centre, those
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related with health worker knowledge on vaccines, and variables related with health
worker perceptions about barriers for vaccination
The aim of this part of the analysis was to identify all those variables that were statistically
related with vaccination status in each category using bivariate and multi variable analysis.
Within each category we used a multivariable technique (logistic regression) to identify the
most important variables and after that they were included in models that combined the most
important individual and ecological variables. First we analysed and identified the most
important individual variables, then the ecological, and finally we combined them and
identified those which were more strongly related to full and hepatitis B vaccination
coverage. Figure 2.1 showed the scheme of the analysis by categories and subcategories.
Figure 3.1. Organization of the statistical analysis for vaccination coverage and related
factors.
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In the bivariate analysis vaccination coverage was analysed separately with the independent
variables within each category. The first step was to calculate Odds Ratios and 95%
confidence intervals for every association (OR and 95%CI). These measures were calculated
using univariable logistic regression since Stata did not allow calculation of OR in tables
when the complex design was taken into account. Nominal variables with more than two
categories, such as ethnic group, were analysed as dummies. Numerical variables were
transformed to logarithms when analysed as continuous variables but none of them showed a
linear trend. Therefore I included only the results analysing them as categorical variables. To
collapse continuous variables in categories I first took into account evidence from previous
studies about the existence of a significant cut-off point. Where this evidence existed I used
it but the distribution by percentiles (25%, 50%, and 75%) was also used and results of both
approaches were compared. In fact most of the numerical variables used did not have a
consistent and known method of collapsing them therefore results using my approach are
presented. These categories were also treated as dummies. When no differences were found
between contiguous categories they were joined to simplify models and interpretations. All
variables which were found related with vaccination coverage (p<0.2) were included in the
multivariable analysis.
Logistical regression models were built usmg the command svylogit and the command
logistic with options for cluster and strata. With the first approach we obtained the most
conservative estimates for confidence intervals and statistical test for individual variables
coefficients but there is no consensus about the correct methods to assess the significance of
whole models and to compare the contribution of individual variables when they are dropped
from the model. Survey commands in Stata use an adjusted Wald test to assess the overall
significance of the model that is an extension of the F test used in linear regression and
variance analysis. Some authors in this field recommend using a more classical approach
(Hosmer Lemeshow test) to assess if the contribution of an individual variable to the model
is significant or not. (Hosmer D and Lemeshow S 2000, page 211-222).
Multiple logistic regression was used to examine which variables were going to be selected
in each category. Then it was used to assess the combined effect of the most relevant
variables in the ecological and individual level on vaccination coverage. The contribution of
every variable to the model in every category was measured using the Hosmer Lemeshow
test with a cutoff point of p::O.l. With the results from the logistic regression we were able to
identify which variables were more statistically related with vaccination status in each of the
categories and in a second step we carried out another multivariable analysis where the most
important variables from each category were evaluated together.
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When the ecological variables were analysed especial efforts were made to detect
collinearity between covariates and to avoid the influence of this correlation on the
estimates. Although some authors have claimed that only correlations coefficients above
80% influence variances and coefficients we decided to follow a more conservative approach
and when two variables showed a correlation above 50% they were not included together in
the same model. (Katz M 1999. page 55-59). When a higher value was found we ran models
containing the correlated variables separately. If one of the variables remained statistically
associated with vaccination coverage it was kept for further analysis and the other was
dropped. When both remained associated the one with the highest OR was used in further
models though that with the lower value was also tested in subsequent models. Some
correlated ecological variables were kept until the last step of the analysis, that with
individual characteristics, and they remained associated with vaccination coverage so more
than one final model had to be fitted in the combined step.
B) Analysis of Hepatitis B infection and related factors: Being HBsAg positive was
considered as the main outcome. Being infected with hepatitis B was also considered in the
analysis but only in the descriptive analysis.
Prevalence of HBsAg positivity was calculated using the same approach for complex
surveys that was described above in vaccination coverage. It was calculated for urban and
rural areas stratified by age groups and by gender. Prevalence of infection with HBV was
described by the same variables. Bar graphs were used at this step to show trends and
differences by categories.
We compared prevalence of HBV infection and HBsAg positivity found in our study with
prevalence from former studies (Cristancho LM 1993). This comparative analysis was
stratified by age, sex, and place of the study. We calculated percentage differences,
proportion of reduction, and 95% confidence interval. Prevalence before vaccination were
obtained from the study of Cristancho 1995 who surveyed a number of rural populations in
the Amazon including Puerto Narifio, Araracuara and Puerto Santander. Only results from
rural areas were included to calculate the prevalence after vaccination because Cristancho
did not include an urban sample of Leticia in her study. Specific results from Araracuara and
Puerto Santander were compared since they were the areas with the highest prevalence
before vaccine introduction.
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Then we attempted to identify explanatory variables for HBsAg positivity and independent
variables were divided into the following categories: I) Child related variables, among
these we considered age, sex, gender, birth order, qualification of the person delivering the
child, and ethnic group. 2) Vaccination characteristics, here we considered time in days
between birth and the first dose of hepatitis B, time between first and second dose, and time
between second and third dose. 3) Mother related variables, which were basically the
serological status of the mothers regarding hepatitis B infection, place where mother was
born, and mother's history of clinical hepatitis.
As before each category was analysed separately, using bivariate (OR and 95%CI) and
multi variable analysis (logistic regression), and the most important variables in each
category were considered for a final analysis using multi variable logistic regression
techniques. As for vaccination coverage I built logistic models using the svy and the logistic
command with cluster and strata option. Criteria to introduce or to drop variables were
similar to those described above.
Figure 3.2. Organization of the statistical analysis for HBV prevalence of infection and
related factors.
C) Analysis of Anti-HBs titres: Anti-HBs titres were considered as the dependent variable
but in the analysis we treated it in two ways. First we divided it into two categories, being
seroprotected or not and in the second as a continuous variable.
In the analysis with titres as categories we tried to identify variables related with not being
protected, i.e.having undetectable levels of anti-HBs. As independent variables in these
analyses we considered children's age, gender, ethnic group, breastfeeding, time in days
between doses of vaccine, and time in days between last dose and the date when the sample
was taken. Bivariable analysis was done calculating OR and 95% Cl as a measure of the
degree of the association. Those variables found related (p<O.I) in the bivariable analysis
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were included in a logistical model where the contribution of each variable to the model was
assessed as described before.
The same independent variables were considered when anti-HBs titres were treated as a
continuous variable. In this case geometric means and medians of titres were calculated for
every category of the independent variable. Means or medians differences were tested with
non-parametric techniques such as the Kruskall Wallis test. A multivariable model was
constructed using lineal regression techniques in order to include those variables that showed
important differences in mean anti-HBs (p<O.I).
Table 3.2. Population distribution in urban and rural areas of the municipality of
Leticia
Village # of Selected for
habitants stud~
Leticia 15400 Y
Ki16metro 18 81 Y
Huacarf 42 Y
Verge I 120 Y
Mocagua 175 Y
Arara + Sta. Rosa 364 Y
Bora 6 N
San Jose Km. 6 635 N
Palmeras 126 N
Santa Sofia 245 N
Los Escobedo 158 Y
San Pedro 17 Y
Zaragoza 347 N
San Jose 24 y
Kilometro II 81 Y
Isla Mocagua 57 N
San Martin de 396 N
Amocayacu
San Sebastian 194 Y
San Miguel 110 Y
Lorna Linda 112 N
San Juan de los Parentes 72 N
Huanganayo 224 N
Macedonia 637 N
Kilometro 7 46 Y
Nazareth 581 N
La Milagrosa 144 N
Multietnica 150 N
Yaguas 140 N
San Antonio 168 N
MoniJlamena 42 N
Total rural area 5494
Y= Included in the study N= Not included
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Table 3.3. Population distribution in urban and rural areas of the municipality of
Puerto Nariiio.
Village # of Selected for
habitants studl:
Puerto Narifio (urban) 1433 Y
Tipisca 77 y
Villa Castillito 25 y
Nuevo Porvenir 22 y
Pozo Redondo 168 Y
Santa Teresa 50 Y
Villa Andrea 59 y
Quebrada Nonten 15 Y
Lago Tarapoto 35 Y
Santaren 47 y
San Juan del Soco 193 y
Isla Patrullero 73 N
Boyahuasu 334 y
Siete de Agosto y Bocas de 539 Y
Atacuari
Naranjales 349 y
20 de Julio 191 N
Nuevo Parafso 54 N
San Francisco 430 N
Hacienda San Francisco 30 N
Total rurall!ol!ulation 2691
Y= Included in the study N= Not included in the study
Table 3.4. POl!ulation distribution in Leticia b,r neighbourhoods and blocks
Neighbourhood # of blocks Population Children under # of blocks
n (%) n (%) 10 y. selected for
n (%) studl:
Colombia 13 (8) 980 (6) 244 (8) 7 (12)
Simon Bolivar 18(l1) 1650 (II) 209 (7) 8 (13)
Esperanza 9 (6) 890 (6) 212 (7) 0(0)
Victoria Regia 8 (5) 360 (0.4) 139 (5) 2 (3)
Porvenir 33 (20) 3400 (22) 671 (23) 6 (10)
San Martin 5 (3) 665 (4) 106 (4) 3 (5)
II de Nv/bre 9 (5) 950 (6) 196 (7) 3 (5)
Gaitan 9 (5) 843 (6) 181 (6) 6 (l0)
Centro A 20 (12) 1675 (II) 261 (9) 6 (10)
lANE 6 (4) 602 (4) 98 (3) 4 (7)
Aguila I (0.6) 300 (2) 61 (2) 0(0)
Centro B 27 (16) 2690 (17) 390 (14) 12 (20)
Humarizal 5 (3) 395 (2) 90 (3) 3 (5)
Total 163 (100) 15,400 (100) 2,858 (100) 60 (100)
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Table 3.5. Expected results of the serological survey.o=2500.
Variable
Prevalence of infection
Prevalence of HBsAg
Expected # of mothers
Expected infected mothers
Expected HBsAg + mothers
Expected HBeAg+ mothers
Children with complete immunization
Children with 2 and 3 dose later than recommended
Children with interval between I and 3 dose later than 6
months
Children with timely and complete schedule
Infected among those timely and completely immunized
Children with incomplete immunization
Infected among incompleted immunised children
Infected among those with untimely schedule
Children born from HBsAg + mothers
Children born from HBsAg+
mothers and unvaccinated
Children born from HBsAg+
mothers vaccinated
Children born from HBeAg + mothers
Children born from HBeAg+ mothers unvaccinated
Children born from HBeAg+ mothers vaccinated
Infected in unvaccinated children from mother HBsAg+
Infected in vaccinated children from mother HBsAg+
Infected in unvaccinated children from HBeAg+
Infected in vaccinated children from HBeAg+
Expected % Expected #
15 (10-20) 375(250-500)
5 (3-7) 125(75-175)
1.5-3.0 chd/m 833-1667
50-70 416-1167
15 (10-20) 250(83-333 )
10% ofHBsAg+ (5-15) 25(4-50)
40-70 1000-1750
30 300-525
50 500-875
50-70% of those with
complete schedule 500- 1225
4-8 20-98
60-30 750-1500
8-16 60-240
6-10 30-122
1.5-3.0 children/mother 375( 124-1000)
30-60 37-600
40-70 50-700
1.5-3.0 children/mother 37(6-150)
30-60 22(2-90)
40-70 26(2-105)
20 7-120
5 2-35
90 20(2-80)
ID 3(0-10)
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Chapter 4: Results on vaccination coverage
Summary: We surveyed 3044 children between one and II years old. Vaccine coverage
was highest for yellow fever (96%), followed by measles (94%), BCG (91%), OPT (90%)
and hepatitis B (88%). Children in rural areas had to wait for longer periods to receive HBV
vaccine dose than children in urban areas. The median age to complete the HBV scheme
was 4 months in urban areas while it was 8 months in rural. Factors related to vaccination
were divided broadly into individual and ecological variables and they were analysed
separately for HBV vaccination and for full vaccination.
The following individual variables were related to not being fully vaccinated: "living in
Puerto Narifio" (OR=4.3 95%CI 204-7.6) and "not being affiliated to the social security"
(OR=1.7 95%CI 1.1-2.6). In urban areas "living in a house roofed with palm tree leaf' was
also associated with a lower chance of full vaccination (OR=3.5 95%CI 1.6-7.8). Belonging
to a non Indian group was protective against no vaccination (OR=Oo4 95%CI 0.2-0.7). The
individual variables related with not being completely vaccinated against hepatitis B were:
"number of siblings above 3" (OR=3.2 95%CI 1.0-11.0) and "living in Puerto Narifio"
(OR=2.3 95%CI 1.3-4.2). Living in Araracuara increased the chance of being completely
vaccinated (OR=0.2 95%CI 0.1-0.7). In urban areas, "living in a house roofed with palm tree
leaf' was again related with less chance of HBV vaccination (OR=3.] 95%CI 1.1-8.2).
The most important ecological variables analysed were the number of contraindications that
health workers mentioned for every vaccine (polio, OPT and hepatitis B), the length of time
working in the community, and the perception about the severity of hepatitis B disease.
After controlling for the most important individual variables we found that the ecological
variables related with lower full vaccination were: "lack of supplies" (OR=3.0 95%CI 1.5-
6.0), perceiving "parents' fear of vaccine side effects" as a barrier (OR=2.2 95% Cl 1.3-3.9),
"number of contraindications against polio" (OR=1.4 95%CI 0.8-2.3). "Working for more
than 14 years in the health centre" was protective against lower levels of full vaccination
(OR=Oo4 95%CI=0.3-0.6). The same variables were related with hepatitis B vaccination
except for "contraindications against polio" that was replaced by "contraindication against
hepatitis B vaccine" (OR=2.3 95%CI 1.1-5.0. The length of time working in the health
centre was associated again in a protective way with hepatitis B vaccination.
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Vaccination coverage and characteristics:
General description: We surveyed 104 clusters, 60 in urban Leticia, 12 in rural Leticia, 19
in the urban area of Puerto Narifio, 9 in rural Puerto Narifio and 4 in other rural areas of
Amazons, namely Puerto Santander and Araracuara.
The census recorded 3573 people and 3044 of them were one year old or older. Most of
them, 1621, lived in Leticia's urban area (56%),341 in Puerto Narifios urban area (7%),
765 in rural areas of Leticia (21%), 508 in the rural areas of Puerto Narifio (9.6%), and 331
(4%) in Araracuara and Puerto Santander. Among the 3475 children of whom data on age
was available, the range was from 0 to eleven years while the median was 5.0 years. Twenty
five percent of the children were less than 2 years old while 75% were under 7. Among 3548
children with gender data available, 1890 (53%) were males and 1658 females (47%). Most
children (82%) were living in their place of birth.
Vaccine information was not available for everyone. It was more frequently found for
hepatitis B with information available for 2242 children, followed by OPT with 2158, BCG
with 2005. yellow fever with 1839, and measles with 1791. Vaccine coverage was higher for
yellow fever (96%), followed by measles (94%), BCG (91%), OPT (90%), and Hepatitis B
(88%). Coverage for hepatitis B was similar for rural and urban areas; only among children
aged one there were differences by area. In rural areas, hepatitis B coverage in this age
group was 67% (67/100) while in urban areas it was 83% (106/127).
Fifty percent of the children under 8 years old (born after vaccine was introduced), received
the first dose of hepatitis B vaccine within the first 45 days after birth, while 25% received it
in the first 3 days and 75% before day 342 after birth. The median interval between the first
and second dose was 41 days and between second and third was 72 days. In general.
intervals in rural areas were longer compared to urban areas. Figure 4.1.
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Figure 4.1. Time in days between hepatitis B doses by
area.
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The median age to complete hepatitis B schedule was 8 months for children between one
and 8 years of age and 75% percent completed it before 16 months of life. Here again
differences were greater between urban and rural areas. In urban areas the median time to
complete the schedule was 143 days and 75% percent of urban children completed the
schedule before 362 days. In rural settlements the median time to complete hepatitis B
schedule was 334 days and only 25% of children completed it before 6 months after birth. In
older children, five years and above, there were no important differences, but among the
youngest rural children, intervals were longer. Figure 4.2 shows intervals by age and area.
Figure 4.2. Median time between birth and third dose of hepatitis
B by area and age
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Figure 4.3. Full vaccination coverage by age and area
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For 1380 children there was enough information to evaluate their full vaccination status.
Full immunisation coverage was 78% (CI95% 74%-83%), but there were differences by
area. Surprisingly, in urban areas full vaccination coverage was 73%, while in rural areas it
was 84%, p=O.OI. Figure 4.3 shows coverage by age and area. A slight difference in
coverage in every age group was observed, especially in the first four years of life and in the
last category, though in this there are very few observations (9 in each area). None of these
differences were statistically significant, p>0.05.
Time between birth and yellow fever vaccine was used as a proxy to evaluate the age at
which children completed the vaccination schedule. The reason to do so was that yellow
fever is the last vaccine applied in Colombia's scheme. Only 38% of children completed the
vaccination scheme in the first year of age, 26% in the second year, 14% in the third year,
and 22% completed it in the fourth year or beyond. Figure 4.4 shows the proportion of
children that completed the vaccination scheme in the first year of life, by age and area.
II. Individual factors related to vaccination coverage.
11.1. Child factors: Table 4.1 shows the distribution of the children's main demographic
variables evaluated in the study and the relationship to vaccination status.
In bi-variable analysis, age was strongly related to being fully vaccinated and being
completely vaccinated against hepatitis B. Children less than 2 years old had the highest
probability of not being completely vaccinated against hepatitis B as well as against other
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diseases. The peak of full vaccination is reached at the age of 6 while the peak of hepatitis B
vaccination is reached at the age of five. At older ages coverage remains stable.
Figure 4.4. Proportion of children completing the basic vaccination scheme in
the first year of life
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As regards geographical characteristics, the urban area of Puerto Narifio had the lowest
coverage of full vaccination and hepatitis B vaccine. The highest coverage was found in
rural areas of Leticia and Puerto Narifio followed by urban Leticia and Araracuara. The
highest hepatitis B coverage was found in Araracuara, though it was also high in rural and
urban Leticia. In rural areas of Puerto Narifio vaccine coverage was higher than in urban
areas.
"Birth order" was related to full vaccination showing a U shaped relation. The first born had
a higher probability of being fully vaccinated compared with those born second through
fifth. Those born sixth or later had again a higher chance of being fully vaccinated. A
similar finding was observed for hepatitis B, though differences were less significant.
"Huitotos" showed the lowest full vaccination while "Mestizos" had the highest, followed
by members of Indians groups other than "Huitotos" or "Ticunas", the biggest Indian ethnic
groups in the area. Hepatitis B coverage was higher in "Mestizos" and Huitotos while it was
lower among "Ticunas" and "non Indian populations" but the overall differences between
groups was not significant (p=O.2).
Being affiliated to social security was protective against not being fully vaccinated.
Unaffiliated people had 76% more chance of not being fully vaccinated compared with
those affiliated. Interestingly, no difference was found regarding hepatitis B vaccination.
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Table 4.1. Vaccination coverage by variables related to children.
Variables Children Fully OR (CI95%) Children Completely OR (CI95%)
with vaccinate Incomplete with vaccinated Incomplete
information d#(%) schedule information with HB HB
for all forHB # (%) vaccination
vaccines vaccine
# (%)* # (%)*
Age P<O.OOOI P=O.OOOI
1 year 158 (57) 65 (41) 1.0 203 (73) 167 (79) 1.0
2/3 years 351 (52) 235 (67) 0.34 (0.2-0.5) 514 (76) 468 (91) 0.37 (0.2-0.6)
4/5 years 354 (55) 269 (76) 0.22 (0.1-0.3) 402 (63) 374 (93) 0.26 (0.1-0.5)
6/7 years 315(49) 236 (75) 0.22 (0.1-0.3) 359 (56) 316(88) 0048 (0.3-0.9)
8/11 years 351 (43) 249 (71) 0.28 (0.2-0.4) 430 (53) 379 (88) 0047 (0.3-0.8)
Area P=O.02 P=O.05
Urban Leticia 723 (49) 514(71) 1.0 837 (56) 745 (89) 1.0
Rural Leticia 408 (60) 282 (69) 1.1 (0.7-1.8) 533 (79) 480 (90) 0.98 (0.5-2.0)
Puerto Narifio 120 (39) 47 (39) 3.8 (2.4-6.1) 136 (44) 99 (73) 3.13 (2.1-4.8)
Rural Puerto 192 (29) 131(68) 1.15 (0.5-2.7) 240 (76) 202 (84) 1.41 (0.7-3.0)
Narifio
Araracuara 125 (48) 80 (64) 1.36 (0.8-2.4) 185 (71) 178 (96) 0.37 (0.1-0.9)
Ethnic group P=O.OO9 P=O.025
No Indians 618 (43) 408(66) 1.0 708 (49) 616 (87) 1.0
Mestizos 196 (58) 163 (83) 004 (0.2-0.6) 283 (84) 269 (95) 0.32 (0.2-0.6)
Ticunas 453 (58) 290 (64) 1.1 (0.65-1.8) 563 (72) 484 (86) 1.11 (0.6-2.1)
Huitotos 72 (48) 43 (60) 1.3 (0.7-2.2) 97 (65) 89 (92) 0.54 (0.2-1.4)
Other groups 203 (60) 150 (74) 0.7 (0.4-1.1) 267 (78) 246 (92) 0.59 (0.3-1.0)
Birth order P=O.04 P=0.16
1 277 (51) 205 (74) 1.0 368 (68) 335 (91) 1.0
2/3 500 (54) 350 (70) 1.2 (0.8-1.8) 628 (67) 553 (88) 1.61 (1.0-2.6)
4/5 321 (61) 209 (65) 1.5 (1.0-2.2) 389 (75) 342(88) 1.87 (1.1-3.1)
6120 175(56) 133 (76) 0.9 (0.6-1.4) 239 (77) 220 (92) 1.10(0.6-2.2)
Number of P=0.2 P=0.2
siblings
1 46 (54) 27 (61) 1.0 77 (90) 72 (94) 1.0
2/3 511 (55) 357 (72) 0.6 (0.3-1.2) 632 (68) 562 (89) 1.8 (0.6-6.0)
4/5 424 (57) 283 (67) 0.8 (0.4-1.6) 510 (68) 442 (87) 204 (0.8-7.1)
6/20 303 (58) 221 (74) 0.5 (0.2-1.2) 393 (75) 360 (91) 1.5 (0.5-4.5)
Health security P=O.OO8 P=0.30
Affiliated 836 (51) 602 (72) 1.0 1133(69) 1020 (90) 1.0
Not affiliated 188 (48) 109 (58) 1.8 (1.2-2.2) 251 (64) 216 (86) 1.67 (0.7-4.0)
* Percentage calculated on the total number of children of every category identified in the survey.
All variables associated with vaccination and showing a p value of 0.2 or less were included
in one step. In multivariable models "ethnic group", area, and "being affiliated to social
security" remained significantly associated to not being fully vaccinated. Besides age, the
strongest association was observed for "area", Puerto Narifio being the place where the risk
of not being vaccinated was the highest. As concerns "ethnic group", the only statistical
difference was observed for "other groups", who were better vaccinated than the others.
"Number of siblings" and "birth order" were not related to full vaccination. Age and area
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were also associated to not being completely vaccinated against hepatitis B, but "ethnic
group" and "being affiliated to the social security" were not. Instead a larger number of
siblings was related to incomplete hepatitis B vaccination. "Birth order" was not related to
hepatitis B vaccination but it was kept in the final model to control the effect of "number of
siblings". Tables 4.2 and 4.3.
Table 4.2 Children's characteristics and not being fully vaccinated. Final model
Variables OR (CI95%) p
Age
I year 1.0
2/3 years 0.20 (0.1-0.3) <0.001
4/5 years 0.11 (0.1-0.2) <0.001
617 years 0.12 (0.1-0.2) <0.001
8111 years 0.20 (0.1-0.3) <0.001
Ethnic group
No Indians 1.0
Mestizos 0.64 (0.3-1.2) 0.17
Huitotos 1.32 (0.7-2.6) 0.42
Ticunas 0.91 (0.5-1.6) 0.73
Other groups 0.53 (0.3-0.99) 0.04
Area
Urban Leticia 1.0
Rural Leticia 1.34 (0.8-2.2) 0.23
Puerto Narifio 4.3 (2.4-7.6) <0.001
Rural Puerto Narifio 1.47 (0.6-3.6) 0.40
Araracuara 1.45 (0.8-2.8) 0.24
Affiliated to health
security
Not affiliated 1.69 (1.1-2.6) 0.02
11.2. Parent factors: In bi-variable analysis, "mother's age at survey time" was associated
with being fully vaccinated but not with hepatitis B vaccination. A child whose mother was
less than 21 years old at the time of the survey had less chance of being fully vaccinated
than one whose mother was older. "Mother's age at child's birth" was not associated with
being fully vaccinated or hepatitis B vaccination.
"Mother's years of schooling" showed some relation to being fully vaccinated in the
multi variable model. Children whose mothers never went to school or who did not complete
primary level had the lowest coverage (70%) of full vaccination. Full vaccination coverage
tended to be higher for children whose mothers attended school for more than 6 years.
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Table 4.3. Children's characteristics and not being vaccinated against hepatitis B.
Final model
Variables OR (CI95%)
Age
I year 1.0
2/3 years 0.24 (0.1-0.4)
4/5 years 0.16 (0.1-0.3)
617 years 0.29 (0.1-0.6)
8/11 years 0.36 (0.2-0.6)
Number of siblings
I 1.0
2/3 2.5 (0.8-7.5)
4/5 3.1 (1.0-10.2)
6/20 2.4 (0.7-8.2)
Birth order
I 1.0
2/3 1.1 (0.7-1.8)
4/5 1.0 (0.5-2.1)
6120 0.8 (0.3-2.3)
Area
Urban Leticia 1.0
Rural Leticia 0.5 (0.2-1.0)
Puerto Narifio 1.5 (0.8-2.7)
Rural Puerto Narifio 0.8 (0.3-2.1)
Araracuara 0.3 (0.1-0.9)
p
<0.001
<0.001
<0.001
<0.001
0.092
0.05
0.15
0.70
0.94
0.67
0.06
0.19
0.60
0.03
In the multivariable model, factors related to parents were not strongly associated with not
being fully vaccinated. Only one category of "mother's schooling" was statistically related,
at the borderline of significance, to not being vaccinated and the same with mother's age at
survey time: only those mothers aged 20/24 showed a difference for their children
No variable in this category was associated to not being vaccinated against hepatitis B. All
of them were included in a logistic model and discarded based on the likelihood ratio test
(p>O.l).
11.3. Socio-economic factors: In this category there are variables related to house
characteristics (roof, floor, walls, piped water, excretal disposal, and crowding), and
variables related to economic affluence of family (owning things like freezer, TV, radio, and
outboard motor). Full vaccination was associated with both kinds of variables but almost all
variables in the second group were statistically related while in the first group only "roof
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material" (p=O.003) and "floor material" (p=O.07) showed a relation to full vaccination. In
the second group the strongest association was observed with "owning a freezer" (p=O.OOI).
Children living in a house without a freezer had an 80% decrease in the chance of being
completely vaccinated. In general, all characteristics that could be related to a better
standard of living were protective against not being fully vaccinated, and the strongest
relation was to roof material. In the multi variable model only "roof material" and "owning a
freezer" remained associated with not being fully vaccinated. Tables 4.6 and 4.7.
Table 4.4. Vaccination coverage according to parents' characteristics.
Variable Children Fully OR (CI95%) Children Completely OR (CI95%)
with vaccinate Incomplete with vaccinated Incomplete
information d# (%) schedule informatio with HB HB
for all n for HB # (%) vaccination
vaccines vaccine
#(%)* #(%)*
Mother's age P=o.04 P=O.43
at survey
16/19 58 (55) 32 (55) 1.0 94 (89) 86 (91) 1.0
20/24 267 (57) 200 (75) 0.4 (0.2-0.8) 352 (75) 313 (89) 1.19 (0.5-2.6)
25/30 334 (54) 246 (73) 0.45 (0.2-0.9) 426 (69) 388(91) 0.96 (0.4-2.4)
31135 289 (59) 191 (66) 0.6 (0.3-1.27) 376 (76) 323 (86) 1.52 (0.6-3.9)
36/51 300 (55) 219 (73) 0.4 (0.2-0.8) 372 (69) 339 (91) 1.0 (0.4-2.4)
Father's age P =0.18 P =0.65
at survey
16-25 y 95 (56) 57 (60) 1.0 132 (77) 115 (87) 1.0
26-30 y 190 (55) 135 (71) 0.59 (0.3-1.0) 256 (74) 228 (89) 0.83 (0.4-1.5)
31-35 y 228 (59) 164 (72) 0.56 (0.3-1.0) 273 (70) 243 (89) 0.80 (0.4-1.7)
36-57 y 501 (57) 361 (72) 0.56 (0.3-0.9) 631 (71) 568 (90) 0.71 (0.4-1.2)
58-76 y 28 (56) 17 (61) 0.92 (0.3-2.7) 37 (74) 30 (81) 1.54 (0.5-4.8)
Mothers P=0.22 P=0.69
education level
(years in
school)
0/4 426 (55) 298 (70) 1.0 593 (77) 534 (90) 1.0
5 304 (59) 222 (73) 0.8 (0.6-1.3) 396 (76) 356 (90) 1.0 (0.6-1.6)
6/8 136(48) 102 (75) 0.7 (0.4-1.2) 196 (70) 184 (94) 0.60 (0.3-1.2)
9/10 63 (55) 51 (81) 0.5 (0.2-1.4) 74 (65) 68 (92) 0.82 (0.3-2.6)
11/17 182 (57) 135(74) 0.8 (0.5-1.4) 227 (71) 204 (90) 1.0 (0.5-2.1 )
* Percentage calculated on the total number of children of every category identified in the survey.
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Table 4.5. Parents' characteristics and not being fully vaccinated. Final model
Variable OR (CI95%) p
Children's age (years)
I 1.0
2/3 0.31 (0.2-0.5) <0.001
4/5 0.21 (0.1-0.3) <0.001
617 0.19 (0.1-0.3) <0.001
8111 0.25 (0.2-0.4) <0.001
Mother's schooling
years
0/4 1.0
5 0.81 (0.5-1.2) 0.305
6/8 0.59 (0.3-1.0) 0.069
9110 OA8 (0.2-IA) 0.165
11117 0.67 (OA-I.I ) 0.139
Mother's age at survey
(years)
16119 1.0
20/24 OA6 (0.2-0.9) 0.029
25/30 0.62 (0.3-1.2) 0.174
31/35 0.89 (OA-1.8) 0.760
36/51 0.60 (0.3-1.2) 0.155
Hepatitis B vaccination was associated with fewer variables. "Roof materials" and "owning
an outboard motor" were related to hepatitis B vaccination and this association remained in
the multi variable analysis. Table 4.8.
11.4. Models combining individual variables:
11.4.1 Not being fully vaccinated: At this stage the following variables were included:
Children's age by categories.
Mother's years of schooling.
Kind of material of roof.
Mother's age at survey.
Ethnic group.
Being affiliated to the Health Security System.
Owning a freezer.
Three basic sets of models were constructed. In the first all participants were included, in
the second only children form urban areas and in the last children from rural areas. Table 4.9
shows the final model when the whole population was analysed. "Age", "area", "ethnic
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group" and "not being affiliated to the social security" were associated with not being fully
vaccinated.
Table 4.6. Vaccination coverage by socio-economic characteristics.
Variables Children Fully OR (CI95%) Children Completely OR (CI95%)
with vaccinate Incomplete with vaccinated Incomplete
information d# (%) schedule informatio with UB UB
for all n for UB # (%) vaccination
vaccines vaccine
# (%)* # (%)*
Roof made P=O.OO3 P=O.Ol
with:
Tile 1284 (50) 899 (70) 1.0 1672 (65) 1488 (89) 1.0
Palm tree leaf 129(34) 67 (52) 2.0 (104-3.0) 223 (58) 183 (82) 1.91 (1.1-3.2)
Floor made P=O.07 P=0.58
with:
Cement 540 (51) 389 (72) 1.0 612(58) 551 (90) 1.0
Wood 972 (53) 622 (64) lA (1.0-2.0) 1232 (67) 1085 (88) 1.20 (0.8-1.8)
Soil 43 (43) 32 (74) 0.9 (004-1.9) 57 (58) 51 (89) 1.02 (0.4-2.6)
Crowding: # P=O.II P=0.78
of people by
room
113 697 (49) 495 (71) 1.0 827 (58) 736 (89) 1.0
4/6 484 (54) 305 (63) lA (1.1-1.9) 614 (68) 540 (88) 1.03 (0.7-1.6)
7/9 197 (58) 134 (68) 1.1 (0.7-1.8) 251 (74) 223 (89) 0.95 (0.6-1.4)
lOllS I ID (45) 74 (67) 1.2 (0.8-1.8) 155 (64) 141 (91) 0.76 (0.4-1.6)
Freezer at P=O.OOI P=O.09
home
y 345 266 (77) 1.0 461 424 (92) 1.0
N 789 513(65) 1.8 (1.2-2.6) 1037 913 (88) 1.55 (0.9-2.6)
TV at home P=O.06 P=0.36
y 493 360 (73) 1.0 644 586(91) 1.0
N 645 421 (65) lA (1.0-2.2) 859 756 (88) 1.27 (0.8-2.2)
Radio at home P=O.05 P=0.22
y 512 374 (73) 1.0 775 628 (81) 1.0
N 617 407 (66) 1.39 (1.0-2.0) 811 714 (88) 1.34 (0.8-2.2)
Outboard P=O.ll P=O.06
motor
y 96 73 (76) 1.0 140 132 (94) 1.0
N 1020 704 (69) 1048 (0.9-204) 1360 1210 (89) 1.78 (1.0-3.3)
Table 4.7. Socio-economic characteristics and not being fully vaccinated. Final model
Variable OR (CI95%) P
Children's Age
I 1.0
2/3 0.24 (0.2-0.4) <0.001
4/5 0.13 (0.1-0.2) <0.001
6n 0.14 (0.1-0.2) <0.001
8/11 0.21 (0.1-0.4) <0.001
Roof made with
Palm tree leaf vs. Tile 1.91 (1.2-3.0) 0.006
Freezer
N 1.71 (1.2-204) 0.004
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Table 4.8. Socio-economic characteristics and not being vaccinated against hepatitis B.
Final model
Variable OR (CI95%) p
Children's Age
I 1.0
2/3 0.22 (0.1-0.4) <0.001
4/5 0.13 (0.1-0.3) <0.001
6/7 0.20 (0.1-0.4) <0.001
8/11 0.32 (0.2-0.6) <0.001
Roof made with
Palm tree leaf vs. tile 2.04 (1.1-3.9) 0.031
Owning an outboard
motor
N 1.85 (0.9-3.8) 0.09
Tables 4.10 and 4.11 shows the final results when the analysis was stratified by area.
"Ethnic group" has a different effect when area is taken into account. In urban areas,
"Mestizos" were better vaccinated than other groups while "Ticunas" had the lowest chance
of being fully vaccinated. In rural areas, "ethnic group" was not associated with full
vaccination. The socioeconomic characteristics were also related to full vaccination but in
different ways for rural and urban areas. In urban areas, "living in a house with a palm tree
leaf roof' is associated with a decrease in the chance of being fully vaccinated, but
ownership is not. In rural areas, "palm tree leaf roof' is also associated with a lower chance
of vaccination, but the relation is not as strong as it is in urban areas. On the other hand,
"owning a freezer" is not associated with full vaccination in urban areas, but it is in rural
areas where not owning one was associated with a lower chance of being fully vaccinated.
Interestingly, not being affiliated to the social security was associated with a lower
likelihood of full vaccination in rural areas but not in urban. Children lacking a social
security card have twice the chance of not being fully vaccinated than children holding one.
11.4.2.Not being vaccinated against hepatitis B:
The variables included at this stage were:
Children's age.
Number of siblings.
Birth order.
Study area.
Roof s material.
Owning an outboard motor.
Ethnic group.
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Table 4.9. Selected individual variables and not being fully vaccinated. All children.
Final model
Variable OR (CI95%) p
Age
I 1.0
2/3 0.20 (0.1-0.3) <0.001
4/5 0.11 (0.1-0.2) <0.001
617 0.12 (0.1-0.2) <0.001
gIll 0.20 (0.1-0.3) <0.001
Area
Urban Leticia 1.0
Rural Leticia 1.3 (0.8-2.2) 0.232
Urban Puerto Narifio 4.3 (2.4-7.6) <0.001
Rural Puerto Narifio 1.47 (0.6-3.6) 0.397
Araracuara 1.45 (0.8-2.7) 0.245
Ethnic group
No Indians 1.0
Mestizos 0.53 (0.3-1.0) 0.048
Huitotos 1.32 (0.7-2.6) 0.422
Ticunas 0.91 (0.5-1.5) 0.731
Other groups 0.64 (0.3-1.2) 0.174
Affiliated to social
security
N 1.69 (1.1-2.6) 0.02
Table 4.10. Selected individual variables and not being fully vaccinated. Urban area.
Final model
Variable OR (CI95%) p
Age
1 1.0
2/3 0.44 (0.2-0.8) 0.005
4/5 0.30 (0.2-0.5) <0.001
617 0.35 (0.2-0.6) 0.001
8/11 0.43 (0.2-0.8) 0.007
Ethnic group
No Indians 1.0
Mestizos 0.42 (0.2-0.7) 0.002
Huitotos 1.06 (0.4-2.8) 0.900
Ticunas 1.65 (1.0-2.8) 0.069
Others groups 0.99 (0.4-2.3) 0.99
Roof made with
Palm tree leaf vs. tile 3.48 (1.6-7.8) 0.003
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Table 4.11. Selected individual variables and not being fully vaccinated. Rural area.
Final model
Variable OR (CI95%) p
Age
I 1.0
2/3 0.16(0.1-0.3) <0.001
4/5 0.07 (0.03-0.2) <0.001
6/7 0.09 (0.04-0.2) <0.001
811I 0.13 (0.1-0.3) <0.001
Roof made with
Palm tree leaf vs. tile 1.7 (1.0-3.0) 0.06
Freezer
N 1.8 (1.0-3.0) 0.031
Affiliated to social
security
N 2.2 (1.3-3.6) 0.005
Again, three basic models were created. One for the whole population, another for the rural
population and one for urban children. In the model including the whole population, four
variables (children's age, number of siblings, study area, and roof's material) remained
statistically associated with not being vaccinated against hepatitis B. "Owning an outboard
motor" and "ethnic group" were dropped from the model (p=O.75 and p=O.3 respectively).
An attempt to reintroduce "mother's schooling" and "mother's age at children birth" in the
final model did not produce any change in the results showed in Table 4.12
In urban areas, "children's age", "number of siblings" and "roof's materials" were found
associated with complete vaccination against hepatitis B. "Number of siblings" showed an
especially strong relation to not being completely vaccinated against hepatitis B. Compared
to children without siblings those who have two or more had a very high risk of not being
completely vaccinated. A clear trend was observed for categories of this variable, and the
risk of not being vaccinated against hepatitis B was as high as 6.5 when number of siblings
was over 5. Children living in a house with a palm tree leaf roof had a higher chance of not
being completely vaccinated against hepatitis B, an association that was stronger in urban
areas than in rural areas or when the whole population was considered. Table 4.13
In rural areas "children's age" and "number of siblings" were statistically associated with
hepatitis B vaccination. The association of "number of siblings" with hepatitis b vaccination
was weaker in rural areas compared to urban ones. Having 4 or more 3 siblings was
associated with a 3 fold increase in the risk of not being vaccinated against hepatitis B
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(OR=3.3 CI95% 0.9-13.1, p=0.08). "Palm tree leaf roof' showed some relation but without
statistical significance (OR= 1.8 CI95% 0.8-3.9 p=0.13)
III. Ecological variables related to individual vaccination data.
IILI Results of health worker questionnaire
111.1.1. General characteristics of health centres: We interviewed 4 nurses,S auxiliary
nurses and IS health promoters. The median time working in their profession was 7 years
ranging from 0 to 32. "Time working in the health centre" also ranged from 0 to 32 years
with a median of 6 years. Most of the health centres included in the study had only one
health worker (15/19), three had between 6 and 17 health workers and 2 had more than 100
employees. Medical doctors were available in four centres and nurses in three.
Table 4.12. Selected individual variables and not being vaccinated against hepatitis B.
Final model
Variables OR (CI95%) p
Age
I year 1.0
2/3 years 0.23 (0.1-0.4) <0.001
4/5 years 0.16 (0.1-0.3) <0.001
617 years 0.30 (0.1-0.5) <0.001
Sill years 0.33 (0.2-0.6) <0.001
Number of siblings
I 1.0
2/3 2.2 (0.7-7.0) 0.092
4/5 3.2 (1.0-11.0) 0.05
6/20 2.7 (0.S-9.1) 0.11
Birth order
I 1.0
2/3 1.0 (0.6-1.7) 0.91
4/5 0.9 (O.4-I.S) 0.76
6/20 0.7 (0.2-2.0) 0.50
Area
Urban Leticia 1.0
Rural Leticia 0.7 (0.3-1.7) 0.44
Puerto Narifio 2.3 (1.3-4.2) 0.005
Rural Puerto Narifio 1.2 (0.4-3.5) 0.67
Araracuara 0.2 (0.1-0.7) 0.01
Roof made with
Palm tree leaf vs. 2.0 (0.S-4.7) 0.13
tile
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Table 4.13. Selected individual variables and not being vaccinated against hepatitis B.
Urban area. Final model
Variables OR (CI95%) P
Age
I year 1.0
2/3 years 0.44 (0.2-0.9) 0.031
4/5 years 0.29 (0.1-0.8) 0.017
617 years 0.52 (0.2-1.3) 0.152
8/11 years 0.72 (0.3-1.8) 0.471
Number of siblings
I 1.0
2/3 5.0 (0.5-45.5) 0.113
4/5 5.7 (0.5-62.7) 0.15
6/20 6.5 (0.7-60.5) 0.09
Birth order
I 1.0
2/3 1.2 (0.6-2.5) 0.58
4/5 1.1 (0.4-2.9) 0.85
6/20 0.7 (0.2-2.7) 0.58
Palm tree leaf vs. tile 3.07 (1.1-8.2) 0.027
The number of children less than 5 years covered by these health centres varied from 10 to
5000, and the index children less than five years/health worker ranged from IOta 1000 with
a median of 74 children/health worker. All health centres had some kind of educational
material on vaccines available for public information. Most of these materials had been
made by the health worker (18/24) and just one centre had a videotape on vaccines available
for public education. Only two health centres (hospitals in Leticia and Puerto Narifio) had
vaccines in storage at the time of the visit. Vaccine temperature records of the previous
week were reviewed in Leticia and Puerto Narifio, They ranged between 2 and 50 centigrade
with a median of 30 centigrade in both hospitals.
111.1.2. General knowledge on vaccines: Participants correctly identified a median of 8
diseases preventable by vaccination (range 0 to 13), most of them included in the schedule
delivered by the Amazon Health Service. Measles, hepatitis and tetanus were the most
frequently recalled, while Haemophilus influenza, chicken pox and meningococcal diseases
were mentioned the least. They were also asked to recall the age when a child should have
been fully vaccinated. About half of them (14/24) identified it as 12 months of age. Table
4.14 shows in more detail how HW performed on these questions.
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Table 4.14. Description of variables related to general knowledge of vaccines among
HW.
Variable Number %
Name of the vaccine preventable
disease mentioned b~ HW ------_._._--_. __ ....._.
Measles 23 13
Hepatitis 21 12
Tetanus 21 12
Pertussis 19 II
Polio 18 10
TB 17 10
Difteria 16 9
Yellow fever 15 8
Mumps 10 6
Rubella 9 5
Chicken pox 3 2
Meningococcal disease 2
Haemophilus influenza 2
Age when a child should have been
fully vaccinated
6 months 4
12 months 14 58
24 months 4 17
48 months 3 12
60 months 4
U 4
Table 4.15 shows the contraindications mentioned by health workers (HW) for polio, DPT
and HB. They identified as major contraindications body temperature above 38.5°, a history
of febrile convulsions, being born prematurely, and previous reactions to the specific
vaccine. Cough was the only contraindication that varied between vaccines, being
identified as a contraindication for polio vaccine but not for DPT or hepatitis B. All other
contraindications were identified in similar proportion for the three vaccines.
111.1.3. Knowledge on hepatitis B vaccine: All HW knew the number of doses needed to
immunise a child against hepatitis B, but few of them were able to recall the right part of the
body to administer the vaccine (6/24). All of them knew that the third dose of hepatitis B
vaccine should be given regardless of the length of time since the second dose (more than 28
days). However, most of them believed that there were contraindications for hepatitis B
vaccine (19/24) and 18 pathological conditions were mentioned. Fever was the most
frequent contraindication followed by diarrhoea and malnutrition. Table 4.16 shows the
frequencies for these variables.
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For HW the most important diseases in the area were: ARI (mentioned 23 times), diarrhoea
(19 times), dermatitis (7 times) and fever (6 times). Hepatitis B was mentioned just once but
22 HW agreed, when asked, that it was an important cause of disease in their area,
mentioning reasons such as frequency of the disease, severity, infectiousness, preventability
and curability.
111.1.4.Perception of barriers for adequate vaccination coverage by health workers:
Health workers were encouraged to give their own point of view concerning possible
reasons why children in their communities were not completely vaccinated. Some structured
questions asking specific points were used but also two open questions were included.
Barriers perceived by health workers were classified in the following categories: 1)
Logistical or administrative, if HW identified problems concerning inadequate supplies or
shortage of human resources in their area as a cause of no immunisation; 2) Parent related
barriers, such as beliefs about vaccine effectiveness or side effects; 3) Geographical barriers,
if they believed that there were children in their area living too far away to be reached
during vaccination activities; 4) Health worker barriers. This point included barriers arising
from deficiencies in HW performance, such as parent's lack of knowledge about when, how,
and why vaccination activities are carried out in the community.
In the structured questionnaire the most common barriers identified were those related to
parents and geographical barriers. Curiously, most health workers believe that they have
enough supplies to deliver vaccination and they do not perceive lack of cold chain as a
barrier to better vaccination coverage. Instead, in logistical causes they remarked on the lack
of health workers despite the fact that most of these communities were relatively small. In
the unstructured questionnaire, parent's beliefs about vaccines were again the most
important barrier identified. Specifically parent's fear about vaccines collateral effects was
the most important cause of non-vaccination. Tables 4.17 and 4.18
111.2. Relationship between individual vaccination and characteristics of health
workers/centres.
111.2.1. Health worker's perception: In this category the same variables were associated
with not being fully vaccinated or not being completely vaccinated against hepatitis B.
However the relation with hepatitis B coverage was stronger.
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A perception that parent's education or parent's fear were a barrier to vaccination was one
of the strongest predictors of low coverage. In areas where HWs were aware of these
barriers, the chance of being fully vaccinated decreased almost twofold and for HB,
fourfold. Perceiving hepatitis B as an important disease because of its severity, as opposed
to infectiousness, was related to both full vaccination and HB. In those areas where HW did
not perceive hepatitis B as a severe disease, the probability of not being fully vaccinated was
90% higher than in places where it was. The relation to incomplete hepatitis B vaccination
was even larger (OR=3.2 CI95% 1.7-6.0). Both associations remained significantly
associated through the multi variable analysis. Tables 4.19, 4.20, and 4.21
The presence of another health provider was not associated with either full vaccination or
HB, in the bivariate analysis (p=0.18 and p=0.17), but it was identified as an important
protective factor against no vaccination in the multivariable model. Tables 4.20 and 4.21.
Other variables related to poor vaccination were perception concerning children who do not
come to the health centre, lack of time in the health centre for vaccination activities and
parent's lack of time to take children to the health centre. The last two variables did not
remain associated in the multi variable analysis.
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Table 4.15. Symptoms or diseases contraindicating the application of polio, DPT and
hepatitis B vaccines as indicated by the health workers in the study.
Symptom or disease Polio vaccine DPT vaccine Hepatitis B
vaccine
Is temperature < 38.5° a
contraindication?
y 2 4 4
N 21 19 19
Is temperature >38.5° a
contraindication?
y 22 23 23
N 1 0 0
Is being prematurely born a
contraindication?
y 20 20 20
N 3 3 3
Is a history of febrile
convulsion a
contraindication?
y 20 22 21
N 3 1 2
Is a history of non- febrile
convulsion a
contraindication?
y 8 9 8
N 15 14 15
Are familiar antecedents of
epilepsy or convulsion a
contraindication?
y 3 2 2
N 20 21 21
Is a previous reaction to
vaccines a contraindication?
y 20 22 21
N 3 1 2
Is cough a contraindication?
y 15 6 5
N 8 17 18
Is leukaemia a
contraindication?
y 15 15 14
N 8 8 9
Is HIV infection a
contraindication?
y 15 14 14
N 8 9 9
Is diarrhoea a
contraindication?
y 14 14 14
N 9 9 9
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vaccine.
Table 4.16. Description of responses given to questions on knowledge about hepatitis B
Question Number %
Number of doses of hepatitis
B needed to immunise a
child
3 doses 24 100
Body's area where hepatitis B
vaccine should be given.
Arm 1 4
Shoulder 3 12
Buttock 17 72
Tight 3 12
Time between first and second
dose of HB vaccine
I month 24 100
Time between second and third
dose
1-6 months
More than 6 months
U
Is there any contraindication
for hepatitis B vaccine?
y
N
U
How many contraindications
for hepatitis B vaccine do you
know?
o
I
2
3
4-high
U
Name of contraindications
Fever
Diarrhoea
Malnutrition
ARI
Dermatitis
Others
19
4
79
17
4
19
4
79
17
4
I 4
3 12
3 12
4 17
II 46
2 8
16 23
11 16
9 13
8 II
5 7
21 30
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Table 4.17. Barriers against vaccination perceived by health workers. Structured
questionnaire.
Barriers N
1) Logistical
Are there enough supplies to deliver
vaccines in this health centre?
Y 2
N 22
Is there a shortage of health personnel for
vaccine delivery in this health centre?
Y 13
N 9
2) Parents related causes
Do you think that parents do not spare
enough time to get children vaccinated?
Y 21
N 2
3) Geographical
Do you think that in your area some people
live too far to take children to be
vaccinated in the health centre?
Y 14
N 9
4) Health worker related
Do you think that people in your
community do not have enough
information on vaccination activities?
Y 9
N 14
Table 4.18. Barriers against vaccination perceived by health workers. Unstructured
questionnaire.
Barriers Number
1)Logistical
Lack of resources for outreach
vaccination activities
2) Parents related causes
Lack of interest on getting children
vaccinated
Fear of vaccine side effects s
Lack of money
Lack of confidence on vaccine
effectiveness
3) Geographical
Population mobility
4) Health worker related
Lack of information about vaccination
activities
Parent's lack of information on
vaccination benefits
2
5
7
4
2
2
4
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For multi variable models a correlation between "lack of time in health centre" and" having
right to be vaccinated by other health providers" (0.56) was found. To avoid co linearity
they were not included at the same time in the same model. For both dependent variables,
the "presence of other health providers" performed better. The best model for full
vaccination is showed in table 4.20. The final model when "lack of time" was included had
lower F and Log likelihood values. "Lack of time in the health centre" (p=0.399), and
"parent's time" (p= 0.642) were not related to not being fully vaccinated and therefore were
dropped.
Table 4.21 shows the best model for not being vaccinated with hepatitis B. Perception
concerning the importance of hepatitis B could not be dropped from the model despite its
high Wald's p value. (Log likelihood ratio test =21.3 p=O.OOO).
Table 4.19. Health workers' perceptions and individual vaccination.
Variable Fully OR Completely OR (CI95%)
vaccinated (CI95%) vaccinated Incomplete
N(%) Incomplete with HB HB
schedule N(%) vaccination
Are there children in your community P=O.OO2 P=O.OOO
that do not come to the health centre
for vaccination?
y 892 (64) 1.9 (1.3-2.9) 1451 (88) 3.2 (2.4-4.2)
N 104(77) 1.0 179 (96) 1.0
Are there children in your community P=0.18 P=0.17
who have the right to be vaccinated by
another health provider?
y 515(66) 0.8 (0.5-1.1 ) 747 (89) 0.7 (0.4-1.2)
N 411(60) 1.0 763 (85) 1.0
Why do you believe that hepatitis B is P=O.OOI P=O.OOO3
an important disease in your area?
Infectiousness 756 (63) 1.9 (1.3-2.8) 1190 (87) 3.2 (1.7-6.0)
Severity 207 (77) 1.0 366 (95) 1.0
What do you believe is an important P=O.OO7 P=O.OOO
reason for children not being
vaccinated in your area?
Parent education! Parent fear to vaccine 747 (63) 1.8 (1.2-2.8) 1162 (86) 4.1 (3.1-5.3)
side effects
Logistic reasons/ Poverty 120 (76) 1.0 210 (96) 1.0
Do you believe that there is not enough P=O.02 P=O.03
time in the health centre for
vaccination activities?
y 701 (63) 1.5 (1.1-2.2) 1128 (87) 1.9( 1.04-3.4)
N 295 (72) 1.0 502 (93) 1.0
Do you believe that in your community P=O.OO8 P=O.OOO
parents do not spare enough time to
take children to health centre?
y 952 (66) 0.5 (0.3-0.8) 1549 (89) 0.3 (0.2-0.5)
N 44 (47) 1.0 81 (71) 1.0
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Table 4.20. OW's perceptions and not being fully vaccinated. Final model.
Variable OR (CI95%) p
Are there children in your community who
have the right to be vaccinated by another
health provider'?
y 0.41 (0.3-0.60) <0.001
Why do you believe that hepatitis B is an
important disease in your area?
Infectiousness 2.65 (0.8-8.5) 0.099
Severity 1.0
What do you believe is an important reason
for children not being vaccinated in your
area?
Parent education/parent's fear 2.55 (1.7-3.9) <0.001
Logistic/poverty 1.0
Are there children in your community who do
not come to the health centre?
y 2.1 (1.6-2.8) 0.01
Children's age
I 1.0
2/3 0.18 (0.1-0.3) <0.001
4/5 0.13 (0.1-0.2) <0.001
6/7 0.13 (0.1-0.2) <0.001
8/11 0.16 (0.1-0.3) <0.001
Table 4.21. OW's perception and not being vaccinated against hepatitis B. Final model.
Variable OR (CI95%) p
What do you believe is an important
reason for children not being
vaccinated in your area?
Logistic reasons/poverty 1.0
Parent's fear to vaccine side 11.0 (8.2-15.5) <0.001
effects/parent's education
Are there children in your community
who have the right to be vaccinated
by another health provider?
y 0.32 (0.2-0.5) <0.001
Are there children in your community
that do not come to the health centre
for vaccination?
y 6.90 (4.9-9.6) <0.001
Why do you believe that hepatitis B is
an important disease in your area?
Infectiousness 3.74 (0.4 -36.6) 0.252
Severity 1.0
Children's age
I year 1.0
2/3 years 0.35 (0.2-0.6) <0.001
4/5 years 0.29 (0.2-0.6) <0.001
6/7 years 0.65 (0.3-1.3) 0.212
8/11 years 0.68 (0.4-1.2) 0.209
III
111.2.2.Variables related to nw's knowledge on vaccines: Unexpectedly, the "number of
correct answers on general knowledge about immune preventable diseases" was inversely
related to full vaccination coverage, which decreases when the number of correct answers
increase. On the other hand, "number of polio and OPT contraindications'' are inversely
related to full vaccination coverage, which is higher where HW mentioned less
contraindications.
For hepatitis B coverage, fewer knowledge variables were related to coverage. The number
of correct answers on general knowledge is again negatively associated with hepatitis B
coverage. In places where HW had more correct answers there were few children with
complete vaccination against hepatitis B. On the other hand, the effect of contraindications
was very specific for hepatitis B. Only contraindications for hepatitis B vaccine were related
to its coverage, and a stronger relation was observed for the nominal version of the variable
("Is there any contraindication.")
There was strong correlation between variables in this category. Contraindications against
polio, OPT and hepatitis B correlated between them (>0.90), and only "number of
contraindications against polio" was included in further analysis. There was also correlation
between "number of correct answers on general knowledge" and "polio contraindications"
(0.69).
For multi variable modelling of not being vaccinated against hepatitis B, the variables
selected were: "general knowledge", "number of contraindications against hepatitis B
vaccine" mentioned spontaneously and if the health worker considered that there was any
contraindication for hepatitis B (YIN). The last two variables were strongly correlated (0.82)
and were not included together in the same model. The final model including the "number of
contra HB" had a larger Log likelihood model (LL= -587.23 vs. LL= -614.24) than the
model with the nominal version (YIN). Table 4.24
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Table 4.22. Vaccination coverage in relation to health worker's knowledge.
Variable Fully OR Completely OR (CI95%)
vaccinated (CI95%) vaccinated Incomplete HB
N (%) Incomplete with HB vaccination
schedule N(%)
Number of correct answers on P=O.OOO P=O.OOO
general knowledge about
immune preventable diseases
0/2 145 (81) 1.0 227 (95) 1.0
3/4 911 (64) 2.39( 1.8-3.1) 1481 (88) 3.0 (2.1-4.2)
Number of correct answers on P=O.07 P=0.32
hepatitis B vaccine
3 60 (84) 1.0 78 (94) 1.0
4/5 787 (65) 2.9 (2.3-3.6) 1219 (88) 2.1 (1.6-2.8)
6n 209 (64) 3.0 (2.0-4.6) 411 (91) 1.5 (0.7-3.5)
Number of polio vaccine P=O.OO4 P=0.31
contraindications mentioned.
0 60 (84) 1.0 78 (94) 1.0
1/3 155 (76) 1.7 (1.3-2.2) 253 (92) 1.31 (0.6-2.9)
4/5 146(59) 3.8 (2.5-5.7) 269 (85) 2.8 (1.3-6.2)
6/9 695 (64) 3.0 (2.4-3.8) 1108 (88) 2.0 (1.6-2.5)
Number of DPT vaccine P=O.02 P=0.57
contraindications mentioned.
0 60 (84) 1.0 78 (94) 1.0
2/5 301 (67) 2.7 (1.8-4.0) 522 (88) 2.1 (1.1-4.0)
6/9 695 (64) 3.0 (2.4-3.8) 1108(88) 2.0 (1.6-2.6)
Is there any hepatitis B vaccine P=0.73 P=O.OOOI
contraindication ?
y 881 (65) 1.1 (0.7-1.6) 1391 (88) 3.5 (1.8-6.7)
N 115 (66) 1.0 239 (96) 1.0
Number of hepatitis B vaccine P=0.32 P=O.07
contraindications mentioned
spontaneously
0 80 (64) 1.0 178 (96) 1.0
2/3 193 (58) 1.3 (0.6-2.8) 340 (82) 4.9 (1.6-14.8)
4/5 688 (67) 0.9 (0.5-1.6) 1051 (89) 2.6 (1.1-6.4)
Number of contraindications P=0.13 P=0.57
mentioned for hepatitis B aside
polio and DPT
0 60 (84) 1.0 78 (94) 1.0
2/5 301 (67) 2.7 (1.8-4.0) 522 (88) 2.0 (1.1-4.0)
6/9 695 (64) 3.0 (2.4-3.8) 1108 (88) 2.0 (1.6-2.6)
The multivariable modelling of not being fully vaccinated included the following variables:
"children's age", "number of correct answers on hepatitis B", "contraindications for polio",
and "general knowledge". The last two variables were not included together in the same
model due to their correlation. Table 4.23 shows the results when "contraindications for
polio" are included. "Number of right answers" was dropped from the model because its
relation to not being fully vaccinated lost significance (p=O.92). In the model including
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correct answers on general knowledge, all variables remained significantly associated:
"children's age" (p<O.OOl), "number of correct answers on general knowledge" (p<O.OOI),
and "number of correct answers on hepatitis B vaccine" (p=O.02). Both variables, "contra
polio" and "general knowledge", were kept for further muItivariable modelling with selected
variables from other categories.
Table 4.23 HW knowledge and not being fully vaccinated. Final model when
considering polio contraindications.
Variable OR P
Number of polio
contraindications
0 1.0
1/3 1.85 (1.3-2.6) 0.001
4/5 3.80 (2.1-6.8) <0.001
6/9 2.7 (2.2-3.3) <0.001
Children's age
I 1.0
2/3 0.21 (0.1-0.3) <0.001
4/5 0.14 (0.1-0.2) <0.001
617 0.15 (0.1-0.2) <0.001
8/11 0.18 (0.1-0.3) <0.001
Table 4.24. HW knowledge and incomplete vaccination against hepatitis B.
Variable OR p
Number of hepatitis B vaccine
contraindications mentioned
spontaneously
o
2/3
4/5
Age (years)
I
2/3
4/5
6/7
8/11
Number of correct answers on
general knowledge about immune
preventable diseases
0/2
3/4
1.0
7.78 (3.1-19.5)
2.69 (1.1-6.7)
<0.001
0.034
1.0
0.34 (0.2-0.6)
0.28 (0.1-0.5)
0.59 (0.3-1.1)
0.62 (004-1.1 )
<0.001
<0.001
0.102
0.115
1.0
7.03 (5.0-9.9) <0.001
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111.2.3.Variables related to geographical or general health centres characteristics.
Logistical barriers represented by "rejection of children looking for vaccination" showed
some relation to not being fully vaccinated (OR=1.6 CI95% 0.9-2.8) and a more strong
association with not being hepatitis B vaccinated (OR=2.7 CI95% 1.2-5.8). An interesting
relation was observed between "time working in the HC" and vaccination coverage (full or
HB). In communities where HW had more than 14 years of continuous work, the likelihood
of not being fully or HB vaccinated decreased by a half approximately (OR=0.6 CI95% 0.4-
0.8 and OR=O.4 CI95% 0.3-0.7). Table 4.25
Geographical variables influenced the likelihood of not being vaccinated fully or against
hepatitis B. The worst coverage was- observed in villages located on the Loretoyaco river
shores and the effect was stronger for hepatitis B vaccine. The highest coverage was
observed in villages located on the Caqueta River.
Statistical correlation was found between the -following variables:
"Number of health workers (HW) in the health centre" and "time working as health
professional" (0.51).
"Number of health workers in the health centre (HC)" and "time working in the
health centre" (0.64).
"Time working in the health centre" and "time working as a health professional"
(0.87). In further multi variable models only "time in the health centre" was included
because its relation to not being fully vaccinated was stronger.
For not being fully vaccinated, "number of HW" and "time in the HC" were not included
together in the same model. The best model was obtained with the set of variables including
"number of health workers" shown in table 4.26. However, "time in the health centre"
remained significantly related to not being fully vaccinated even after controlling by
"geographical situation" and "children's age" (OR=0.47 IC95% 0.33-0.68). Therefore it was
taken into account for the final models combining all ecological variables
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Table 4.25. Vaccination coverage in relation to geographical or health centres
characteristics.
Variable Fully OR (CI95%) Complete OR (CI95%)
vaccinat Incomplete HB Incomplete
ed vaccination vaccination HB
N(%) N(%) vaccination
Have children looking for P=0.12 P=O.Ol
vaccination in the last
month been rejected due to
lack of supplies?
y 793 (64) 1.6 (0.9-2.8) 1248 (87) 2.7 (1.2-5.8)
N 180 (73) 1.0 347 (95) 1.0
Geographical village's P=O.II P=O.OOO7
situation
Amazon river 942 (66) 1.0 1462 (89) 1.0
Caqueta river 47 (68) 0.93 (0.3-2.5) 104 (98) 0.15 (0.1-0.3)
Loretoyaco river 34 (46) 2.2 (0.9-5.5) 68 (72) 3.2 (1.5-7.0)
Number of health workers P=O.OO8 P=0.25
in the health centre
I 443 (69) 1.0 725 (89) 1.0
14117 98 (45) 2.8 (1.7-4.6) 236 (82) 1.8 (0.8-4.1)
100 515 (66) 1.2 (0.7-1.8) 747 (89) 0.9 (0.5-1.8)
Number of nurses in the P=0.23 P=0.84
health centre
0 443 (70) 1.0 725 (89) 1.0
113 613 (64) 1.3 (0.8-2.0) 983 (88) 1.1 (0.6-2.0)
Time working as health P=O.02 P=O.03
professional
0114years 269 (56) 1.0 524 (83) 1.0
15/21 years 787 (68) 0.6 (0.4-0.9) 1184 (90) 0.5 (0.3-0.9)
Time working in the health P=O.OO5 P=O.OOI
centre
0114years 312(56) 1.0 593 (82) 1.0
15/21 ~ears 744 (69) 0.58 (0.4-0.8) 1115(91) 0.4 (0.3-0.7)
For hepatitis B vaccination, a correlation was detected between "time in the health centre"
and "time as a health worker", and only the first was included in multivariable models. The
final model is shown in table 4.27. "Logistic impairments" and "time working in the health
centre" remained strongly associated with hepatitis B vaccination while "living on the
Loretoyaco River" became not statistically associated.
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Table 4.26. Health centres geographical and general characteristics and their
relationship to not being fully vaccinated.
Variable OR (CI95%) p
Have children looking for
vaccination in the last month been
rejected due to lack of supplies?
y 1.80 (1.0-3.0) 0.036
Children's Age
I 1.0
2/3 0.18 (0.1-0.3) <0.001
4/5 0.12 (0.1-0.2) <0.001
617 0.12 (0.1-0.2) <0.001
8111 0.16 (0.1-0.2) <0.001
Number of health workers in the
health centre
I 1.0
14/17 3.14 (1.9-5.3) <0.001
100 0.84 (0.6-1.3) 0.426
Geographical village's situation
Amazon river 1.0
Caqueta river 1.06 (0.6-1.9) 0.851
Loretoyaco river 2.31 (1.0-5.6) 0.063
Table 4.27. Health centres geographical and general characteristics and their relation
to not being vaccinated with hepatitis B. Final Model.
Variable OR (CI95%) p
Have children looking for
vaccination in the last month been
rejected due to lack of supplies?
y 2.71 (1.1-6.5) 0.025
Children's Age
I 1.0
2/3 0.33 (0.2-0.6) <0.001
4/5 0.25 (0.1-0.5) <0.001
617 0.54 (0.3-1.0) 0.061
8/11 0.55 (0.3-1.0) 0.050
Geographical village's situation
Amazon river 1.0
Caqueta river 0.11 (0.04-0.3) <0.001
Loretoyaco river 1.51 (0.6-3.6) 0.352
Time working in the health centre
0/14 years 1.0
15/21 years 0.37 (0.2-0.6) 0.001
111.2.4.Models combining significant ecological variables:
Not being fully vaccinated: The following variables were selected for models combining
ecological variables:
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a) Perceptions: "Having right to be vaccinated by other health providers", "reasons
for children not being vaccinated", and "reasons for hepatitis B importance".
b) Knowledge: "Number of polio contraindications".
c) General characteristics of HC: "Geographical situation", "rejecting a child due
to lack of supplies" and "number of years working in the health centre".
"Having right to other health providers" was correlated with "number of polio
contraindications" (0.66) and with "number of years in the health centre" (0.91). None of
these variables were considered together in the same model; instead, two sets of variables
were constructed. One set included: "Children's age", "Having right to be vaccinated by
other health providers", "reasons for children not being vaccinated", "geographical
situation", and "rejecting a child due to lack of supplies". "Geographical situation" was
dropped from this model due to lack of significance (p=O.72). Table 4.28 shows the final
results of this set.
Table 4.28. Model combining knowledge, perceptions, geographical, and general
characteristics of health centres and not being fully vaccinated. First set.
Variable OR (CI95%) P
Children's age
I 1.0
2/3 0.32 (0.2-0.5) <0.001
4/5 0.23 (0.1-0.4) <0.001
6n 0.23 (0.1-0.4) <0.001
8/11 0.28 (0.2-0.5) <0.001
Have children looking for vaccination in the
last month been rejected due to lack of
supplies?
y 2.33 (0.9-5.9) 0.08
Are there children in your community who
have the right to be vaccinated by other health
providers?
y 0.41 (0.3-0.6) <0.001
What do you believe is an important reason for
children not being vaccinated in your area?
Logistic reasons/poverty 1.0
Parent's fear to vaccine side effects/parent's 2.30 (1.5-3.4) <0.001
education
The second set included: "Children's age", "number of polio contraindications", "reason for
children not being vaccinated", "rejecting a child due to lack of supplies", "number of years
working in the health centre", and "reason for hepatitis B importance". "Reason for children
not being vaccinated" and "reason for hepatitis B importance" were dropped from the model
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(p=0.698 and p=0.702). "Rejecting a child due to lack of supplies" had to be excluded
because it introduced some degree of co linearity between the categories of "contra polio".
Table 4.29 shows the final result for this group.
Table 4.29. Model combining knowledge, perceptions, geographical, and general
characteristics of health centres and not being fully vaccinated. Second set
Variable OR (CI95%) p
Children's age
1 1.0
2/3 0.33 (0.2-0.5) <0.001
4/5 0.22 (0.1-0.4) <0.001
617 0.24 (0.2-0.4) <0.001
8111 0.27 (0.2-0.4) <0.001
Number of polio contraindications
0 1.0
1/3 1.54 (1.2-2.0) <0.001
4/5 2.25 (1.6-3.1 ) <0.001
6/9 2.10(1.7-2.6) <0.001
Time working in the health centre
0114 years 1.0
15/21 years 0.50 (0.4-0.7) <0.001
Summarizing, variables from every area (HW's perceptions, HW's knowledge and health
centres) were related to not being fully vaccinated and the magnitude of their relation was
similar. Some variables increased the risk of not being fully vaccinated: Perceiving that
parent's fear was a major barrier for children's vaccination (OR=2.3 CI95% 1.5-3.5),
logistical shortcomings represented in children's rejection (OR=2.3 CI9S% 0.9l-S.9), and
number of polio vaccine contraindications mentioned by HW (the OR increased above 2.0
when more than 3 contraindications were mentioned). The protective factor was the
presence of a health provider other than the Amazon Secretary of Health in the community
(OR=0.41 CI95% 0.28-0.61). These ecological variables were selected for further analysis
combined with individual variables.
Incomplete Hepatitis B vaccination:
The following variables were selected:
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a) Perceptions: "Having right to be vaccinated by other health provider", "reasons
for children not being vaccinated", and "reasons for hepatitis B importance".
b) Knowledge: "Number of hepatitis B vaccine contraindications" (categorical)
and "whether or not hepatitis B contraindications existed" (YIN).
c) General health centres characteristics: "Rejecting a child due to lack of
supplies" and "number of years working in the health centre".
There was a correlation between the knowledge variables (0.78); the nominal variable was
used in the analysis rather than the categorical because the latter correlated strongly with
two other variables: "having right to be vaccinated by other health providers" (0.65) and
"number of years in the HC" (0.68). The first also correlated with "reason for children not
being vaccinated" (0.82). "Rejecting a child due to lack of supplies" correlated to "reasons
for hepatitis B importance" (0.80).
Two sets of variables were constructed to avoid co linearity. One contained "children's
age", "having right to another health provider", "reason for children not being vaccinated",
and "reason for hepatitis B importance". All of them were associated with not being
vaccinated against hepatitis B. The higher p value was achieved by "reason for hepatitis B
importance", but it could not be removed from the model (Log likelihood ratio test:
Chi2=20.07, P=O.OOO)."Reasons for hepatitis B importance" was replaced by "rejecting a
child" and, again, all variables remained associated with not being hepatitis B vaccinated.
The second set of variables contained: "children's age", "having right to another health
provider", "considering that there are contra indications for HB", and "reasons for hepatitis
B importance". "Having right to another health provider" was replaced by "number of years
working in the health centre" and this variable was also significantly related to not being
vaccinated against hepatitis B (OR=0.37 CI95% 0.23-0.61). The strongest relation was
found with "hepatitis B contraindications" (OR=7.2 CI95% 3.9- 13.0) followed by the
"perception about the reason for hepatitis B importance" (OR=3.5 CI95% 1.2-10.1). Table
4.30.
Summarizing, there were ecological variables associated with both not being fully
vaccinated and with incomplete hepatitis B vaccination. "Rejecting a child looking for
vaccination" (logistical), "reasons for children not being vaccinated" (perception), "vaccines
120
contraindication" (knowledge), and "number of years working in the health centre" were
associated with both dependent variables. Reason for hepatitis B importance was only
associated with not being completely vaccinated against hepatitis B.
Table 4.30. Model combining knowledge, perceptions, health centres geographical and
general characteristics, and not being vaccinated against hepatitis B.
Variable OR (CI95%) P_._--------_
Children's age
I 1.0
2/3 0.36 (0.2-0.6) <0.001
4/5 0.29 (0.2-0.6) <0.001
617 0.65 (0.3-1.3) 0.199
8/11 0.63 (0.4-1.2) 0.134
Why do you believe that hepatitis
B is an important disease in your
area?
Infectiousness 3.5 (1.2-10.1) 0.018
Severity 1.0
Are there children in your
community who have the right to
be vaccinated by another health
provider?
y 0.42 (0.2-0.7) 0.002
Is there any hepatitis B
contraindication vaccine
y 7.16 (3.9-13.0) <0.001
N 1.0
IV. Models combining ecological and individual variables and not being fully
vaccinated: The following variables were included in these models:
Individual variables:
Children's age by categories.
Study area.
Name of the ethnic group.
Being affiliated to the Health Security System.
Ecological variables:
Number of polio contraindications polio by categories.
Rejecting a children looking for vaccination due to lack of supplies.
Reasons for children not being vaccinated.
Number of years working in the Health Centre.
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Having right to be vaccinated by another health provider.
"Study area" correlated with three ecological variables, "polio vaccine contraindications"
(0.63), "other health providers in the community" (0.80), and "number of years working in
the health centre" (0.79). Therefore, "study area" was kept out of the analysis. Other
correlations were found between:
"Number of polio contraindications" with "other health providers in the community" (0.59).
"Number of years working in the health centre" with "other health providers in the
community" (0.83).
Two sets of variables were constructed in order to avoid co linearity. One set included all
individual variables (except study area) plus "rejecting a child", "other health providers",
and "reasons for not vaccinating". The other one included the same individual variables plus
"contra polio", "number of years working in the health centre", and "rejecting a child due to
lack of supplies".
Interestingly, all variables in both categories remained associated in both sets. The strongest
association was observed for logistical troubles (children rejection) (OR=3.0 in one set and
OR=1.6 in the other one). Another strong association was observed with "number of years
working in the health centre" (OR=0.4 CI95% 0.3-0.58) when HW had more than 15 years
in post. Both indicators of better health security coverage (ecological and individual) were
associated with not being fully vaccinated though the ecological variable shows a stronger
relation (OR=0.32 vs. OR= 1.55/1.45). Tables 4.31 and 4.32.
An attempt to drop "number of polio contraindications" from the model in table 4.32 was
done, but its contribution to the overall model was at the border line of statistical
significance (Log likelihood test: Chi2=5.72, p=0.057) and therefore it was kept in the
model. There was a large number of missing values mainly due to the influence of the
variable "being affiliated to the social security" (- 400 observations). Therefore, a new
category of this variable was created to evaluate whether this loss of information influenced
the results in models 4.31 and 4.32. The new variable was introduced in both models but no
major changes in the magnitude of the associations was observed for any variable, though p
values became lower and Cl became narrower (number of observations jumped from 747 to
1203 and from 951 to 1460 respectively).
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Table 4.31. Individual and ecological variables and their relationship to not being fully
vaccinated. First set. Final model
Variable OR (CI95%) p____ o___ •• _
1.0
0.17 (0.1-0.3) <0.001
0.11 (0.05-0.2) <0.001
0.10 (0.05-0.2) <0.001
0.18 (0.1-0.3) <0.001
1.0
0.39 (0.2-0.9) 0.022
2.0 (0.8-5.2) 0.151
0.84 (0.5-1.6) 0.585
0.53 (0.3-1.0) 0.062
1.55 (1.0-2.4) 0.053
Age
1
2/3
4/5
6/7
8/11
Ethnic group
No Indians
Mestizos
Huitotos
Ticunas
Other groups
Affiliated to social security
N
Are there in your community
children who have the right to be
vaccinated by other health
providers?
y
Have children looking for
vaccination in the last month been
rejected due to lack of supplies?
y
What do you believe is an
important reason in your
community for children not being
fully vaccinated?
Parent's educationlParent's fear
Logistic
0.32 (0.2-0.6) <0.001
3.0 (1.5-6.0) 0.002
2.25 (1.3-3.9)
1.0
0.004
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Table 4.32. Individual and ecological variables and their relation to not being fully
vaccinated. Second set. Final model
Variable pOR (CI95%)
Age
I
2/3
4/5
6n
8/11
Ethnic group
No Indians
Mestizos
Huitotos
Ticunas
Other groups
Affiliated to social security
N
Number of polio contraindications
o
1/3
4/5
6/9
Have children looking for
vaccination in the last month been
rejected due to lack of supplies?
y
Number of years working in the
health centre
0/14
15/21
1.0
0.18 (0.1-0.3)
0.10(0.1-0.2)
0.10 (0.1-0.2)
0.17 (0.1-0.3)
1.0
0.51 (0.3-0.9)
1.7 (0.9-3.1)
1.04 (0.6-1.8)
0.48 (0.3-0.9)
1.45 (1.0-2.1)
1.0
Dropped
1.38 (0.8-2.3)
1.35 (0.8-2.2)
1.6 (1.0-2.4)
1.0
0.43 (0.3-0.6)
<0.001
<0.001
<0.001
<0.001
0.036
0.091
0.868
0.020
0.050
0.198
0.190
0.040
<0.001
v. Models combining ecological and individual variables and not being hepatitis B
vaccinated.
The following variables were included:
Individual:
Children's age.
Number of siblings.
Birth order.
Study area.
Ecological:
Having right to be vaccinated by another health provider.
Reason for children not being vaccinated.
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Reason for hepatitis B importance.
Rejecting a child due to lack of supplies.
Contraindicarions for hepatitis B vaccine (YIN).
Number of years working in the health centre.
Strong correlation between variables was detected as follows:
"Study area" correlated with "having right to be vaccinated by another provider" (0.83) and
with "number of years in the He" (0.82).
"Having the right to another health provider" correlated with "number of years working in
the He" (0.82).
"Reasons for children not being vaccinated" correlated with "contraindication for hepatitis
B vaccine" (0.81).
"Reasons for hepatitis B importance" correlated with "rejecting a child due to lack of
suppJies". (0.83).
Variables were divided in two sets. One included: "children's age", "number of siblings",
"having right to another health provider", "reason for children not being vaccinated" and
"reason for hepatitis B importance". The other one included: "children's age", "number of
siblings", "number of years working in the He", "existence of contraindications for hepatitis
B" and "rejecting a child due to lack of supplies".
From the first set of variables. "reasons for hepatitis B importance" was dropped (p=0.590)
and no variable could be dropped in the second set. Results for both sets are shown in tables
4.33 and 4.34. There were variables related to both inadequate hepatitis B vaccination and
with not being fully vaccinated. Variables that increased the risk of not being vaccinated
were: "Perceiving parents' education or parents' fear of vaccination side effects" (OR=8.0
eI95% 4.8-13.3), "logistical shortcomings", and "rejecting children", (OR=3.2 CI95% 1.8-
5.5). The variables that reduced the risk of inadequate vaccination for hepatitis B were:
"presence in the community of more health providers" (OR=0.5 eI95% 0.3-0.9) and "time
working in the health centre" (>14 years). The only variable related to hepatitis B
vaccination that was not associated with full vaccination was "number of siblings" that
remained associated in both models though the effect was slightly lower in the second set.
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Table 4.33 Ecological and individual variables and their relationship to not being
vaccinated against hepatitis B. First set. Final model
______ ....:.V.=ar:_:i::::ab::,:l:.::_e _::O:_:R::..=(CI95%L Y- ._..
Age
I
2/3
4/5
617
8111
Number of siblings
I
2/3
4/5
6/20
Birth order
I
2/3
4/5
6/20
Are there in your community children
who have the right to be vaccinated by
another health provider?
y
What do you believe is an important
reason in your community for children
not being fully vaccinated?
Parent's education/Parent's fear
Lo istic
1.0
0.21 (0.1-0.4) <0.001
0.15 (0.1-0.3) <0.001
0.29 (0.1-0.6) 0.001
0.32 (0.2-0.6) 0.003
1.0
2.6 (0.8-8.0) 0.09
4.2 (1.2-14.6) 0.024
4.00.1-14.5) 0.037
1.0
1.0 (0.6-1.7) 0.93
0.7 (0.3-1.5) 0.41
0.5 (0.2-1.6) 0.26
0.48 (0.3-0.9) 0.014
8.1 (4.8-13.5)
1.0
<0.001
Table 4.34. Ecological and individual variables and their relation to not being
vaccinated against hepatitis B. Second set. Final model
Variable OR (CI95%) p
1.0
0.23 (0.1-0.4) <0.001
0.16 (0.1-0.3) <0.001
0.26 (0.1-0.5) <0.001
0.33 (0.2-0.6) <0.001
1.0
2.8 (0.9-8.6) 0.06
3.3 (1.0-10.5) 0.05
2.8 (0.8-9.1) 0.09
1.0
1.1 (0.6-1.9) 0.78
1.1 (0.5-2.4) 0.15
0.8 (0.3-2.4) 0.72
1.0
0.38 (0.2-0.6) <0.001
2.3 (1.1-5.1) 0.03
1.0
Age
I
213
4/5
617
8111
Number of siblings
I
2/3
4/5
6120
Birth order
I
2/3
4/5
6/20
Time working in the health centre
0114
15/21
Is there any hepatitis B
contraindication
y
N
Have children looking for vaccination
in the last month been rejected due to
lack of supplies
y
N
3.2 (1.8-5.5)
1.0
<0.001
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Chapter 5: Serological results.
Summary. Among 2145 children aged I to eleven years examined, the overall prevalence of
HBV infection was 6.2% (95%CI 4.7-7.9) while the prevalence of HBsAg+/anti-HBc+ was
1.1% (95%CI 0.4-1.8%). Prevalence of infection and HBsAg+/anti-HBc was higher in rural
than urban areas (9.2% and 2.6% versus 2.6% and 0.17%). Infection and prevalence of
HBsAg+/anti-HBc+ was also higher in children 8 years and older especially among girls.
There has been a reduction in the prevalence of HBV infection and HBsAg+ of between
60% to 75% since the vaccine was introduced, especially in the most endemic areas such as
Araracuara .. Factors related to HBV infection and to being HBsAg+/anti-HBc were divided
into child-related, mother-related, and vaccine-related (time from birth to first dose and time
between doses).
For HBV infection the most important child-related variables were: belonging to an ethnic
group different to Ticunas or Huitotos (OR=4.6 95%CI 2.4-8.6), belonging to Ticunas
(OR=2.4 95%CI 1.2-4.6), and not being born in a hospital or health centre (OR=2.4 95%CI
1.5-4.1). Among the mother-related variables the most important association was found with
being born to an Anti-HBc+ mother (OR=1.7 95%CI 1.1-2.6). None of the vaccine-related
variables was found associated with being HBV infected. The most important child-related
variables associated with HBsAg+/anti-HBc+ were: not being born in a hospital or health
centre (OR=6.5 95%CI 1.5-2.7.6) and living with more than 5 siblings (OR=3.3 95%CI 1.1-
10.0). The most important mother-related variable was being born to an Anti-Hbc+ mother
(OR=3.5 95%CI 1.0-11.8). Time from birth to first dose of HBY vaccine was related to
being HBsAg+/anti-HBc+ even after controlling for mother and child-related variables.
Receiving the first dose of vaccine two months or later after birth was related with an
increase in the risk of being HBsAg+ especially among those who received it after 2 years of
life (OR= 12.5 95% Cl 1.2-125.7). Time between first and second dose was related with
being HBsAg+/antiHBc+ only in rural areas. Receiving the second dose 35 days after the
first was associated with a two fold risk of being HBsAg+ (OR=2.3 95%CI 1.4-3.8)
In a sample of 481 children HBsAg-/antiHBc- we quantified levels of anti-HBs. We found
that 23% of them did not have detectable anti-HBs while anti-HBs levels ranged from 0 to
10,000 mIU/ml. The GMT and the median of anti-HBs were 66 mIU/ml and 123 mIU/ml
respectively. 13% of the children had anti-HBs levels above 1,000 mIU/m!. The variables
related to lack of detectable anti-HBs were "time from third dose to sampling" and "time
from birth to first dose of HBY". Children who received the first dose within 14 days from
birth had lower levels of anti-HBs (GMT=33 mIU/ml vs. 66 to 174 among the other groups)
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I. General description of HBV infection prevalence.
For serological studies, 2145 children aged I to II years were bled. The median age was 6
years while 52% were males. Hepatitis B (HBV) infection prevalence was 6.2% (95% Cl
4.7-7.9%) which corresponded to 138 children with positive results for either, HBsAg or
anti-HBc. For anti-HBc, 124 children were positive (5.8%, 95% Cl 3.7-6.9%), for HBsAg,
39 (1.7%, 95% Cl 1.0-2.4%), and 25 (1.1%, 95% Cl 0.4-1.8%) were positive for both
markers. Hepatitis delta antibody was tested on 34 children with positive results for HBsAg
or anti-HBc and 4 were positive (12%,95% Cl 3.9-28.4%).
In urban areas 1104 children were studied. For anti-HBc, 29 were positive (2.6%, 95% Cl
1.5-4.2%), for HBsAg, 8 (0.8% 95% er 0.4-1.5%), for both markers, 2 (0.17% 95% Cl 0.01-
1.2), and 35 for at least one of them (3.3%, 95% Cl 2.3-4.7%). In rural areas, 1041 children
were bled. Prevalence for all markers was statistically higher in rural than in urban areas.
For anti-HBc, 95 were positive (9.2%, 95% Cl 7.0-12%), for HBsAg, 31 (2.7%,95% Cl 1.7-
4.4%), for both marker, 23 (2.6%, 95% Cl 1.4-4.6%), and for at least one of them, 103
(10.3%,95% Cl 8.2-13.0%).
The prevalence of anti-HBc was analysed by area and age. Figure 5.1 showed that this
prevalence was higher in rural areas in all categories of age. The increase in prevalence
started from six years of age in rural areas and from about 8 years in urban areas. In rural
areas there was a considerable increase from 10 years to 11 and 12, as prevalence jumped
from around 10% to more than 20%. This increase is less noticeable in urban areas.
Figure 5.1. AntiHBc prevalence by age and area
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A difference in anti-HBc prevalence by sex was observed. Overall, 68 out of 1007 girls were
positive (6.1%, 95% Cl 3.4-6.5%) while among boys there were 56 out of 1105 (4.7%,95%
Cl 4.3-8.4%), p=0.056. In rural areas, the statistical difference became wider because girls
had a prevalence of 10% (53/498) and boys 7.7% (42/532), p=O.OI. On the other hand, no
important difference was observed in urban areas (2.8% in girls and 2.4% in boys). Figure
5.2 shows the trend of the anti-HBc prevalence by age and sex in rural areas. Females were
more likely to be positive than males, especially after 10 years of age.
Figure 5.2. AntiHBc prevalence in rural areas by age and sex
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HBsAg prevalence was analysed by age and area following two approaches. First, all
children with available serological data (n=]881) in each area were included in the
denominator and HBsAg+/anti-HBc+ children were included in the numerator. Figure 5.3
shows the results using this method. Two peaks of HBsAg prevalence can be observed. The
smaller one in children aged 3 to 5 years while the larger is seen in children 9 years old and
older. The increase with age is clearly sharper in rural than in urban areas. As for the second
approach, only anti-HBc+ children were in the denominators to calculate HBsAg prevalence
(n=124). Figure 5.4 shows the results that resembled those observed in figure 5.3; however,
a decrease in the HBsAg prevalence is observed at age II in contrast with the increase
observed with the first approach.
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Figure 5.3. HBsAg prevalence by age and area. All children
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Figura 5.4. HBsAg prevalence by age and area. Only AntiHBc +.
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With the first approach no difference was observed in HBsAg prevalence by sex. In both
groups the prevalence was 1.1% and this did not vary when the area was taken into the
analysis. In rural areas, prevalence was 2.3% for both groups while in urban areas it was
0.2%. When age and rural area were taken into account an interesting pattern arose. The first
peak of HB Ag prevalence occurs in males only, while the second and most important rise is
in both genders. It is important to note that females tend to have a higher prevalence than
males at age 7,9, and II. Figure 5.5.
Figure 5.6 show the result when only anti-HBc+ children are included in the denominator.
Again, a peak in the male HBsAg prevalence wa observed at age 3, which coincided with
the trend observed in figure 5.5. A higher prevalence in girls at age II was observed as well.
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Figure 5.5. HBsAg prevalence in rural areas by age and sex. All Children.
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Figure 5.6. HBsAg prevalence in rural areas by age and sex. Only AntiHBc+
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II. Overall impact of hepatitis B vaccine in the Amazon:
Compared with data taken from Cristancho 1995, there has been an important reduction in
both infection and prevalence of HBsAg. Reduction in infection is greater in children 5-9
than in children 10-14 years. The largest reduction in infection is observed in children 5-9
years old in Araracuara (77%), while, in general, no reduction was observed in HBsAg
prevalence for children aged 10-14. This lack of effect is observed for both genders but it is
especially marked for females among whom HBsAg prevalence seems to be higher than
before vaccine introduction. Table 5.].
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Table 5.1. Prevalence of hepatitis B infection and HBsAg found before and after the
introduction of hepatitis B vaccine by age group and place.
Variable % Prevalence before % Prevalence after % Reduction
vaccination * (n) vaccination (n)** (95% Cl)
Overall
Children 5-9 years. Infection 32lk (334) 9% (493) 72 (59-78)***
Children 10-14. Infection 66% (189) 25%(160) 62 (49-72)***
Male children 5-9 years. Infection 34% (157) 9% (247) 73 (59-83)***
Female children 5-9 years. Infection 30% (177) 10% (246) 67 (48-78)***
Male children 10-14 years. Infection 85% (144) 19% (87) 78 (64-85)***
Female children 10-14 years. Infection 76% (135) 32% (72) 58 (40-70)***
Children 5-9 years. HBsAg + 7% (334) 2% (495) 71 (35-84 )***
Male children 5-9 years. HBsAg + 8%(157) 2% (247) 75 (26-90)***
Female children 5-9 years. HBsAg + 6%(177) 2% (248) 67 (-3-85)
Children 10-14 years. HBsAg + 9% (279) 10% (161) -II (-58-52)
Male children 10-14 years. HBsAg + 10% (144) 6% (87) 48 (-46-79)
Female children 10-14 years. HBsAg + 7% (135) 15% (73) -114 (-205-0.8)
Araracuara and Puerto Santander
Children 5-9 years. Infection 39% (Ill) 9% (125) 77 (54-86)***
Children 10-12 years. Infection 87% (75) 28% (75) 68 (53-78)***
Children 5-9 years. HBsAg + 9% (111) 2%(125) 73 (6-93) E
Children 10-12 years. HBsAg + 12% (75) 9% (74) 25 (-100-69)
Male children 5-9 years. HBsAg + 10% (57) 1.7% (57) 83 (-34-98)
Male children 10-12 years. HBsAg + 15% (40) 2.4%(41) 84 (-29-98)
Female children 5-9 years. HBsAg + 7% (54) 1.5% (68) 78 (-72-98)
Female children 10-12 years. HBsAg + 9% (35) 18% (33) -lOO
Puerto Nariiio
Children 5-9 years. Infection 9% (II) 2% (105) 78(-113-97)
Children I0-14 ~ears. Infection 86% (22) 13% (31) 85 (62-94)
* Year 1992 **Year 1999 (including only children from rural areas) ***p<O.OOI E p<0.05
III. Prevalence of hepatitis B infection and related factors:
111.1Child- related variables:
The influence of these factors were analysed separately for anti-HBc and HBsAg
prevalence. When anti-HBc was analysed all children positive for this marker were included
in the numerator and when the analysis focused on HBsAg, children positive for both
HBsAg and anti-HBc went into the numerator
Anti·UBc prevalence: All child characteristics in table 5.2 were associated with being anti-
HBc positive. The strongest associations were observed with ethnic group and qualification
of the people attending the birth.
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Children belonging to Indian groups (Huitotos, Ticunas, and Others) had a higher chance of
being infected than those who did not (Non Indians). The highest prevalence was observed
among children belonging to the "Other Indian groups" who had a 7 times greater chance of
being positive for anti-HBc. while "Ticunas" and "Huitotos" were three times more likely to
be positive. In rural areas similar associations were observed while in urban areas only
"Other groups" had an increased risk of being anti-HBc positive (OR=3.7 95% Cl 1.3-11.0)
When a child's birth was not attended by a physician or a nurse, which also meant that it
was not attended in a hospital or health centre, his (her) risk of being anti-HBc positive was
4 times higher than that of a child born in a health facility. For children living in rural areas
this relation was stronger than for children living in urban areas (OR=3.1 95% Cl 1.4-6.7 in
rural and OR= 1.91 95% Cl 0.9-4.2 in urban areas).
Living in a household with more than 4 siblings increased by 70% the chance of being anti-
HBc positive. This relation disappeared when the data were analysed for rural and urban
areas separately (OR= 1.2 95% Cl 0.8-1.84 in rural and OR= 1.3 95% Cl 0.4-4.2 for urban
areas). On the other hand, "being born to a mother with four or more previous deliveries"
increased the risk of infection by 50%. As with number of siblings, no relationship was
found when the analysis was stratified by area (OR= 1.4 95% Cl 0.8-2.2 for rural and
OR=0.7 95% Cl 0.2-2.1 for urban areas).
"Birth order" and "number of siblings" were strongly correlated (0.7l) and, therefore, it was
decided to keep only "number of siblings" for further analysis based on the size of the
effect.
Age was also related to infection but the most important difference appeared among children
aged 8 to 11 years. The oldest children had twice the risk of the others. This difference was
found only in rural areas since in urban places the increase in prevalence among the oldest
age group was small and not statistically significant. No relation was observed between
breastfeeding and anti-HBc prevalence.
Multivariable models were constructed separately for rural and urban areas. The following
variables were included: "age groups", "birth received by ..", "ethnic group", and "number of
siblings". Table 5.3 shows the results when children from all areas were analysed. Ethnic
groups ("Others groups" and Ticunas) showed the most important associations with being
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positive for anti-HBc. but "birth received by somebody different to a doctor or nurse" was
statistically related as well. "Number of siblings" was dropped due to lack of statistical
significance and small effect size (OR=0.95 95% Cl 0.6-1.5, p=0.81). The results for rural
areas were very similar. see table 5.4. In urban areas only "ethnic group" was statistically
related to being anti-HBc positive. specifically. belonging to "Other groups" increased the
risk by 4 fold (OR=3.7 95o/c Cl 1.3-11.0). Belonging to Ticunas was associated with a 2 fold
increase of the risk, but it was not statistically significant (OR=2.0 95% Cl 0.8-4.8)
HBsAg Prevalence: The same variables related to anti-HBc prevalence were associated
with being positive for HBsAg and anti-HBc. Table 5.2. As before, children belonging to an
ethnic group had a larger chance of being HBsAg positive. "Other Indian groups" and
"Huitotos" showed the highest prevalence of HBsAg followed by "Ticunas". All these
relations were stronger than those observed with anti-HBc. For example, a child belonging
to the Huitoto Indians had seven times greater chance of being HBsAg+/anti-HBc+, but this
ratio was less than three when anti-HBc alone was considered. None of the Indian groups
had HBsAg positive children in urban areas and therefore the association with HBsAg
prevalence was limited to rural settings.
Children whose birth was not attended by medical personnel had a higher prevalence of
HBsAg. This was the strongest relationship found with child related variables. As with other
variables. this relation was more important in rural than in urban areas. Local midwives,
relatives, and the mother themselves attended all births from HBsAg+ children in rural areas
(n=23). On the other hand, in urban areas, MD or nurses attended the births of all HBsAg
positive children (n=2).
Age was important in rural but not in urban areas. The sharp increase in the HBsAg
prevalence among children aged 8 to II years did not occur in urban areas where this group
had a low prevalence (0.3%). In rural areas this age group had an HBsAg prevalence of
6.6% .
"Living with more six or more siblings" was also associated with a higher chance of being
HBsAg positive. As with the other variables, this relationship was important for children
living in rural but not in urban settings. In rural areas, the risk of being HBsAg positive was
5 times higher among those with four or more siblings (OR=4.9 95% Cl 1.5-16.2). In urban
places, no child with this characteristic was found HBsAg positive. A similar finding was
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observed with birth order. This was related to HBsAg only in rural settlements (OR=2.8
95% Cl 1.3-5.9), but no child in the risk group were found HBsAg positive in urban areas.
Table 5.2. Prevalence of UB infection by children-related variables.
Variable Anti-UBc + UBsAg+/Anti-UBc+ -_._--
Anti-UBc- Anti-UBc+ OR (95% Cl) UBsAg - UBsAg + OR (95% Cl)
N (%) N(%) N(%) N(%)
Age groups P<O.OOOI P<O.OOOI
(years)
1-3 485 (95.3) 22(4.7) 1.0 434 (99.8) I (0.2) 1.0
4-5 453 (97.5) 13 (2.5) 0.5 (0.3-1.0) 432 (99.3) 3 (0.7) 2.6 (0.3-27.2)
6-7 470 (96.2) 19 (3.8) 0.8 (0.4-1.6) 454 (99.7) 2 (0.3) 1.1 (0.1-11.5)
8-11 581 (90.8) 70 (9.2) 2.0 (1.1-3.7) 561 (97.0) 19 (3) 10.0 (1.2-90.8)
Birth order P=O.05 P<O.OOl.
1-3 982 (94.6) 60(5.4) 1.0 926 (99.8) 9 (0.2) 1.0
4-20 542 (92.0) 51 (8.0) 1.5 (1.0-2.3) 511 (97) 15 (3) 3.4 (1.6-7.2)
Number of P=O.02 P=O.OO3
siblings
1-5 1265 (95.0) 67 (5.0) 1.0 1202 (99.5) 8 (0.5) 1.0
6-20 360 (91.9) 34 (8.1) 1.7 (1.1-2.7) 345 (96.8) II (3.2) 6.2 (2.1-18.2)
Birth P<O.OOOI P<O.OOOI
received by
MDlNurse 1139 (97.3) 32 (2.7) 1.0 1089 (99.8) 2 (0.2) 1.0
Other 833 (90.3) 92 (9.7) 3.9 (2.4-6.6) 778 (97.3) 23 (2.7) 13.0 (3.0-57.0)
Ethnic group P<O.OOOI P=O.Ol
Non Indians 640 (98.0) 17 (2.0) 1.0 602 (99.7) 2 (0.3) 1.0
Huitoto 147 (94.0) II (6.0) 2.7 (1.1-6.3) 142 (98.0) 3 (2.0) 7.3 (1.0-51.3)
Other Indian
groups 235 (86.0) 44 (14.0) 6.9 (3.4-13.8) 229 (97.0) JO (3.0) 11.3 (2.3-55.9)
Ticunas 648 (92.0) 46 (8.0) 3.5 (1.7-6.9) 603 (98.4) 9 (1.6) 6.0 ( 1.0-36.4)
Mestizo 319 (98.0) 6 (2.0) 0.8 (0.4-1.9) 305 (99.6) I (0.4) 1.2 (0.1-14.0)
Table 5.3. Final model of children-related variables and anti-Hlsc prevalence. All areas
Variable OR (95% Cl) P
Age groups
(years)
1-3 1.0
4-5 0.4 (0.2-D.9) D.D3
6-7 0.8 (0.4-1.6) 0.49
8-11 J.9 (J.D-3.6) 0.D4
Birth received by
MDlNurse 1.0
Other 2.4 (1.5-4.1 ) 0.00 1
Ethnic group
Non Indians I.D
Huitoto 1.9 (D.9-4.3) D.ID
Other Indian
groups 4.6 (2.4-8.6) D.DOO
Ticunas 2.4 (1.2-4.6) 0.01
Mestizo D.8 (D.4-2.0) D.7D
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area
Table 5.4. Final model of children-related variables and Anti-HBc prevalence. Rural
Variable p
Age groups
(years)
1-3
4-5
6-7
8-11
Birth received by
MDlNurse
Other
Ethnic group
Non Indians
Huitoto
Other Indian
groups
Ticunas
Mestizo
OR (95% Cl)
1.0
0.5 (0.2-1.1 )
1.0 (0.4-2.6)
2.7 (1.2-6.0)
0.09
0.98
0.02
1.0
2.5 (1.1-5.6) 0.03
1.0
2.1 (0.7-6.4) 0.17
4.4 (1.7-10.9)
2.5 (1.0-6.4)
Dropped because no
Anti-HBc+ was
found in rural areas
0.003
0.05
In the multi variable model the following variables were included: "age groups", "birth
received by ..... "number of siblings". and "ethnic groups". Table 5.5 shows the final model
when all areas were included in the analysis. "Number of siblings" and "birth received by .."
were statistically related to HBsAg prevalence. but ethnic group or age were not. Among
ethnic groups the highest relation was observed with "Other groups", but the relation was
not statistically significant (OR=2.6 95% Cl 0.6-11.8, p=0.22). In order to evaluate if the fall
in the strength of the association between "ethnic group" and HBsAg was due to a loss in
the number of observations. a new category for missing values was created in the variable
"number of siblings". The number of observations in the model increased sharply from 1557
to 1892 and the relation between "Other groups" and HBsAg prevalence increased, but still
did not reach statistical significance (OR=3.6 95% Cl 0.8-16.1, p=0.09).
In rural areas none of the variables reached formal statistical significance in relation to
HBsAg positivity but several had a large point estimate of effect; "number of siblings"
(OR=3.4 95% Cl 0.9-12.4. p=0.07). "Other Indian groups" (OR=4.4 95% Cl 0.5-36.6,
p=0.16), belonging to Ticunas (OR=4.0 95% Cl 0.4-45.4, p=0.24), and "age group 8-11"
(OR=6.4 95% Cl 0.4-97.7, p=O.17). In urban areas none of the independent variables were
related to HBsAg.
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Table 5.5. Final model of children-related variables and HBsAg prevalence. All areas
Variable OR (95% Cl) P
Age groups
1-3 1.0
4-5 2.1 (0.2-22.8) 0.54
6-7 0.8 (0.1-10.0) 0.89
8-11 6.0 (0.6-65.4) 0.14
Birth received
by
MDfNurse 1.0
Other 6.5 (1.5-27.6) 0.01
Number of
siblings
1-5 1.0
6-20 3.3 (1.1- ID.O) 0.03
III. 2. Mother-related variables:
Anti-HBc prevalence: The strongest relation was observed with "place where mother was
born". Prevalence of anti-HBc was the highest among children whose mothers were born in
rural Amazon (9%) having almost 4 times greater risk of being positive than children from
mothers born in other places (OR=3.6 95% Cl 2.1-6.3). This relation was present in rural
(OR=4.2 95% Cl 1.8-9.8) but not in urban areas (OR=I.1 95% Cl 0.4-3.4).
Children born to HBsAg+ mothers had the highest prevalence in this group (10%), followed
by those born to HBeAg+ mothers (9.6%), and to anti-HBc+ mothers (8.4%). However, a
statistically significant relation was observed only among children born to an anti-HBc+
mother (OR=2.6 95% Cl 1.7-4.1). For those born to an HBsAg+ mother, the relation was not
significant (OR=2.0 95% Cl 0.9-4.4, p=0.09). Being born to an HBeAg+ mother was even
less related to anti-HBc prevalence (OR=l.9 95% Cl 0.4-8.2, p=O.4). Table 5.6
The effect of "mother's serological status differed by area". In rural areas, children born
from an anti-HBc+ mother had an anti-HBc prevalence of 11.5% (73/634), while in urban
areas it was 2.2% (7/241). In rural areas, the risk of being anti-HBc+ doubled in children
born to an anti-Hllc+ mother (OR=2.2 95% Cl 1.4-3.6), while no increase in the risk was
observed in urban areas. Children born to HBsAg+ mothers and living in rural areas had an
anti-HBc prevalence of 14% (6/48), while in urban areas it was 0% (0116). However, the
increase in the risk of being anti-HBc+ for those born to an HBsAg+ mother was not
significant in rural areas (OR=l.7 95% Cl 0.8-3.8).
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The "mother's history of clinical hepatitis" was not related to HBsAg prevalence, though in
urban areas it slightly increased the risk of being anti-HBc+ (OR=2.6 95% Cl 0.8-8.2,
p=O.I).
In the multivariable models "children's age group", "place where the mother was born",
"mother's anti-HBc status", and "mother's HBsAg status" were included. "Place where
mother was born" (rural Amazon vs. others) and being born from an anti-HBc+ mother
remained significantly associated with anti-HBc prevalence (OR=3.4 95% Cl 2.0-5.8 and
OR= 1.7 95% Cl 1.2-2.5 respectively). In rural areas, multivariable models yielded similar
findings but in urban areas none of the variables were related to anti-HBc prevalence.
Table 5.6. Anti-UBc and UBsAg prevalence by mother-related factors.
Variable Anti-UBc + UBsAg+! Anti·UBc+
Anti·UBc· Anti·UBc+ OR (95% UBsAg. UBsAg+ OR (95% Cl)
N(%) N(%) Cl) N(%) N(%)
Place where P<O.OOOI P<O.OOI
mother was born
Rural Amazon 910 (91.0) 94 (9.0) 3.6 (2.1-6.3) 857 (97.8) 22 (2.2) 9.1 (1.9-42.9)
Other 935 (97.3) 26 (2.7) 1.0 888 (99.7) 2 (0.3) 1.0
Mother's P=0.19 P=O.57
antecedent of
clinical hepatitis
y 100 (91.0) 9 (9.0) 1.7 (0.7-3.9) 92 (99.3) I (0.7) 0.6 (0.1-4.6)
N 1712 (94.6) 110(5.4) 1.0 1617 (99) 23 (1.0) 1.0
Born from an P=O.09 P=0.33
UBsAg positive
mother
y 58 (90.0) 6 (10.0) 2.0 (0.9-4.4) 55 (97.1) 2 (2.9) 2.6 (0.4-18.3)
N 1695 (95.0) 104 (5.0) 1.0 1600 (98.9) 21 (1.1) 1.0
Bomfroman P<O.OOOI P=O.OOI
infected mother
(Anti-UBc)
y 802 (91.6) 80 (8.4) 2.6 (1.7-4.1) 761 (97.6) 21 (2.4) 6.6 (1.8-25.1)
N 948 (96.6) 32 (3.4) 1.0 892 (99.6) 3 (0.4) 1.0
Born from an P=0.4 P=0.76
UBeAg positive
mother
y 25 (90.4) 2 (9.6) 1.9 (0.4-8.2) 24 (100) 0(0) Undefined
N 1964 (95.0) 122 (5.0) 1.0 1857 (99) 25 (I)
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Table 5.7. Final model of mother-related variables and anti-Hlsc prevalence. Rural
areas.
Variable OR (95% Cl) P
Age groups
1/3 1.0
4/5 0.4 (0.2-1.1) 0.07
6n 1.0 (0.4-2.7) 0.93
8/11 2.63 (1.0-6.6) 0.04
Born from an
infected mother
(Anti-UBc)
y 1.7 (1.1-2.6) 0.02
N 1.0
Place where
mother was born
Rural Amazon 3.6 (1.5-8.3) 0.005
Other 1.0
HBsAg prevalence: The strongest relation was observed with the variable "place where
mother was born". Children whose mothers were born in rural Amazon were 9 times more
likely to be HBsAg+ than children whose mothers were born elsewhere. When this
association was stratified by areas, the magnitude of the OR and the p values fell sharply
and became non statistically significant in both areas (OR=3.5 95% Cl 0.4-30.6, p=0.24 in
rural areas and OR=4.0 95% Cl 0.2-67.0, p=0.33 in urban areas).
Among the variables related to mother's serological status the strongest relationship was
found with the "mother's anti-HBc status". The risk of being HBsAg+ was 7 times higher
when a child was born from an anti-HBc+ mother and this relation was even stronger in
rural areas though it lost precision (OR=8.3 95% CII.0-69.4, p=0.05). In urban areas, none
of the children born to an anti-HBc+ mother was HBsAg positive and, therefore, assessing a
relationship was not possible. The association between being born from an HBsAg+ mother
and HBsAg prevalence was not significant even after stratifying by area (OR=1.8 95% Cl
0.3-13.3 in rural areas and no HBsAg+ children were found in the risk category in urban
areas).
A clinical history of hepatitis in mothers was not related to HBsAg prevalence in children.
In the multivariable model the following variables were included: "age group", "mother's
anti-HBc status", "mother's HBsAg status", and "place where the mother was born". Table
5.8 shows the results from the final model for all areas. "Mother's HBsAg status" was
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dropped from the model because it was no longer related to HBsAg prevalence (OR= 1.5
95% Cl 0.2-10.9, p=0.69). In rural areas, only "mother's anti-HBc status" was associated
with HBsAg prevalence (OR=6.9 95% Cl 0.8-61.2, p=0.08)
Table 5.S. Final model of mother-related variables and HBsAg prevalence. All
children.
Variable OR (95% Cl) P
Age groups
1/3 1.0
415 2.3 (0.2-24.3) 0.48
6n 1.0 (0.1-10.9) 0.97
8/11 9.5 (1.0-90.4) 0.05
Born from an
infected mother
(Anti-HBe)
y 3.5 ( 1.0-11.8) 0.04
N 1.0
Place where
mother was born
Rural Amazon 6.0 (1.5-23.1) 0.01
Other 1.0
111.3.Vaccination characteristics.
There were 1407 (66%) children with data available on hepatitis B vaccination. According
to the vaccination card, 91% (1277) of those children had completed the basic scheme for
hepatitis B (3 doses). There were no differences in HBsAg prevalence between vaccinated
and unvaccinated children. The prevalence in children completely vaccinated was 1.2%
(15/1129) while no HBsAg+ was found among unvaccinated children (01119), p=0.3.
Interestingly, HBsAg prevalence among children without vaccination data was very close to
the prevalence in vaccinated children, 1.1% (10/658). Similar results were observed when
the dependent variable was anti-HBc prevalence. Anti-HBc prevalence among vaccinated
children was 6% (7611258) while no positive was found among those with an incomplete
vaccination series (01126). Children without vaccine information had an anti-Hbc+
prevalence of 5.2% (481729)
The time lag between hepatitis B doses and its relation to hepatitis B markers was assessed
using the following indicators: time in days from birth to first dose, time in days from first to
second dose, and time in days from second to third dose. Figure 5.7 shows the distribution
140
of medians and quartiles (Q], Q,). The median time from birth to first dose was 77 days, the
value for Q, was 9 days, and for Q, was 417 days. The median time from first to second
dose was 47 days, Q, was 31 days, and Q, was 114 days. The median time from second to
third dose was 87 days, Q, was 33 days, and Q, was 87 days. The largest inter quartile range
was observed for time from birth to first dose while the shortest was for time from first to
second dose.
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Figure 5.7. Box plot showing time lag distribution between hepatitis B doses.
HBsAg prevalence: The relation between HBsAg prevalence and time between doses was
assessed first by comparing the time distribution by HBsAg status categories. Figures 5.8 to
5.10 how how these times were distributed by percentiles between HBsAg+ and HBsAg-.
The sharpest difference was observed with "time between birth and first dose". For
uninfected people, the Q, and median values were 10 and 77 days, respectively, while for
infected peoples, they were 161 and 8 I7 days (PKruskall.wallis=O.003). "Time from first to
second dose" also differed by HBsAg status. Q, and median values for HBsAg- were 31 and
44 days, respectively, but for HBsAg+ they were 47 and 80 days (PKruskall-Wallis=0.12)."Time
from second to third dose" showed smaller, non statistically significant differences. Q, was
33 day in HBsAg- and 62 days in HBsAg+ while median was 100 days in HBsAg+ but 86
in HBsAg- (pI<ruskall-waWs=0.54).
Figure S.B. Time from birth to first HB dose by HBsAg status. Percentiles.
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Figure 5.9. Time from first to second HB dose by HBsAg status. Percentiles
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Figure 5.10. Time from second to third HB dose by HBsAg status. Percentiles
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Percentile of time between do es were stratified by age and differences remained for the
variable "time between birth to first dose" and for "time between first to second dose".
Table 5.9 haws the number of days by age group, time interval, and HBsAg status. Time
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lllIHBsAg+
IIHBsAg-
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between birth and first dose was longer for HBsAg+ through all ages and percentiles,
excepting children aged 1-3 years among whom only one HBsAg+ was present. For "time
between first to second dose" HBsAg- children had shorter intervals in all age groups,
especially for QJ and Ql. When "time between second and third dose" was analysed, only
one to three years old HBsAg- children had shorter intervals for QJ .
Table 5.9. Percentiles of time lag distribution by age and HBsAg status.
2. P50 23
HBsAg- HBsAg+ HBsAg- HBsAg+ HBsAg- HBsAg+
Days Days Days Days Days Days
Time from
birth to first
dose
1-3 years 2 161 30 161 80 161
4-5 years 3 130 53 130 162 130
6-7 years 34 913 141 1080 503 1247
8-11 years 104 604 486 817 1089 1197
Time from
first to
second dose
1-3 years 31 180 42 180 98 180
4-5 years 31 47 49 72 109 98
6-7 years 32 60 47 60 127 61
8-11 years 32 33 41 117 102 143
Time from
second to
third dose
I -3 years 32 270 54 270 157 270
4-5 years 34 64 67 67 143 70
6-7 years 35 62 147 92 249 123
8- I 1 ~ears 38 33 143 166 246 236
Time variables were grouped into four or five categories based on percentile value and/or on
the number of HBsAg+ children by categories. Then, prevalence of HBsAg+ by category
and OR plus confidence intervals were calculated. "Time from birth to first dose" and "time
from first to second dose" showed the strongest association with HBsAg prevalence. Delay
in receiving the second dose, 36 days or longer after the first was related to an increase in
the risk of being HBsAg+ though it decreased in the final category (148 days or longer).
"Time from birth to first dose" was linked to an increase in the risk of being HBsAg+ when
the first dose was applied after 2 months. Delay in receiving the third dose tended to
increase the chance of being HBsAg+, but the difference did not reach statistical
significance. Table 5.10
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Table 5.10. Distribution of HBsAg prevalence by time lag between HB doses.
Variable HBsAg+1 Anti-HBc+
HBsAg - HBsAg + OR (95% CI)* OR (95% CI)*
N(%) N(%) Rural areas
Time from birth P=O.07
to first dose
0-14 days 294 (99.4) I (0.2) 1.0 1.0
15-60 days 190 (I(0) 0 Undefined Undefined
61-183 days 196 (99.4) 2 (1.2) 6.6 (0.5 - 90.4) 6.7 (OA-119.0)
184-665 days 193 (99A) I (0.6) 2.2 (0.1 - 40.4) 1.0 (0.05-22.7)
666-3253 192 (96.5) 7 (3.5) 8.9 (0.9-88.2) 4.1 (0.4-46.1)
Unknown 816 (98.8 ) 14 (1.2) 4.1 (0.5-35.4) 3.1 (0.4-26.8)
Time from first P=0.15
to second dose
28-35 days 464 (99.4) 3 (0.6) 1.0 1.0
36-62 days 198 (98.1) 4 (1.9) 3.3 (1.2-8.9) 3.0 (1.7-5.2)
63-147 days 212 (97.9) 4 ( 1.5) 3.2 (0.9-11.2) 3.3 (0.8-13.3)
148-1877 days 207 (99.0) 3 (1.5) 2.5 (0.7-9.2) 2.0 (0.6-7.0)
Unknown 800 (99) 11(1.0) 1.3 (0.3-4.7) 1.9 (0.5-6.9)
Time from P=O.5
second to third
dose
28-32 days 237 (99.3) 2 (0.7) 1.0 1.0
33-61 days 190 (99.3) I (0.7) 1.1 (0.1-14.1) 2.1 (0.1-44.6)
62-128 days 192 (97.4) 5 (2.0) 2.7 (0.5-12.6) 4.7 (0.8-28.7)
129-235 days 198 (98.8) 2 (1.2) 1.2 (0.1-13.8) 2.7 (0.2-42.8)
236-2787 days 207 (98.8) 4 (1.8) 1.8 (0.3-12.7) 3.6 (0.3-43.7)
Unknown 857 (99) II (1.0) 0.9 (0.2-4.2) 2.5 (0.3- 17.0)
* Adjusted by age group
The same analysis was done for rural areas and the magnitude of the association between
HBsAg prevalence and "time from birth to first dose" decreased. For "time from first to
second dose", the relation was similar to that observed for the whole population. However,
for "time from second to third dose", it seems that there was an increase in the magnitude of
the relation between different time categories and HBsAg prevalence, though none reached
statistical significance. Table 5.10
Since few unvaccinated children (among those with vaccination card) were found in the
study and none were HBsAg positive, it was decided to create a category in each time
variable to include children without vaccination data aimed at evaluating if they had a
different risk of being infected than children with data, under the supposition that many
might be unvaccinated. The largest difference was found for children without data on "time
between birth and first dose" (OR=4.1 95% Cl 0.5-35.4), though it was not statistically
significant (p=0.20). Table 5.10
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Combined analysis of vaccine-related and other covariates with HBsAg prevalence:
Those factors related with HBsAg prevalence in previous steps were analysed together with
time from birth to first dose and time from first to second HB dose using logistic
multivariable models to control for potential confounding effects and to evaluate
interactions. The following variables were included at this stage:
I)Birth attended by MD/nurse or others.
2) Number of siblings.
3) Mother's anti-HBc status.
4) Mother's HBsAg status
5) Time from birth to first HB dose. In order to improve the efficiency of the multi variable
analysis, the first category (0-14 days) was collapsed with the second (15-60 days). This
decision was based on the fact that the second category had the lowest prevalence (0 cases)
and, therefore, it could form part of the baseline category.
6) Time from first to second dose. This variable was recoded collapsing the last two
categories to one, 63 days and more. This decision was taken since these two categories had
the same HBsAg prevalence (see table 5.10)
7) Age group.
The multi variable analysis was done separately for "time between birth and first dose" and
for "time between first and second dose". These two variables can not be combined since
they correlate at 0.70.
Modelling time from birth to first dose: Table 5.11 shows the results when all covariates
were included together. Children who received the first dose after the second year of life had
12 times more chance of being HBsAg+ than those who received it within two weeks after
birth. Receiving the first dose of the vaccine after 2 months of life was also riskier, but it did
not reach statistical significance. Not having accurate data on vaccination dates was also
associated with a higher HBsAg carriage risk when compared with children who received
the first dose within two weeks of life. It did not reach statistical significance but it might
have been only a matter of the number of positives in the baseline category (n= I). Being
born from an anti-HBc+ mother increased the risk of carriage by three times.
Area was included and kept in the model to control for its potential confounding effect since
living in rural areas was associated with being HBsAg+ and with having longer intervals
from birth to first dose. This variable and "birth received by ... " correlated at 0.56 but
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models run without one of them did not show any important change in the magnitude of the
associations or standard errors, and therefore were included together.
Table 5.11. Time from birth to first dose, covariates and their relationship to HBsAg
status. (Urban and rural areas)
Variable p
Age groups (years)
1-3
4-5
6-7
8-11
Time from birth and
first dose
0-60 days
61-183 days
184-665 days
666-3253
Unknown
Birth received by
MDlNurse
Other
Number of siblings
1-5
6-20
Mother Anti-HBc+
y
N
Area
Urban
Rural
OR (95% Cl)
1.0
1.5 (0.1-19.4)
0.6 (0.05-6.0)
3.3 (0.3-33.8)
1.0
7.2 (0.5-115.1)
2.6 (0.1-50.0)
12.5 (1.2-125.7)
6.6 (0.6-66.4)
1.0
2.7 (0.9-8.0)
1.0
2.7 (1.0-7.3)
3.4 (1.1-11.2)
1.0
1.0
2.2 (0.9-5.6)
0.74
0.62
0.30
0.16
0.53
0.03
O.ll
0.07
0.05
0.04
0.09
The model was repeated creating a category for missing values on number of siblings
(n=391), but results were remarkably similar for all variables included in the model. The
model was also fitted excluding those without data on "time from birth to first dose" and,
again, results resembled closely to those observed in table 5.11. Fitting an interaction term
for "mother's anti-HBc status" and "time from birth to first dose" was attempted but it was
impossible due to the small number of cases. However, in bivariable analysis it was
observed that the relation between "time from birth to first dose" and HBsAg prevalence
varied across mother's serological status. Table 5.12.
An attempt to built a similar model for rural areas was hampered because "number of
siblings" had missing data and estimates for other variables (birth attendance and mother's
anti-HBc status) became so unstable that they were dropped from the model (cells with 0). It
was decided to model them one by one with time from birth to first dose. Table 5.13 shows
the results for rural areas when "mother's anti-HBc status" is included in the model. The
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magnitude of the associations with HBsAg prevalence was similar to those found when all
areas were included in the same model. though there was a loss in statistical significance
due to a decrease in the sample size. Other models including "number of siblings" or "birth
received by .." showed similar results, but the one in table 5.13 had the highest F and
likelihood value.
Table S.12. Relation between time from birth to first dose, HBsAg prevalence and
mother's Anti-HBc status. (Rural areas)
Time from birth to Mother Anti-HBe+ Mother Anti-HBe-
first dose HBsAg- HBsAg+ HBsAg- HBsAg+
N (%) N(%) N (%) N(%)
0-60 days 119(99.4) I (0.6) 65 (100) 0
61-183 days 76 (96.0) 2 (4) 27 (100) 0
184-665 days 81 (98) 1 (2) 35 (lOO) 0
666-3253 69 (91) 6 (9) 28 (100) 0
Unknown 184(95.5) II (4.5) 103 (99.0) 1 (1.0)
Table S.13. Model containing time from birth to first dose, covariates, and their
relation to HBsAgprevalence. (Rural areas)
Variable p
Age groups
1-3
4-5
6-7
8-11
Time from birth and
first dose
0-60 days
61-183 days
184-665 days
666-3253
Unknown
Mother Anti-HBc+
y
N
OR (95% Cl)
1.0
0.9 (0.92)
0.7 (0.05-8.0 )
6.4 (0.8-53.9)
0.92
0.75
0.08
1.0
10.0 (0.5-203.8)
2.0 (0.1-48.8)
8.4 (0.7-102.3)
5.9(0.7-51.1)
0.12
0.65
0.09
0.10
6.9/0.8-63.1 )
1.0
0.08
Modelling time from first to second dose: When both areas, rural and urban, and other
covariates were analysed together, "time from first to second dose" was not statistically
related to HBsAg prevalence. These results did not change even after running the model
without area or when missing values for the time interval variable were removed from the
model. Table 5.14.
147
It was not possible to fit an interaction between "mother's anti-HBc status" and "time from
first to second dose" but in bivariable analysis it could be observed that the relation between
HBsAg prevalence and time from first to second dose was different by categories of
mother's infection. Table 5.15
Table 5.14. Time from first to second dose, covariates and their relation to HBsAg
status. (Urban and rural areas)
Variable p
Age groups
1-3
4-5
6-7
8-11
Time from first to
second dose
28-35 days
36-62 days
63-1877 days
Unknown
Birth received by
MDlNurse
Other
Number of siblings
1-5
6-20
Mother Anti·UBc+
y
N
Area
Urban
Rural
OR (95% Cl)
1.0
2.1 (0.2-22.2)
0.9 (0.08-10.3)
6.2 (0.6-70.8)
1.0
1.6 (0.7-3.8)
1.2 (0.4-3.6)
0.8 (0.2-3.7)
1.0
2.8 (1.1-7.1)
1.0
2.6 (1.0-7.0)
3.1 (1.0-9.8)
1.0
1.0
1.9 (0.8-4.4)
0.53
0.96
0.13
0.29
0.67
0.79
0.02
0.05
0.05
0.15
Table 5.15. Relation between time from first to second dose, HBsAg prevalence and
mother's Anti-Hflc status. (Rural areas)
Time from first to Mother Anti·UBc+ Mother Anti-Hlsc-
second dose --=U=B=-s-A:-g-.---U=B-sA-:--g+----U-B__;s:...:A:..::g...::.:.:.:.:.:.....:..::.:::.::....::.:U=B:..::S-A-g-+--
N(%) N(%) N(%) N(%)
91 (97.7) 2 (2.3) 50 (100) 0
84 (95.0) 4 (5) 31 (100) 0
186 (96.2) 7 (3.8) 83 (100) 0
168(96.4) 8(3.6) 94(98.7) 1 (1.3)
28-35 days
36-62 days
63-1877 days
Unknown
For rural areas, the relation between "time from first to second dose" and HBsAg prevalence
was stronger. A delay to receive second dose, between 36 to 62 days from the first, was
associated with a twofold increase in the risk of being HBsAg positive. No statistical trend
was observed since the risk increase for the next category did not reach statistical
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significance (p=0.28). Interestingly. those children without data available on this variable
did not have an increase in the risk of being HBsAg positive. Being born from an anti-HBc
positive mother and having a larger number of siblings also remained associated with a
higher risk of being HBsAg positive. The variable "birth received by .." was not included in
the model because it had empty cells in rural areas. Table 5.16
Table 5.16. Time from first to second dose, covariates and their relation to HBsAg
status. (Rural areas)
Variable
Age groups (years)
1-3
4-5
6-7
8-11
Time from first to
second dose
28-35 days
36-62 days
63-1877 days
Unknown
Number of siblings
1-5
6-20
Anti-HBc+ mother
y
N
OR (95% Cl) P
1.0
1.3 (0.1-16.7) 0.83
0.96 (0.1-11.4) 1.0
8.4 (0.8-91.6) 0.08
1.0
2.3 (1.4-3.8)
2.0 (0.6-7.4)
1.4 (0.3-5.3)
0.003
0.27
0.64
1.0
3.2 (1.0-10.5) 0.05
5.9 (0.7-48.3)
1.0
0.09
Anti-HBc prevalence: "Time from birth to first dose" was statistically significant related to
anti-HBc prevalence. The time interval was longer for anti-HBc+ than for anti-HBc- in all
percentiles. Figure 5.11. The largest differences were observed for the median (145 days for
anti-HBc+ and 77 days for anti-HBc-) and for the 751h percentile (732 days for anti-Hllc+
and 405 days for anti-HBc-). p=0.05.
When time between doses was analysed no important differences were found. The median
time from first to second dose was larger for anti-HBc+ than negatives but the difference
was small (62 days for anti-HBc+ and 46 days for anti-HBc-). p=0.17. The median time
from second to third dose was 87 days for anti-HBc+ and 123 days for anti-HBc-. p=20.
Figure 5.12 and 5.13
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Figure 5.11. Time from birth to first dose by AntiHBc status.
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Figure5.12.Time from first to to second dose by AntiHBc status.
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Figure 5.13. Time from second to third dose by AntiHBc status.
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Table 5.17 how the results when anti-HBc+ prevalence was analysed by categories of
"time from birth to fir t dose" and time between doses. Overall, no statistically significant
difference wa ob erved for any of these variables. Only one category in "time from first to
second dose" wa related with being anti-Hfsc+. Children receiving the second dose
between 63 to 147 day from the fir t dose had two times more chance of being anti-Hbc+.
When the analy i wa tratified by area, some categories of the variable "time from birth to
first do e" showed a tronger relationship with being anti-HBc+ but none reached statistical
ignificance.
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Table 5.17. Time lag between Hepatitis B doses and their relationship with being anti-
UBc positive.
Variable
Anti-HBc - Anti-HBc + OR (95% CI)* OR (95% CI)*
N(%) N(%) Rural areas
Time from birth P=0.25
to first dose
0-14 days 313 (96) 13 (4) 1.0 1.0
15-60 days 204 (96) 8 (4) 1.2 (0.4-3.1) 1.9 (0.8-4.8)
61-183 days 206 (95) 10 (5) lA (0.6-3.4) 1.9 (0.9-4.1)
184-665 days 206 (96) ID (4) 0.9 (0.3-2.6) 1.1 (0.3-3.9)
666-3253 201 (92) 17 (8) 1.5 (0.5-4.2) lA (0.3-5.9)
Unknown 859 (94) 66 (6) 1.5 (0.7-2.9) 2.1 (0.8-5.8)
Time from first P=OA2
to second dose
28-35 days 482 (96) 21 (4) 1.0 1.0
36-62 days 213(94) 13 (6) 1.5 (0.8-2.8) lA (0.8-2.4)
63-147 days 229(93) 18 (7) 1.9 (1.02-3.4) 1.5 (0.7-3.0)
148-1877 days 225 (93) 16 (7) 1.8 (0.9-3A) 1.2 (0.5-2.7)
Unknown 840 (95) 56 (5) 1.1 (0.6-2.2) 1.3 (0.5-3.0)
Time from P=0.64
second to third
dose
28-32 days 251 (95) 12 (5) 1.0 1.0
33-61 days 197 (96) 8 (4) 0.9 (OA-2.3) 1.1 (0.5-2A)
62-128 days 206 (94) 15 (6) 1.3 (0.5-3.2) 1.5 (OA-5.8)
129-235 days 217(93) 15 (7) 1.2 (0.6-2.5) 1.2 (0.5-3.0)
236-2787 days 219 (93) 17 (7) 1.4 (0.7-2.7) 1.9 (0.7-5.1)
Unknown 899 (95) 57 (5) 0.9 (OA-1.9) lA (0.4-4.6)
* Adjusted by age group
Combined analysis of vaccine-related variables and covariates: Those factors related
with anti-HBc prevalence in previous steps, were analysed together with "time from birth to
first dose" and "time from first to second dose" using logistical multivariable models.
Variables included at this stage were:
1) Birth attended by MD/nurse or others.
2) Ethnic group.
3) Mother's anti-HBc status.
5) Time from birth to first dose of hepatitis B vaccine.
6) Time from first to second dose.
7) Age group.
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None of the time variables, "time from birth to first dose" or "time from first to second
dose", was related with anti-HBc prevalence after controlling for the effect of the covariates.
This lack of effect was observed both when all children were analysed and after stratifying
by areas. On the other hand "belonging to an ethnic group", "being born from an infected
mother", and "birth attended by somebody different to MD/nurse" remained statistically
significant in the multi variable analysis. Children belonging to "Other Indians groups" or
"Ticunas" had the highest risk of being infected (OR=4.6 95% Cl 2.4-8.8 and OR=2.4 95%
Cl 1.3-4.5 respectively). Being born from an anti-HBc+ mother increased the risk of being
anti-HBc+ by 50% (OR= 1.45 95% Cl 1.1-2.1). Finally, those whose birth was attended by
non medical personnel (MD or nurse) had twice the risk of being infected (OR=2.3 95% Cl
1.5-3.7).
IV. Analysis of anti-HBs titres:
Only children negatives for anti-HBc and HBsAg were included in this part of the analysis.
A randomly selected sample of 481 was studied. Age of participants ranged from I to 12
years (median and mean coincided in 5 years) and 51% were female. Fifty six percent came
from urban areas (n=272) and 56% belonged to an ethnic group (n=270). Levels of anti-HBs
ranged from 0 to more than 10.000 IV/ml but the geometric mean was 66 lV/ml (95% Cl 52-
83), and the median was 123 lV (95% Cl 86-147). Twenty three percent of the population
(n=112) did not have detectable antibody «10 Il.I/rnl), in 23% (n=115 children) anti-HBc
levels ranged between 10 to 99 lV/ml, in 40% (n=193) between 100 to 999 Il.l/ml, and 13%
(n=61 )1000 IVlml or higher.
Anti-HBs levels and related variables. Table 5.18 shows the results of the bivariable
analysis. "Breastfeeding'' and "time between birth and first dose of hepatitis B" were related
to having detectable anti-HBs. The proportion of children without antibody among those not
breastfed was 44% compared to 22% in children who were (p=0.03). The proportion of
children without antibody was also higher among those receiving the first dose of hepatitis B
vaccine close to the date of birth. Conversely, those who received the first dose between the
second and the sixth month of life had the smallest chance of being anti-HBs negative.
Gender. ethnic group. time between doses, and age were not related to not having antibody.
Similar findings were observed when the dependent variable was the quantity of antibody.
Time between birth and first dose was the most important predictor of the level of anti-HBs.
Those receiving the first dose long after birth had the highest level. Receiving the second
dose closer to the first was also associated with lower quantity of anti-HBs but this was not
statistically significant.
Table S.lS. Anti-HBs levels by selected variables.
Variable # without # with anti- # with anti- Anti-HBs
anti-UBs (%) HBs> 1OmIU/mi. UBs~lOOO GMT [Median]
(%) rnIU/mi (%)*
Breastfeeding P=O.03 P=0.13 P=0.13
N 8 (44) 10(56) I (5.5) 22 [60]
Y 104(22) 359 (77) 60 (13) 69 [120]
Time between birth P=O.02 P=O.OI P=0.OO2
and first dose
0-14 days 19 (33) 39 (67) 3 (5) 33 [68]
15-60 days 10 (19) 42 (81) 4 (8) 81 [169]
61-183 days 4 (8) 45 (92) 9 (18) 174 [153]
184-665 days 9 (20) 36 (80) 9 (20) 66 [I 10]
666-3253 days 10 (17) 49 (83) 14 (24) 145 [357]
No data 60 (27) 158 (72) 22 (10) 47 [79]
Time between first P=0.24 P=0.14 P=O.09
and second dose
28-35 24 (23) 80 (77) II (11) 64 [119]
36-62 8 (17) 38 (83) 4 (9) 85 [148]
63-147 10 (17) 50 (83) II (18) 93[142]
148-1877 9 (18) 41 (82) II (22) 126 [223]
No data 61 (28) 160 (72) 24 (II) 50 [82]
Time between second P=0.41 P=0.S8 P=O.22
and third dose
28-32 days 12 (29) 29 (71) 2 (5) 47 [III]
33-61 days 8 (22) 29 (78) 3 (8) 56 [86]
62-128 days 7 (17) 34 (83) 6 (14) 83 [150]
129-235 days 12(20) 47 (80) 7 (12) 87 [147]
236-2787 days 7 (14) 41 (85) 10 (21) 148 [182]
No data 66 (26) 189 (74) 33 (13) 55 [94]
* This category is included in the total number of those with anti-UBc levels> 10 mIU/mi
Anti-HBs levels and ''time to sampling". The minimum period between the third dose and
time of sampling was two months while the maximum was 114 months. Fifty percent of the
children were bled 47 months or longer after the third dose and 25% were bled after 65
months.
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Figure 5.14. Proportion of people without detectable Anti-HBs by time
since the third dose.
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Figure S. 14 show the proportion of people without detectable surface antibodies. It seems
to increase when the time from the last dose increases though no clear pattern is observed
because, after a sustained raise, there is a decrease in the proportion of children without
antibody at five and six years since the last dose. Differences by area were observed. In the
first two years, no change in antibody level is observed for rural areas while in urban areas
the proportion of children without antibodies rises from 12% in the first 11 months, to more
than 20% during the second and third year. Then, this trend switches from urban to rural
areas.
Figure 5.15. Median of AntiHBs titres by time from third dose.
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Figure S.IS shows the median level of antibodies by "time since the third dose of hepatitis"
B. In the fir t eighteen months the median of anti-HBs titres for the whole population
reached a peak of 2S0 IU/ml. Then, a fall is observed and the median of anti-HBc level
remained around J 80 ill/mi until 7 years, when another fall occurs. The small number of
observations (n=9) in this category might be influencing the magnitude of the decrease in
anti-HBc levels .. The initial peak is sharper in urban than in rural areas but after eighteen
months no important difference was observed.
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Anti-HBs level by "time from birth to first dose" and "time from third dose to
sampling". Figure 5.16 haws the distribution of anti-HBs levels (median) by "time since
third dose to ampling" and "time from birth to first dose". Children who received the first
do e in the first 15 day after birth showed the lowest median of anti-HBc levels. The largest
peak of antibodies within the first year, was observed among those receiving the first dose
between 15 to 60 days after birth (p=O.OI). The differences disappear two years after the
third dose, though tho e receiving the first dose 61 to 180 days from birth showed the
highest median anti-HBc level after the 41h year and the largest peak at year 7 (p=O.4S).
Figure 5.16. Median of AntiHBs titre by time from birth to first dose.
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Figure 5.17. Children without surface antibody by time from birth to first dose.
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Figure 5.17 how the percent of people without detectable anti-HBs. Children who received
the fir t do e clo er to birth (0/14 days) had the highest proportion without anti-HBc
followed by tho e who received it between 15 to 60 days.
155
Multivariable analysis. A multi variable analysis, using logistic regression, was used to
evaluate factors related to surface antibody sera-negativity. The following independent
variables were included: "time since third dose", "time from birth to first dose", "time from
first to second dose", and "breastfeeding". Only "time since third dose" and "time from birth
to first dose" were related to being negative for anti-HBs. The likelihood of being anti-HBs
negative became greater as the time since the third dose increased and the largest ORs were
observed at years 4 and 7. On the other hand, children who received the first dose of
hepatitis B from day 61 up to day 183 after birth were less likely to be anti-HBs negative.
Table 5.19.
Multivariable models were also fitted for children without vaccination data, in order to
determine variables related to being anti-HBs negative among them. "Age" and
"breastfeeding" were included in the modelling, but only "breastfeeding" was related with
being anti-HBs negative. Children who did not receive maternal milk were four times more
likely to be anti-HBs negative. (OR=3.97 95% Cl 0.8-IB.I, p=0.09)
Mean antibody level (log transformed) was modelled using linear regression. The following
independent variables were included: "time since third dose", "time from first to second
dose", and "breastfeeding". "Time since third dose" and "time from birth to first dose"
remained associated with antibody levels. Means were higher among those who received the
first dose either, between 61 to IB3 days, or after 22 months after birth (666 days or more).
Linear models were also run using robust methods, in order to avoid the influence of
outliers, but results were similar. Table 5.20
Averages of anti-HBs levels were modelled with "age" and "breastfeeding" for children
without information on their vaccination date. Children who were not breastfed had a lower
mean antibody level than those who did (mean difference= 10 IUlml 95% Cl: 1.0-93,
p=O.04). Antibody titres fell as age increased but this was not statistically significant.
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Table 5.19. Vaccination characteristics and its relationship with being Anti-HBs
negative. Logistic model.
Variable OR (95% Cl) p
Time since third dose
(years)
<I
I
2
3
4
5
6
7/+
Time between birth and
first dose
0-14 days
15-60 days
61-183 days
184-665 days
666-3253 days
1.0
2.0 (0.3-11.6)
1.6 (0.2-10.3)
I.9 (0.3-10.7)
4.1 (0.R-20.9)
2.4 (0.4-13.2)
2.0 (0.3-13.9)
5.9 (0.7-49.1)
1.0
0.6 (0.2-1.5)
0.18 (0.05-0.6)1
0.5 (0. I7 -1.4)
0.6 (0.2-1.8)
0.42
0.60
0.45
0.09
0.31
0.49
0.09
0.26
0.005
0.18
0.37
Table 5.20. Anti-DBs titres (log transformed) and its relationship with time since third
dose and time from birth to first dose. Linear regression model
Variables 13 Coefficient P
(95% Cl)
Time since third
dose (years)
<I 1.0
I -0.48 (-1.1-0.12) 0.12
2 -0.5 (-1.1-0.14) 0.12
3 -0.43 (-1.0-0.16) 0.15
4 -0.7 (-1.3 - -0.15) 0.01
5 -0.4 (-1.0-0.14) 0.13
6 -0.25 (-0.9-0.45) 0.48
7/+ -0.85 (-1.7- 0.03) 0.06
Time between
birth and first
dose
0-14 days 1.0
15-60 days 0.32 (-0.1-0.7) 0.13
61-183 days 0.7 (0.2-1.1) 0.001
184-665 days 0.15 (-0.3-0.6) 0.50
666-3253 days 0.47 (0.01-0.9) 0.04
"Time since third dose" and "time from birth to first dose" were, again, related with
having an antibody level ~ 1000 ID/ml. Interestingly, the association was stronger for
years since the third dose than for time from birth to first dose. This finding is opposed to
the effects observed when the dependents variables were anti-HBs negative or mean anti-
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HBs. Children were less likely to have antibody above 1000 IU/ml at year I, 2, and 4 after
the third dose. On the other hand. children receiving the first dose between 61 and 183 days
after birth were almost four times more likely to have an anti-HBs titre ~1000 IU/m!. Table
5.21
Table 5.21. "Time since third dose" and "time from birth to first dose" and their
relationship with having Anti-HBs titres ~ 1000IU/ml. Logistic model.
Variable OR (95% Cl) P
Time since third
dose (years)
<I 1.0
I 0.2 (0.04-0.98) 0.04
2 0.09 (0.01-0.85) 0.04
3 0.6 (0.16-2.2) 0.43
4 0.2 (0.03-0.77) 0.02
5 0.33 (0.09-1.3) 0.12
6 0.3 (0.07-1.7) 0.19
7/+ 0.28 (0.03-3.02) 0.30
Time between
birth and first
dose
0-14 days 1.0
15-60 days I.3 (0.3-6.6) 0.7
61-183 days 3.9 (0.9-16.2) 0.06
184-665 days 2.3 (0.5-10.9) 0.30
666-3253 days 3.1 (0.7-14.4) 0.14
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Chapter 6: Discussion.
This chapter discuss the weaknesses and strengths of this research. It is divided it in two
broad parts.-One is about vaccine coverage and factors found to be related to it. The second
is on serological findings, vaccine effectiveness, and factors related to with HBV infection
among children (including vaccination characteristics). In each part I start by discussing
those methodological issues that could influence the interpretation or extrapolation of our
results as well as the limitations and strengths of the research. Potential sources of biases,
both selection and misclassification, are analysed and discussed. This methodological
discussion is followed by an attempt to put the results in an international or national context
and to explain the causes and relevance of our findings.
I. Vaccine coverage and related factors:
1.1 Methodological concerns: The objective of this study was to measure the success of the
introduction of a new vaccine into the Amazon EPI in terms of coverage. In addition, we
attempted to measure those factors that could be influencing vaccine intake .. In order to
accomplish these objectives a population survey was carried out followed by a case control
analysis.
As with all cross-sectional surveys, a potential weakness in assessing causality is that effect
variables and some exposures were measured at a single time point. However, the most
important relations found in the study consisted of fixed variables such as HW's knowledge
or perceptions and belonging to an ethnic group, which means that the temporal criteria still
hold. (Elwood M 1998, page 20)
The potential sources of selection bias in this study are due to sampling, non-response, and
differential survival. Non-response to some variables was the most frequent problem. There
was no vaccine information available for a large number of children, and this lack of
information was related to some of the independent variables assessed. However it is
unlikely that this potential source of information bias causes the differences observed. Let's
take, for example, the differences shown in table 6.1 and estimate whether lack of
vaccination information could have led to these findings. Vaccination coverage differed by
24% between urban Leticia and urban Puerto Narifio (71% vs. 39%), but the difference in the
proportion of children without information is 10% (49% vs. 39%). If the difference in
information were the cause of the difference in coverage at the lowest level observed, 39%,
then only 8% of children without information in Leticia would have to have been already
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vaccinated. that is only 61 out of 752 children without information. This is equivalent to 9
times less chance of actually being vaccinated when compared with the coverage among
children with a vaccination card. At the other extreme if the true coverage were equal in the
two areas at a level of 719c. then 171 children out of 187 without information in Puerto
Narifio would have to have been vaccinated. Clearly it is highly implausible that these
differences exist between children with and without vaccination records.
Table 6.1. Simulation of changes that should occur in order to vanish the observed
differences for full vaccination.
Urban
Leticia
Urban Puerto
Narifio
Number of children 1475
Number with information 723 (49%)
Observed coverage (full vaccination) 514 (71%)
Children that should be vaccinated
among those without information to
equate coverage at 39%. 61 (8%)
Children that should be vaccinated
among those without information to
equate coverage at 71%. 533 (71%)
307
120 (39%)
47 (39%)
73 (39%)
171 (91%)
We believe that the true prevalence of vaccination coverage in the area of study should lie
very close to the values described in chapter 4, despite a proportion of children not having a
vaccination card. Some evidence from the study seems to support this. First, we found that
when vaccines were considered separately, more than 60% of the children in the census had
accurate information on them. Sixty three percent (63%) of the children had written
information for hepatitis B, 61% for OPT, and 60% for measles and yellow fever. The
proportion of children with information was even higher for children under five years old
(73-76%). This proportion of children with accurate information on vaccine status is higher
than that found in other studies on vaccination coverage in South America, and other
developing countries, where this proportion barely reached 50%(Cassio de Moraes et al
2000, Cutts F 1989, Cutts F 1990, Oa Silva L 1997.). As we have seen in table 6.1, children
without information should have extreme differences in vaccination coverage compared to
children with an information card, in order to change the overall coverage in a significant
way. Second, serological results did not support the idea that children with and without
information on hepatitis B vaccination have significant differences in vaccination coverage.
Children without information on hepatitis B did not have a higher prevalence of Anti-HBc or
HBsAg than children with information. HBsAg and Anti-HBc prevalence were 1.2% and 5%
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respectively among vaccinated children while they were 1.1% and 6% among those without
information and these differences did not change even after controlling for mothers'
infection status or children' sage.
Some potential sources of information bias have been avoided in this study. "Recall bias" is
not possible since people who answered the questionnaire were unaware of their children
vaccination status. "Interviewer bias" is also unlikely since interviewers did not know the
criteria to classify a child as fully vaccinated.
The likelihood of misclassification of vaccination status cannot be completely ruled out. An
important proportion of the children (around 20%) did not have dates of vaccination in their
vaccination cards. only the number of doses they had received. Some others (3-12%) had
dates that we could not use because we were unable to interpret whether the numbers stood
for months or days. This bias would tend to decrease the true magnitude of an association
and therefore would not negate positive findings. On the other hand, some variables related
to vaccination found in other studies may not have been found in this study due to
misclassification. (Rothman & Greenland 1998; Rothman 1986; Kristensen et al 2000;
Elwood M 1998)
Some factors found in other studies to be vaccine coverage predictors did not show an effect
in this study. Mother's years of schooling is one of the most important. The possible reasons
for not having found an association in this study include non-differential information bias;
where exposure is not adequately measured leading to exposed and non-exposed participants
being confused. (Rothman & Greenland. 1998). Information on number of years of schooling
was collected in oral interviews with mothers. and it may have been difficult to recall the
exact number of years that they spent studying, especially amongst the older ones.
Unfortunately. we had no way of measuring the quality of this information during the field
survey. Another potential explanation could be that the level of variation in education was
less than in other studies. Actually this may be one of the plausible causes since most
mothers in our study (67%), were classified in only one category of analysis, one or more
years of primary level Other studies in Latin America have found that low maternal
education level is related to lower coverage in their children. but as a weak association
(Moura da Silva 1999). Kutty has pointed out that maternal education is not a predictor of
child vaccination when the program is conducted in a proactive way. (Kutty V 1989)
1.2. Importance of the results: This is the first field evaluation of the process and impact of
a hepatitis B vaccine in the EPI in an endemic area in Latin America. By 2000, hepatitis B
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vaccme had been introduced in most Latin American countries, but usmg different
vaccination policies. Cuba, Colombia and Brazil were the first countries in the region to
introduce universal child hepatitis B vaccination in the early 90's. Others have introduced
the vaccine more recently. but vaccination is limited to high endemic areas. In a thorough
search of the most important medical literature data bases we were unable to identify similar
population-based studies on hepatitis B vaccine evaluation. (Tambini et al, 1998; Slusarsky
& Magdzikw, 2000; Cabezas C et al 2000; Cabezas C et al 1995).
One of the strength of the present study was that not only hepatitis B vaccination was
analysed, but also full vaccination coverage, and reasons for incomplete coverage. These
factors were studied at two levels, individual and ecological. In the latter category, the
variables of interest were related to health workers knowledge and attitudes. This is not a
common approach in the literature where most studies on vaccination and coverage have
focused mostly on individual factors such as socio-economic differences or on maternal
factors.
Results on coverage are encouraging since a new vaccme has reached a high coverage
similar to others with similar schedules such as OPT. This is especially remarkable because
this is an area where geographical and logistic barriers can easily hamper the efforts of health
services to provide vaccination to the population living in the forest. According to health
workers' perception, hepatitis B is considered an important public health risk and this has
played an important role in attaining this high coverage.
Despite the high coverage found for hepatitis B and other vaccines it is important to
highlight the lack of adherence to the Ministry of Health schedule. The time interval between
hepatitis B doses is longer than recommended which appears to influence vaccine
effectiveness. As we will see later, these delays had many causes and some of them could be
corrected by direct action of the health authorities. This delay in completing the schedule is
more frequent in rural areas where resources for vaccine storage and health worker
transportation are scarce. In these areas no public system of transportation is available and
even villages close to Leticia can be difficult to reach and, what is even more important for
health workers, to leave. Therefore, vaccination activities in remotes areas can only be
started when a round trip is ensured for the HW.
Our results will help health authorities to become aware of the characteristics that
vaccination activities have in remote and/or isolated areas. First, there were differences
between the vaccine coverage reported to the central level by the Health Secretary (HS) and
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those actually found in the field. For hepatitis B, the coverage found was slightly higher than
the one reported by the Health Secretary. According to this last source, children born in 1995
reached 74% coverage with three hepatitis B doses, in 1996 it was 79%, in 1997,88%, and
in 1998, 59%. For the same years, we found 93%, 91%, 91% and 79% coverage. One reason
for these differences could be the size of denominators used by the HS in calculating
coverage, which might be inflated since regional authorities use them to demand resources
from the central level. The two sources agree, however, in the fact that coverage with other
vaccines is slightly higher than hepatitis B. (PAI-MINSALUO 2001)
Another reason for the differences in 1998 could be the changes in the national health care
organisation. According to the central EPI office, vaccine coverage seems to be decreasing
around the country since 1997, after a health care reform was implemented in Colombia
(PAI-MINSALUO 2001). This reform consisted in allowing private enterprises to have an
active role in health care, health promotion and prevention while the State paid them a fixed
amount of money for every person reported to be covered by them. This has been followed
by governmental attempts to reduce bureaucracy in the public health sector which has often
left regional health services without enough personnel to carry out their monitoring and
supervision work adequately.
Official vaccine coverage in Colombia has decreased by 30 to 50% for polio, hepatitis Band
OPT from 1994 to 1999. Hepatitis B vaccine has shown one of the sharpest decreases, from
95% in 1996 to about 50% in 1999. This fall may not be completely true but influenced by
loss of information at the local level since new actors, other than state-run health centres, are
delivering vaccines and some of them have not received adequate training in how to report
vaccination activities. In fact, the decrease in HB coverage observed in our study was less, in
percentage terms, than that reported by the HS (14% in our study, 93% to 79%; and 29% in
the HS, 88% to 59%). Other studies from developing countries showed that the quality of
routine information could be influenced by changes in procedures or by lack of supervision
and monitoring at the local level, though in most reported cases coverage overestimation is
the main concern (Onta SR et al 1998; Streefland P 1995 page 49; da Silva et al 1997)
1.3. Factors related to coverage: The study found that the proportion of fully vaccinated
children is lower than the coverage reached by individual vaccines, and it is especially low
among children under two years, which coincides with other vaccine coverage evaluations in
South America (Moura da Silva 1999). This suggests that children in the Amazon did not
complete the basic scheme of immunisation in their first year of life, but in their second or
even in their third year, especially in rural areas. A fact that is confirmed when the length of
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time to complete hepatitis B scheme is analysed. Fifty percent of children in urban areas
completed hepatitis B vaccination before six months, but in rural areas fifty percent of
children completed this vaccine over 10 months after birth and it is worse in children older
than 5 years. This lag is also observed for yellow fever vaccine since most children received
this vaccine in their third year of life.
Different factors underlie delays in completing the basic scheme, among them the lack of
cold chain for vaccine storage and the calendar of agricultural activities in these
communities. When harvest time arrives, villagers leave their houses and stay several weeks
or months in the jungle, away from public health services. So, if a vaccination team arrives at
the village while people are away, children must wait for several months to receive
vaccination doses. This delay to complete schedules has been observed even in urban areas
in South America. Cassio da Moraes carried out a vaccination survey in Sao Paulo and he
found that the basic DPT scheme was not completed in the first year for all children.
Between 15% and 50% of children in that study completed the first three doses of DPT
during the second year of life. (Cassio da Moraes J 2(00)
Individual features related to not being vaccinated were age, area where children lived,
ethnic group. being affiliated to the social security and some socio-economic characteristics.
For health services evaluation the finding that not being affiliated to the social security is
related to less coverage is important. In Colombia no evaluation has been carried out on the
impact that the health reform has had on health care and prevention programs. It is
interesting that the main effect of this variable has been found in rural areas where
vaccination is provided by public health services alone. The explanation for this association
is not that people without a security social card are rejected from vaccination centres, but
rather that people without this document tend to exclude themselves and their children from
the vaccination service in the belief that health workers might reject them. The concept of
wide social security coverage has been recently introduced in Colombia and its significance
may not yet be well understood by people, especially among those with low levels of
education or living in isolated areas where information on people's rights is scarce. This
finding is usual in developed countries like the USA, where private health care system are
predominant, but for us it is new. This relationship has been less studied in developing
countries where social security is weaker. For example, in a recent study in Brazil, no
differences were found in vaccine coverage by social security status (Moura da Silva 1999)
Other variables closely related to socio-economic disadvantage were found to be associated
with not being vaccinated. Living in a house with palm tree leaf roof was associated with
164
lower full vaccination which is a reflection of socio-economic differences since the poorest
people in urban and rural areas tend to live in houses with roofs made of this material, which
is considerably cheaper and easier to find than tile or corrugated. Economic and educational
differences are commonly reported as associated with low vaccination coverage. This might
be due not only to discriminatory programs but also to differences in the way that the more
educated people look for vaccination services. It has been found that the poorest and less
educated people have a passive acceptance of vaccination activities while active demand for
vaccination is a more common attitude among those with a higher educational level.
Another important individual variable was the place where children live. Living in urban
Puerto Narifio was associated with low coverage for hepatitis B and other vaccines. This is
shocking because Puerto Narifio is one of the few places in the Amazon which have
conditions to store vaccines: in fact, enough doses of all vaccines were found stored in the
hospital of that town at the time of the study. Therefore, we believe that factors related to
health workers' attitudes or knowledge is probably more important than logistic constraints
to explain this low coverage. In fact, nurses who have been appointed only for a one year
term carry out vaccination in the hospital and have little experience as they are newly
graduated. At the time of the survey, the nurse in charge had been less than a year in the
hospital and her knowledge of vaccines was deficient to say the least. She mentioned four
false contraindications for hepatitis B vaccination: children with fever above 38 degrees,
children born prematurely. malnourished children, and antecedents of hospitalisation. For
polio and OPT she also mentioned false contraindications such as fever above 38 degrees,
febrile or non febrile convulsion and previous reaction to the vaccine. Regarding attitudes
toward the job, she felt that there was little time for vaccination activities and more
personnel were needed. All these HW's characteristics could lead to low vaccination among
the population cared for by such a HW.
Some indigenous groups in Mexico have showed low vaccination coverage explained by
health worker's hostile attitudes towards traditional health beliefs and knowledge in these
communities. Such attitudes may raise a barrier between health providers and communities
that could lead to a decrease in the demand for health services including vaccination. More
educated health workers, especially those with little experience in community work with
ethnic groups, might show more hostility to these traditional beliefs among indigenous
communities, which could well be the case in Puerto Narifio. (Nigenda-Lopez G et al, 1997)
There were differences by ethnic group that could be only partially explained since we did
not collect information about knowledge or attitude towards vaccination from mothers, and
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these are the mam factors that might help us to explain the reason for this difference.
Differential exclusion of people belonging to a specific ethnic group is not plausible because
in this region there are no marked social differences between them as is the case in other
developing countries such as India where the caste system interferes with accessibility to
vaccination (Streefland Pet al 1999).
Ticunas had the lowest coverage when full vaccination was analysed for urban areas. The
existence of more barriers in urban areas to vaccination, e.g. command of Spanish, is a
potential explanation, though "Huitotos" and "Others Indians groups" had a greater coverage
in urban areas. Therefore, it is plausible that maternal beliefs in vaccine's good or bad effects
contributed to this difference. Another factor that can help to explain differences in
vaccination coverage by ethnic groups is education level that could be regarded as a proxy
for mother's knowledge or beliefs on vaccination. Only 12% of Ticunas' mothers had more
than 5 years of education while among Huitotos mothers it was 19% and among "Other
groups", 18%. This proportion was even higher among non-Indians and Mestizos (62% and
70% respectively). It is plausible that the lower the mother's education level the higher the
chance that she has incorrect knowledge or beliefs about vaccination.
Less individual variables were related to hepatitis B compared to full vaccination. An
explanation for this phenomenon is that people and health workers identify hepatitis B as an
important menace since the fulminant hepatitis clinical picture is impressive and it frequently
produce familial cluster of deaths and disease. Another potential explanation is that hepatitis
B vaccine has been more available than other vaccines in this region since the Ministry of
Health identified hepatitis B as a priority in these areas. Other vaccines recently introduced
in the Colombian EPI have not reached as good coverage as hepatitis B. Haemophilus
influenzae, for example, has reached coverage of no more than 50% in the first two years
after introduction (Agudelo C et ai, 2000; Higuera Bet aI2001; PAI-MINSALUD 2000).
"Place where children live" is related to hepatitis B in a similar way as to full vaccination.
Puerto Narifio had the lowest coverage but the highest is observed in Araracuara. In this
town there are people still affected by chronic hepatitis and cirrhosis that must be
periodically evacuated for treatment, and fulminant hepatitis had the highest occurrence in
the region. Therefore people are aware of the severity of the disease and the need to have
children vaccinated. In a recent study about factors related to hepatitis B vaccination in
adolescents, those who believed that hepatitis B was a severe disease with no easy treatment
had a higher chance of completing the hepatitis B schedule (O'Rourke 200 I).
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Among the variables associated with socio-economic disadvantage, roof material showed the
strongest relation to hepatitis B vaccination. Other socio-economic factors had weaker
associations confirming that hepatitis B vaccine has been widely available in the Amazon.
The fact that being affiliated to the social security is not related to hepatitis B vaccine is
another reason to suggest that hepatitis B vaccine has been delivered in a fairer way or that
people feel that this vaccine is more important that others.
Another individual characteristic related to hepatitis B was size of family that, on the other
hand, is not related to being fully vaccinated. We did not collect evidence that could help to
explain this relation but it could be strongly related to poverty and probably to mothers' lack
of time to attend vaccination activities. Similar findings have been reported in Brazil where
living in a house with more than three children reduced vaccine coverage by 20 to 30%,
though that difference disappeared in the multi variable analysis (Moura da Silva 1999)
Gender has been found associated with coverage in other developing countries, but it was not
so in our study. Other studies in Latin America have not found differences in vaccine
coverage between males and females. On the other hand, studies from India showed that
boys tended to be more vaccinated than girls, especially in some rural areas (Moura da Silva
A. 1999; Cassio da Moraes J. 2000; Greenough P. 1995; Streefland p. 1995)
1.4. Health workers' (HW) knowledge and perceptions and their relationship to
vaccination coverage: Knowledge of vaccines and perceptions about barriers to vaccination
were measured among health workers who were in charge of the vaccination activities in the
area under study. Hepatitis B was the vaccine second most commonly mentioned
spontaneously by health workers. thus confirming our previous statement about the high
degree of awareness among health workers in the area of the importance of hepatitis B as a
public health problem. On the other hand. it is clear that other recently introduced vaccines
such as Haemophilus influenzae or meningococal vaccines are hardly recalled by health
workers since only one mentioned them. Regarding general knowledge on vaccines, only
half of the health workers were able to respond correctly to a simple question about the age
when children should complete the basic scheme of vaccination. while almost the same
contraindications were identified for several different vaccines such as polio. hepatitis Band
DPT.
Another deficiency in knowledge was detected in regard to hepatitis B vaccine. Most HW
identified the buttock as the place for hepatitis vaccine application and this explain the lower
antibody titres observed among children studied for anti-HBs. A stronger concern arises
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when contraindications for hepatitis B vaccme are examined. Fever, diarrhoea, and
malnutrition were identified as contraindications against hepatitis B and this might partially
explain why some children are not completely vaccinated as is demonstrated when further
analysis is conducted on the relation of this variable and vaccine coverage. Among Amazon
children these three conditions have a high incidence especially in rural areas; therefore false
contraindications could also contribute to longer periods between doses and to delays in
completing the schedule.
Health worker's perceptions and knowledge influenced level of vaccination coverage.
Perceptions of why children were not vaccinated explained low full vaccination as well as
low hepatitis B vaccination, but the association was stronger with hepatitis B vaccination. A
good example is parental fear of vaccine side effects. Children living in communities where
HW perceived this as a barrier had about three times less chance of being fully vaccinated,
while for hepatitis B the decrease in that probability was II times. In this study there was no
survey on parental knowledge or attitude to vaccines and that lowered our ability to evaluate
if this perception was justified or not. The correlation between this perception and other HW
characteristics was assessed in order to try to better explain the relation. More
contraindications against polio and hepatitis B were mentioned by the HW who perceived
parental fear, but at the same time they had more correct answers on hepatitis B and other
vaccines. Mothers had more years of schooling in areas where parental fear was perceived
(median 5 years vs. 3 years) and poverty indicators were lower (47% owning a freezer vs.
7% and 6% having a palm's made roof vs. 16%). These findings stress the need to provide
more information on vaccines and side effects to these communities.
Parental fear of side effects should be understood under the prermse that people from
different areas could assign different values to the act of vaccination based on previous
experiences that include perception of health worker efficiency and honesty (Greenough P
1995). Those HW who perceived parental fear might be at the same time identified by the
community as inefficient or as having bad vaccination practices. Paying more attention to
mobilisation of political will than to public attention when introducing immunisation
campaigns may be an additional explanation to the low vaccination coverage reached in
those areas where parental fear is prevalent. In most developing countries, for health services
vaccination only means reaching a target number of doses applied and this is particularly
critical at local level. Prevention or public health notions are not as important as the number
of doses delivered. It is well known that vaccines are not free from side effects, and in the
case of DPT or BeG parents are less likely to return to complete schedules when their
children have been affected by one of their collateral problems (Wright P 1995; Nichter M
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1995; Streefland P 1995 page 648). Other perceptions related to coverage, such as perceiving
that hepatitis B was a serious disease, were found as well.
Parental vaccination acceptance could be influenced by issues such as parent's occupation,
time available to attend a vaccination session, distance that should be covered and questions
that should be answered during the session. In the Amazon, mothers have to work in farming
activities which take them between 5 to 6 hours daily. This makes it difficult for them to take
children to the health centre except when a vaccination date is stipulated in advance or when
vaccination is delivered every day and all through an entire day.
Streefland et al stress that there are three modes of non-acceptance of vaccination. In the
first, mothers are willing to go but unable to do so. In our conditions heavy workload and
long distances are important barriers for mother's attendance at vaccination activities. People
living in Amazon rural areas need to harvest their agricultural products at different periods of
the year. This kind of activity usually involves moving all the family some hours away into
the jungle in order to increase the manpower in the field. Moving has been related to low or
incomplete vaccination coverage even in developed countries (Findley S et ai, 1999)
In the second mode, mothers refuse to go, it has been pointed out that malfunctioning or
inadequacy of the vaccination services could be the leading reason for this rejection. We did
not measure the proportion of mothers rejecting vaccination nor the reasons underlying that
rejection. However, there were some health workers who perceived parental rejection of
vaccination activities in their communities and in some stages of the analysis this variable
looked an important predictor of lower coverage for full vaccination.
Another mode of non-acceptance is questions about the need for vaccination. This collective
non-acceptance may go beyond the sum of individual refusals and become organised
resistance. Religious objections, doubts about the role that the state should play in the control
of individual risks and even conspiracy-type theories have been involved as causes for this
mode of non acceptance. The latter aspect, we believed, is the most relevant among
populations with low levels of education. Nichter (1995) mentions that in India and the
Philippines people strongly believed that Tetanus Toxoid (TT) was being used in women for
family planning purposes. This does not seem to be the case in the Amazon, at least in the
areas where the survey was done, since most people seem to trust in vaccine's efficacy.
Furthermore, mothers welcome vaccination activities with great enthusiasm in remote
villages.
169
False contraindications were strongly correlated to low vaccination coverage for both full
vaccination and hepatitis B vaccines. The number of contraindications against polio was
related to the chance of not being fully vaccinated while contraindications mentioned for
hepatitis B vaccine were specifically related to lower coverage for this vaccine. This finding
is important because it reinforces the point that our questionnaire was able to discriminate
specific associations related to HW's knowledge. The lack of a continuous education process
would be the most probable cause of this failure and periodic training should help to improve
vaccination coverage in some areas. Some authors have called attention to this aspect
emphasizing that educating health workers on contraindications would not necessarily
guarantee higher vaccination coverage. In health sectors, especially in rural areas,
responsibility for death is avoided at all costs. So, health workers cannot be expected to
vaccinate ill children if they are accountable for children's health by a community that
deems vaccinating during illness a sign of disregard. (Nichter M 1995)
Time working in the health centre was also related to vaccination coverage, the longer the
time the higher the coverage. At this point, it is important to note that health promoters have
stayed for longer periods in their communities than professional nurses and this could be one
reason underlying differences in coverage. Professional nurses are requested by law to spend
a year working in rural communities which is seen by some of them as hard and boring duty.
Therefore, they may be less tolerant to the community's perceptions about need or risk of
vaccination and so be ruder towards mothers which would lead to rejection or to low quality
of family care. Longer time working in the same community could be related to a sense of
trust in the competence of health providers. Giddens (cited in Streefland et ai, 1999) defines
trust as "confidence in the reliability of a person or system, regarding a given set of
outcomes or events, where that confidence expresses a faith in the probity or love of another,
or in the correctness of abstract principles (technical knowledge)". Health workers in small
villages usually live in the same health centre and share every day events with the
community, so it is plausible that the longer the time living in the community the stronger
the confidence and trust the people will put in them.
Curiously, when HW were asked to identify barriers against vaccination they did not identify
any that could be related to their performance as health providers in their communities. The
most important barriers identified by them were those related to parents attitudes towards
vaccination that, on the other hand, should not be perceived as important if continuous
education activities were provided by them to the community. Continuous health education
in the communities is one of the most important roles for HW at the local level. However,
sometimes they forget this and see themselves as providers of clinical services only. In most
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of the village's health centres inspected by us there was no public information displayed on
vaccine activities. This could be due to the high proportion of illiterate mothers in rural
communities, but also to lack of interest of the health worker. Whether it could be argued
that not necessarily providing more information to mothers could lead to higher coverage it
is true that better informed parents could seek for vaccination activities more actively.
In a review of the literature on vaccination and reasons for low coverage, these were
analysed separately for developed and developing countries. The authors reviewed 42
articles, 16 from developing and 12 from developed countries. Three factors they thought
affected immunisation coverage: immunisation policy, psychological aspects, and the role of
health workers as providers of information for the community. Common people in
developing and developed countries could share false beliefs and myths about vaccine
efficacy and vaccination risks. People in developed countries have more access to vaccine
information than in developing countries, and many vaccine rejections have been made by
parents based on information about vaccine safety published in journals, newspapers or
given by health providers. In 1984, an editorial in the Lancet blamed for low measles vaccine
coverage the attitudes of physicians who do not provide enough information to parents about
vaccination benefits. Regarding psychological aspects they remarked that parent's fear of
vaccine side effects and lack of motivation were important barriers to reaching high
immunisation coverage. (Nigenda-Lopez G et al 1997).
Logistic barriers were not identified spontaneously as a problem. This is probably due to the
fact that most HW in rural areas are used to working in these areas and probably believe that
not having vaccines in the health centre or travelling long distances in order to vaccinate
children is natural. However, a question asking for a specific logistical barrier, "children
rejected due to lack of supplies", was related to not being fully vaccinated. Teams based in
Leticia or Puerto Narifio periodically go out to the river and stay for several weeks visiting
every village, vaccinating and carrying out other medical activities along the Amazon River.
These trips, so called "correrias", should be done three times a year, but they are extremely
costly and delays in the schedule are common. Lack of cold chain is the main reason for
delivering vaccines in rural areas using "correrias"; however, it seems that other approaches
could be cheaper and more effective to keep good vaccination levels in rural populations
than this outreach vaccination strategy. Providing rural health centres with gas or petroleum
refrigerators appears to be a more comprehensive strategy for adequate vaccination activities
in these hard to reach areas.
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Viability of vaccination programs is determined by coverage, quality of vaccination service
delivery. acceptance of vaccination and the way it is provided, and prospects of long term
sustainability. In most countries. under WHO and UNICEF pressure, emphasis in national
vaccination programs is put on reaching high coverage, developing logistic arrangements,
and management procedures. But once the "take off "period is over, in what form and under
what conditions can vaccination programs be expected to continue? A possibility in
developing countries is that vaccination programs stagnate after starting due to political or
economic constraints on resources (Streefland P 1995 page: 647). Until now the Colombian
government has maintained the political will to buy hepatitis B vaccines partly because
Cuban manufacturers have been able to keep prices at a low level affordable to us. Financial
and managerial restrictions are seen as a threat for further immunisation developments in
Colombia. These restrictions emerge mainly from the fact that our external debt has grown
sharply in the last 8-10 years, thus worsening a trend to reduce State expenditure. Political
instability and health workers security can also contribute to low coverage in some areas of
the country. Another threat to vaccination program sustainability comes from changes in the
parents' perception of the severity of vaccine preventable diseases. It is possible that after
some more years of continuous vaccination and after a large reduction in the number of cases
of fulminant hepatitis, parental perception of hepatitis B related diseases could change and
acceptance of this vaccine could decrease. But it has not been seen so far, despite the fact
that there have been no cases of fulminant hepatitis in the last two years in these
communities (Spier R. 1999: Greenough P 1995). A technological advance that could help to
maintain hepatitis B vaccine sustainability is the introduction of combined vaccines.
Colombia is about to add to the EPI schedule a combined vaccine containing hepatitis B,
Haemophilus influenzae and OPT. A drastic reduction in the number of injections needed to
immunise a child might increase parental support of vaccination. (Andre F, 2001; Nolan T et
al 200 I; Kurstak E 200 I)
The way people look for immunisation could also be a good predictor of vaccination
sustainability. Nichter made a distinction between active demand and passive demand for
vaccination. Active means that the public is informed about benefits and need for specific
vaccination. Passive acceptance denotes compliance, the public yields to the
recommendations and social pressure, if not prodding, of health workers and community
leaders (Nichter M 1995). The role of the HW is prominent in promoting active demand.
Education activities could enhance mothers' knowledge of vaccines leading them to seek
more actively for vaccination for their children and decreasing their anxiety about side
effects. It is probable that most of the fears about vaccine side effects found in the
communities in this study came from more educated mothers, as has been pointed out before.
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Resistance to vaccination activities may be an important barrier to achieving adequate
coverage. This resistance may arise from different sources; one from the public and also
from health workers themselves. How and why vaccination acceptance becomes a prevailing
pattern in a community is the result of various factors. In rural Amazon the same staff in the
health centres are involved in curative and preventive health care and in most villages under
study, contact between primary health workers and patients usually includes a range of
activities which lead communities to perceive health workers as important members of the
community. On the other hand. delays in the schedule of "correrias" and, therefore, delays in
completing the vaccination schedule may lead communities to reject vaccination or to
become resistant to these activities. In Ethiopia's rural areas it has been documented that late
arrival at villages due to transport difficulties for vaccination teams have led to communities'
rejection of vaccination activities. This is reinforced by the HWs attitude of being in a hurry
and by poor vaccination practices when HWs are under time pressure in remote areas.
(Srreefland P et aI, 1999).
It has been reported that when national or regional health measures are introduced from
above, resistance among health workers may be induced. This is especially true if high rank
health officers use intimidation and/or coercion against local HWs in order to increase
vaccination coverage. This can lead to HWs negative attitudes and low motivation for
vaccination activities that jeopardises the vaccination program's sustainability. (Greenough
P, 1995 page 633). While health workers interviewed in our study showed some deficiencies
in their knowledge and perception about vaccination it is clear to me that most of them are
deeply identified with their role as health providers in these communities and with the
success of vaccination activities if they have adequate logistic support. This would assure
that the sustainability of the vaccination program will not be hampered by health workers'
resistance or by communication barriers between local people and the HW.
It is very encouraging to find that more than 90% of children had received BCG vaccine in
such poor areas. Besides the benefits that BCG has in counteracting tuberculosis infection, it
has been suggested in recent studies that children receiving BCG have a reduced chance of
dying in the first six months of life (Kristensen 2000; Fine 2000).
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II. Serological results and vaccine effectiveness:
11.1. Methodological issues: Selection bias could arise in studies where the population is
requested to donate blood samples. It is not an uncommon feeling among ethnic groups in
the Amazon that these samples are used for copying genetic characteristics of their
populations. The field team was asked by old Huitoto leaders in some communities if one
objective of drawing blood samples was cloning them. Another potential source of selection
bias in community-based surveys is self-selection bias, where people who referred
themselves to participate are different from those who are theoretically eligible for the study.
This was avoided in our study because participants were engaged in the study by random
cluster selection followed by a house to house search in selected clusters only and because
those people who had survived a fulminant hepatitis episode and who referred themselves to
participate, were bled but their results were excluded from the analysis.
We found that 35% of all non-infected children lacked vaccination data but 52% of the
HBsAg+/Anti-HBc+ did not have vaccination card as well. . This differential proportion in
missing data might be seen as a potential source of selection bias, but as Schlesselman has
pointed out, different proportions of missing data between cases and controls does not
introduce selection bias in itself. If the exposure proportion were equal between cases with
and without data and the same is true for controls then, the OR based only on the
respondents would be equal to the OR in the entire population. We try to test this fact
indirectly using the distribution of another important risk factor, mothers' Anti-HBc status.
The prevalence of this variable across the levels of cases and controls, with and without data,
is showed in table 6.2.
Table 6.2. Proportion of Anti·HBc+ mothers by cases and controls and across levels of
vaccine information. Rural areas.
Cases Mother
HBc+
Anti-
Cases with
vaccination data 10/10 (100%)
Cases without
vaccination data 11112 (92%)
Controls
Controls with
vaccination data 345/500 (69%)
Controls without
vaccination data 1841287 (64%)
We can see that the distribution of the exposure to Anti-HBc+ mothers is similar between
cases with and without data, and between controls with and without data. This suggests that
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lack of information on vaccine status is not an important source of selection bias in our study
and that results on children with information can be extrapolated to the whole population
from which they were selected. (Schlesselman J 1985 page 132)
Comparing infection data from time periods before and after vaccination may be a subject
for concern because different study methods and laboratories procedures were used. The
serological survey made by Cristancho before vaccination started was done by gathering
people in health centres and taking samples from all who agreed to participate in the study.
Therefore. selection bias was more probable in her study. However. public awareness about
hepatitis B infection in these communities was high at the time ofCristancho's study and this
was the first time that a vaccine was offered, so high rates of participation were likely. Less
validity should be assigned to Cristancho's results in Puerto Narifio because she recognised
in her report that due to logistic problems, the response of the community was lower than
expected, and few children were included in the sample. On the other hand, our survey was
done house to house and we tried to motivate reluctant people to participate. In fact, the
proportion of people who refused to participate was very low - less than 5% of the target
population, and the main reason for not being included in the study was absence from the
village due to farming or fishing. This high rate of participation is certainly due to the level
of awareness about hepatitis B in these communities.
Potential concerns in the interpretation of the results arise from the type of the study itself.
Causal relationship may be hard to assess for some factors when a cross-sectional survey
design is used. Mothers' anti-HBc status is one such factor where the causal relationship may
be difficult to interpret. because both the factor and the outcome were measured at the same
time. Theoretically, it is not possible for us to determine accurately if mother infection
actually preceded children's infection especially in urban areas, where prevalence is low, or
in the youngest mothers. However, for this relation other causal criteria hold and we can
mention: strength of the association, consistency, plausibility, and coherence. (Rothman K
and Greenland S 1998 pages 24-28; Mahoney F 1999 pages 360-62; Hilleman M 200 I).
Other variables, namely time from birth to first dose or time between doses, filled the
temporality criteria more clearly because time is a fixed variable and, when controlling by
age, we are controlling for age at infection. In table 5.9 we can observe that HBsAg+
children probably received the first two doses of hepatitis B after becoming infected. For
example, one child was HBsAg+ in the age group 1-3 years and he received the first dose
more than 6 months after birth, while the second dose was given to him 6 months after the
first one. This meant that he completed two doses of hepatitis B, which had a protective
effect of 70-80%, when he was one year old well after the intended EPI schedule.
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Furthermore, this child received the third dose 9 months after the second one, i.e. 21 months
after birth. During such a long interval. a child living in rural areas and born from an infected
mother has many opportunities to be in contact with HBV and to become a carrier.
"Recall bias" or "interviewer bias" were avoided by us because both the interviewed and
interviewer were blind regarded case status. Case and controls were classified after the
laboratory results were obtained, and this happened after the field data collection.
Additionally, exposure to vaccine was confirmed only when a vaccination card was
available. Other potential source for misclassification bias was the absence of information on
vaccine status in a large proportion of the target population. In fact, we assessed the direction
of this potential problem by collecting blood samples on children without vaccme
information and processing it for HBV markers. It seems as if most children without
information were actually vaccinated as they had a similar risk of hepatitis B infection than
children with vaccination card and furthermore, they had similar Anti-HBs levels than
children with vaccination card (70% had levels >10 IV/ml).
Another source of concern was the study's lack of power to detect associations that have
been identified as important in other studies. The most relevant was the association between
HBsAg mothers' status and their children's HBV infection. Only 3% of the HBV negative
children were exposed to that risk factor and it yielded statistical power of only 30%. This
means that we had a higher probability, == 70%, of overlooking an association that truly
existed. The same is true for evaluating the role of being born to an HBeAg positive mother.
Few children were found to be born to such a mothers and lack of power limited our ability
to find a statistical relation. It should be born in mind that in a cross sectional study it might
be hard to assess the relationship between surface antigen, e antigen, and child infection
because those markers may have been present when children were born but not at the time
when the study is carried out, several years later. In Alaska, it has been found that up to 70%
of people HBeAg + can lose this marker after 6 to 10 years of follow up (Harpaz R et al
2000). Table 6.3 shows that prevalence of HBsAg varies across age groups in mothers from
the Amazon. There are two peaks of HBsAg prevalence, at age groups 20 to 24 years and 35
to 39 years, but, at mid age groups or in the older, prevalence decreases. This reinforces the
idea about cross sectional studies being a weak tool to assess the role of HBsAg+ mothers
when evaluating vaccine effectiveness especially in areas where horizontal, and not perinatal
transmission, is the main source of infection for children.
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Table 6.3. Distribution of hepatitis B infection and HBsAg carriage by age, among
mothers.
Age Number tested. Number Number tested. Number Number
groups Total tested. Rural. Total tested. tested.
population. (% Anti- population. Rural. Rural area.
(% Anti-HBc+) HBc+) (% HBsAg+) (% HBsAg+) (# HBeAg+)
15-19 y 49(33) 29 (52) 49 (0) 29 (0)
20-24 Y 228 (38) 114(53) 229 (3.9) 115 (7.0) 4 (2)
25-29 Y 285 (36) 116 (60) 287 (3.5) 115 (4.3) 5 (2)
30-34 Y 254 (47) 109 (72) 254 (3.9) 109(3.7) 3 (2)
35-39 y 190(47) 91 (76) 190(5.3) 90 (9.0) 5 (4)
40-44 Y 103 (51) 33 (70) 103 (2.9) 33 (3.0) I (I)
45-59 Y 65 (75) 40 (90) 65 (3.0) 40 (5.0)
Case misclassification is another potential source of concern for studies that rely on
serological tests. When factors associated with HBsAg prevalence were analysed, HBsAg+
cases were restricted to those who were HBsAg+/anti-HBc+, and those who were positive
for HBsAg only were not included in further analysis. This allowed us to decrease the
probability of including false HBsAg+ positives as cases which would lead to an
underestimation in the magnitude of the association. In fact an assessment was done to
evaluate the potential effect of including children HBsAg+/anti-HBc- among the cases. The
absorbance ratio. observed absorbance/cut-off point. was compared between those samples
HBsAg+/anti-HBc+ and HBsAg+/anti-HBc-. The median of the absorbance ratio in the first
groups was 42 while it was 4.7 in the second group. The 251h percentile was 26 in the first
group and 2.5 in the second while the 751h percentile in the first group was 66 and 20 in the
second. These findings confirmed that many samples HBsAg+/Anti-HBc- were false
positives and. therefore, should have been excluded from further analysis. as we did. On the
other hand. this approach could decrease the sensitivity of the case definition but it has been
demonstrated that a lower sensitivity would not bias the RR if the non-detected cases are not
included in the denominator. Therefore, children HBsAg+/Anti-HBc- were exclude from
denominators as well (Rothman and Greenland 1998, pages 128-132).
11.2. Hepatitis B infection and vaccine effectiveness: Compared with results from studies
done before HBV vaccine introduction in the region the prevalence of hepatitis B infection
and HBsAg positivity has decreased. Both markers have fallen between 60% to 80%
depending on the age group and gender. In five to nine-years old children the reduction is
greater than for older ages (72% for infection and 71% for HBsAg positivity). When
stratified by area, reduction is greater among children living in Araracuara and Puerto
Santander (77% for infection and 73% for HBsAg positivity) while there is no difference by
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gender in this age group. At the oldest ages (above 9 years) there is a statistical reduction in
the prevalence of infection (62%, 95% Cl 49-72%), but not for HBsAg positivity (-11%).
Additionally, in this age group HBsAg prevalence was higher in females than in males.
This decrease in effectiveness might be an effect of the age of children when vaccination
campaigns were started. Children under 8 years were born after vaccination started so they
have more chance to have received HBY doses early in life and, therefore, of the vaccine
preventing development of HBsAg positivity. Children who are now older than 9 years were
three years or older when vaccine was introduced and had at least two factors which could
potentially lead to decrease the vaccine efficacy. First, they may have been more difficult to
reach by vaccination teams, either for starting the scheme or for completing it, since they are
more likely to refuse vaccine injections than younger children. This is supported by the fact
that older children were less likely to have a vaccination card. In 36% of the children in our
survey it was not possible to establish what their real vaccination status was, and this
absence of information increased with age. A second factor might be that they were more
likely to have been infected before the vaccine campaign started. Before vaccine was
introduced in Araracuara five year old children had a 14% prevalence of HBY infection
(95% Cl 4-37%) and a similar prevalence of HBsAg. (Cristancho LM 1992). It means that,
in Araracuara and other rural areas, around 10% (4-20%) of children aged I to 4 years where
already infected at the time of being vaccinated. In Thailand, Poovorawan et al. (200 I) found
a trend to increasing HBsAg prevalence with age because in children aged I to 2 years it was
4% but jumped to 9% in those aged I I to 12 years.
Despite the large number of hepatitis B vaccine effectiveness evaluations published over the
last 15 years there are still relatively few population based reports on the reduction in HBY
infections after vaccine introduction. This information gap is especially important in Latin
American where Brazil, Peru, Cuba, and Colombia have introduced hepatitis B vaccination
but there has not yet been a comprehensive evaluation of its effectiveness. Only Cuba and
Colombia have introduced vaccine using a universal vaccination strategy; other countries in
Latin America use hepatitis B vaccination only in endemic areas (Tambini et al, 1998;
Slusarsky & Magdzikw, 2(00). Recently, a Peruvian group of researchers has made an
assessment of the impact of the introduction of hepatitis B vaccine in the Huanta Valley, an
endemic area of Peru located on the highest places of the Andes. There the vaccine was
introduced in 1994 using a 0-2-4 months schedule and coverage in newborn children was
98%, while it was 84% among those children aged one to 4 years and born before the
vaccine introduction. They measured the whole prevalence of hepatitis B infection and found
a reduction from 83 to 92% in the prevalence of all markers of infection. However, they did
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not evaluate if vaccination characteristics such as length of time between doses could
influence effectiveness or the impact of other risk factors for HBV infection. Besides almost
all the vaccination process was supervised directly by researchers since this was a pilot study
area before the introduction of HB vaccine in Peruvian endemic areas (Cabezas C et al 2000;
Cabezas C et al 1995).
In a recent report from Taiwan the authors showed the effectiveness of a recombinant
Hepatitis B vaccine. The study involved two year old children and results are similar to those
we are presenting from the Amazon. A prevalence of HBsAg of 2.5% was reported which
resembles the prevalence of the same marker in our children of the same age living in rural
areas (2.7%). When global infection (any marker positive) is considered, a prevalence of
6.5% was found in Taiwan while it was 10.3% in children from rural areas in our study.
Children born from HBsAg negative mothers had a similar HBsAg positivity proportion to
ours (0.6o/c to 1%). (Hsu Mei 2(01)
We were unable to determine what the real prevalence of HBsAg carriers was in this study
since only one sample was collected from every participant though the high absorbance ratio
showed by those HBsAg+/anti-HBc+ might indicate that many of them are carriers. Other
studies have found that effectiveness against chronic carrier status is higher than against
HBsAg positivity as measured in cross sectional studies. In China a median effectiveness of
78% against HBsAg prevalence was found after 15 years of follow up in a cohort of children
vaccinated when they were aged 3 to 36 months. However, protection against hepatitis B
chronic carrier status was 96% compared with 78% against HBsAg positivity, an important
quantitative and qualitative difference (Liao Su 1999).Effectiveness against infection was
84% .HBsAg prevalence in vaccinated children ranged from 0 to almost 6% (median 2%)
during the study period, while anti-HBc prevalence ranged from I to 11% (median 4%)
In the Pacific islands, a known high endemic area, a plasma derived vaccine was introduced
at the beginning of the 90' s. Wilson et al (2000) carried out a cross sectional serological
study in five Pacific countries, in order to determine the vaccine's ability to reduce hepatitis
B infection. The sample included children aged 12 to 24 months (mother's were bled as
well) and as a control group 10 to 13 year old children born before vaccine introduction. In
vaccinated children, they found a prevalence of infection that ranged from 5 to 12% with a
median of 9%, while HBsAg prevalence ranged from 0.7% to 3.8% .. In the control group,
the HBV infection prevalence ranged from 47% to 77% while HBsAg prevalence was 7% to
27% (median= 13%). Among mothers, infection prevalence ranged from 78% to 94% while
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HBsAg was found between 7% and 19%. As expected, higher prevalence In mothers
correlated with higher prevalence in vaccinated and unvaccinated children.
The HBeAg prevalence found by Wilson among HBsAg positive mothers (52%) is higher
than the level we found in the urban Amazon but similar to levels in mothers from rural
settlements. They found that 27% of children born from an HBeAg positive mother were
HBsAg +( 13/48) while none was found positive among children with the same risk factor in
our study (0/24). It has been estimated that children born from an HBeAg positive mother
have a 70-90% chance of becoming HBsAg positive while it is only 5 to 10% when mothers
are HBsAg positive but HBeAg negative (Mahoney F and Kane M. 1999). The risk of
HBsAg antigenaemia in children born from HBsAg positive mothers was higher in children
from the Pacific Islands than in our study (OR= 15.0 vs. none).It has been described that
there are differences in the chance of perinatal transmission between different areas because
HBeAg prevalence and HBV -DNA levels vary among HBsAg+ mothers across regions.
(Mahoney F 1999, Shapiro C and Margolis H 1992, Botha Jet al 1984) . Mothers in Asian
countries are more infectious to their children than mothers in Africa, and our results showed
that perinatal transmission risk is even lower for Amerindian children. This finding has been
repeatedly observed in other studies in Amerindian populations living in the Amazon. In a
recent study in the Brazilian Amazon area, Miranda Braga et al found an HBeAg prevalence
of only 6% among 70 HBsAg+ Indians examined. All of them were children under IO years
old from the same family, data that supports the idea that perinatal transmission in the
Amazon areas has only a marginal importance. Reasons for these differences in perinatal
transmission rates are still unclear, but ethnic and therefore genetic characteristics could well
be involved. (Hino K et al 200 I; Tsebe K et al 200 1; Miranda Braga W et al 2001).
Poovorawan Yet al (2001) remarked that 35 to 40% of all HBV infections around the world
are caused by perinatal transmission which is less than the proportion of perinatal
transmission we found in our sample population.
In our study the proportion of HBsAg positive children born from an HBsAg mother was
10% compared to 68% in the Pacific countries and around 50% in Taiwan (Wilson et al 200;
Hsu et al 2001). These differences reinforce that perinatal transmission in the Amazon is less
important than in other endemic countries. Another point in favour of this statement is the
higher effectiveness we found with the vaccine alone compared with the findings in Taiwan
(Hsu et al 200 I; Beasley et al 1983). Beasley found that protection against hepatitis B
positivity was 95% when using HBIG plus vaccine but only 75% when using vaccine alone.
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There are differences in vaccination policies between Colombia and other countries. HBIG is
used in Taiwan for children born from HBeAg positive mothers, which represents almost
20e;( of their children. while in most endemic countries, including Colombia, vaccine is used
alone because the proportion of children born from HBsAg positive mothers is lower and
because HBIG is expensive .. In Liaos study Chinese children received hepatitis B vaccine in
a 0-1-6 months schedule while in the Pacific Islands a 0-2-5 months schedule was applied.
Another difference that is important to remember is the type of vaccine evaluated since there
are not many studies published evaluating the performance on the field of a recombinant
vaccine, which was the focus in our results. Even now. 15 years after the licensing of the
yeast-derived vaccines, there are more published studies evaluating plasma-derived vaccines.
The important decrease in HBsAg prevalence among children born from HBsAg positive
mothers suggest that vaccination is adequate to control HBV infection even without HBIG ..
A simple maternal screening plan focusing on mothers who live in rural zones would help to
reach elimination quicker. (Andre F and Zuckerman Al 1994). In a recent study from
Gambia. Viviani et al showed one of the highest protective efficacies against carrier status
(95%) using only hepatitis B vaccine. similar to those found in Taiwan where HBIG is
incorporated in the scheme for children born from HBeAg positive mothers. One important
aspect that distinguishes this study is that children received four doses of plasma derived
vaccine (at birth, 2,4, and 9 months of age). By nine years of age, 8% of vaccinated children
became infected compared with 50% in the unvaccinated group (83% protective effect in
vaccines) and true cumulative infection prevalence was 13%. (Viviani Set al 1999)
HBsAg prevalence in girls older than 10 years old was more than twice as high as prevalence
in boys, while before vaccination boys in the same age group had higher HBsAg positivity
than girls. There are at least two potential explanation for this difference. One is differential
access to hepatitis B vaccination by gender among children who were alive when vaccination
started. We processed data on HBV vaccination specifically in this age group and no
differences by gender were observed among children aged 10 or 11, but at age 12 boys had
higher coverage than girls though numbers were very small, only 20 boys and 19 girls were
included in the survey. Twelve boys (60%) and 15 girls (79%) did not have accurate
information on HBV vaccine status, but among those with vaccine records seven boys were
fully vaccinated (7/8) compared with only 2 girls (2/4).
Another explanation for the gender difference might be differences in exposure to HBV.
Health workers in the area said that girls are frequent victims of sexual abuse, especially in
rural communities. Even in the absence of violence, Colombian girls tend to initiate sexual
life earlier than Europeans (16 vs. 20 years) and a study from Puerto Asis, a town in the
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Colombian Amazon region. showed that women in these areas start sexual life even earlier
than the Colombian average (around II years).
One important finding in our study was the difference in hepatitis B infection and HBsAg
positivity between rural and urban areas. Though in both, infection prevalence increases with
age. it is much sharper in rural areas. On the other hand, HBsAg prevalence seems to
increase with age in rural but not in urban areas. Children are more exposed to HBY in rural
than in urban areas because more adults and older children are HBY infected or HBsAg
positive and HBsAg positive mothers were more prone to be HBeAg positive in rural than in
urban areas. This finding is important for public health decisions because our data provides
the opportunity to put more emphasis on control measures in rural areas rather than urban.
Strengthening vaccine delivery and increasing vaccination opportunities for rural areas
should be one of the first steps to be taken.
The only published study comparable to urban Leticia is one from Manaos, in the Brazilian
Amazon, where 21% prevalence was found. However, this result was not stratified by age
group or sex. so comparison could only be done at an aggregate level (Silveira T et al 1999).
Other results from urban areas in endemic Latin American countries came from the
Dominican Republic. Overall, prevalence there was 21% but by age it was 9% in children I
to 10 years while in those aged 16 to 40 years it was 30%. Women had a higher prevalence
than men (24% vs. 13%). Socio-economic factors were associated with HBY infection in this
study and people classified in the lowest socio-economic classes had higher infection
prevalence. An important role for sexual transmission was found in the Dominican Republic
and Brazil where prevalence showed a sharp increase in people older than 15 years. It is
important to note that this increase is observed in those countries with the highest prevalence
but not in those with the lowest ones such as Argentina, Chile and Mexico (Silveira T et al
1999)
Our study has an important strength in the fact that the analysis took into account risk factors
for hepatitis B infection other than mother's serological status; this is not a frequent
approach in other studies. It is clear from our results that some of these variables continue to
be an important predictor of hepatitis B infection even after vaccine introduction. Number of
siblings and child's birth condition were the most important individual variables identified.
Regarding birth condition. those children whose birth was not attended by a nurse/MD were
twice more likely to be found HBsAg positive than those who were attended by a doctor or
nurse. This relation was even stronger in rural areas where the odds ratio increased to more
than 10-fold. Some factors could explain this difference; one is that being born in a hospital
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or health centre would mean receiving the first dose of hepatitis B vaccine closer to the birth
date. Another potential explanation would be that practices around birth carried out by
traditional midwives or by mothers themselves increase the child's risk for HBV infection. It
might be possible that when the child is born in the community he (she) would have more
exposure to mother's blood because the procedure to cut the umbilical cord may be delayed.
Health workers in rural areas said that in births attended by the mother herself it is not rare
that she has to cut the cord with her teeth thus increasing the likelihood of putting children in
contact with HBsAg positive body fluids.
Wilson et al also explored the impact of other risk factors in hepatitis B infection. They
found that female gender was associated with a higher risk of being infected (any marker
positive) as well as having received only two doses of vaccine. Gender differences were
similar to those observed by us, but in their study they could not claim that the explanation
might be sexual transmission since only children less than 24 months were included.
We found that number of siblings was an important factor associated with HBsAg
prevalence. The reason for this lay in the role that horizontal transmission has in maintaining
HBV endemicity in the Amazon. More children in a crowded environment mean more
opportunities to be in close contact with HBsAg positive children and to be exposed to an
infection source. No relation between HBV infection or HBsAg positivity and number of
siblings was found in Pacific children (Wilson et aI2(01).
One important point raised by Wilson 2000 is the cost effectiveness of HBV vaccination.
They estimate that vaccination prevents 10 of every 100 children from becoming HBsAg
carriers at a cost of US$ 37 per prevented carrier, assuming that vaccine price is US $0.5 per
dose which is the same price that Colombia pays for the Cuban vaccine. Assuming that 25%
of HBsAg positive children would die prematurely, these prices, plus the reduction in
number of HBsAg carriers, would mean a cost of US $190 per premature death prevented.
We were able to demonstrate that delay in dose delivery is associated with a higher
likelihood of being HBsAg positive. This aspect has not been frequently addressed by other
studies either because vaccination timing was standardised (clinical trials) or because the few
studies focusing on time between doses have chosen anti-HBs titres as the evaluation
outcome. This is important because former studies, focusing on Anti-HBs titres as the main
outcome, have concluded that hepatitis B vaccine could be delivered following almost any
schedule (0-1-3. 0-2-4, 0-1-6, etc ..). Instead, our results showed that while longer intervals
could produce higher Anti-HBs titres they might favour infection leading to the HBsAg
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carrier status. Ruff T et al showed in Indonesia that a delay to receiving the first dose after
the birth of more than week, was associated with a higher risk of being HBsAg+. (Inskip H
et al 1991; Hadler S et al 1989; Ruff T et al 1995). Wilson et al did not find a relationship
between delays in applying the first or second vaccine dose and hepatitis B infection or
HBsAg positivity despite finding that a significant number of children received vaccine
doses in a different schedule to that recommended. The proportion of children receiving the
first dose on time was 22% to 90% depending on the country while timeliness for the second
dose ranged between 46% and 76%, and by 6 months of age fully immunised children
ranged between 22 and 84%.
It is interesting to note that our study did not find differences in infection rates between
completely vaccinated children and incompletely vaccinated children. Lin D et al found in
Taiwan that incompletely vaccinated children had twice the chance of being HBsAg+/anti-
HBc+. However, it is important to recall that perinatal transmission is the most important
source of HBsAg carriers in Taiwan while it is negligible in the Amazon. (Lin 0 et al 1998)
Our study is more representative of the true serological HBV infection and HBsAg
prevalence after vaccine introduction than others published because it was evaluated routnien
vaccination and almost every child who fulfilled the age criteria, and whose guardian agreed
to participate, was included. Our results are prompting some changes in the way this
program is conducted in the Amazon region. Maternal screening has started in these areas in
order to identify high risk children and to ensure them an adequate vaccination schedule
while health authorities are studying the feasibility of extending this screening to other
endemic areas in the country.
11.3. Anti-DBs titres: A high proportion of participants in our study were found without
detectable levels of anti-HBs despite having written vaccination evidence. One year after the
third dose, almost 20% of children in our study had anti-HBs levels below 10 IV/ml which is
high compared with findings from others studies, where children have been vaccinated under
more controlled conditions. One year after being vaccinated with three or four doses of
plasma HB vaccine, only 4-5% out of 631 of children was found with anti-HBS levels below
10 IUlml in Holland. In the same study, only I% of children vaccinated with four doses of a
recombinant vaccine had undetectable anti-HBs levels. (Del Canho et al 1992). Other studies
from Taiwan, The Gambia. China, and Canada showed results very similar to Holland.
(Wong V et al 1984; Jack A et al 1998; Xu Z et al 1995; Marion S et al 1994)
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A large difference was found with the amount of anti-HBs levels as well. In our study, the
anti-HBs geometric means titre (GMT) one year after the third dose was 250 IV/ml while it
ranged from 1142 IV/ml to more than 15000 in Del Canhos study. For the same length of
follow-up. anti-HBs GMT ranged from 270 to 2068 IV/ml in other studies. (Jack A et al
1998;XuZetaI1995;MarionSetaI1994).
When longer periods of follow-up were considered, the differences in anti-HBs levels
between our study and others became less important. In our results, children bled 5 years
after the third dose had an anti-HBs GMT of 135 IV/ml and 19% did not have detectable
anti-HBs levels. In more controlled studies and for the same length of follow-up GMT
ranged from 41 to 158 IV/ml while the proportion of children without detectable levels was
between 12% and 37%. Eight or more years after the third dose our children had an anti-HBs
GMT of 78 IV/ml and 33% of them did not have detectable anti-HBs levels. This is very
similar to the information reported by Jack et al in The Gambia, where 32 % of children
lacked anti-HBs 9 years after being vaccinated with four doses of hepatitis B. At the same
time, they found that the anti-HBs GMT was 19 IV/ml. In Canada and after 8 years of
follow-up, Marion et al reported that the proportion of children without anti-HBs detectable
levels reached 30% while the anti-HBs GMT was 106 IV/ml. (Wainright R et al 1989;
Whittle H et al 1991; Xu Z et al 1995; Marion S 1994; Del Canho Ret al 1992; Jack A et al
1998).
Other studies, carried out on populations under regular vaccination programs, have found
high proportions of vaccinated children without detectable anti-HBs levels. Poovorawan et al
found an overall rate of 44% children without anti-HBs, even higher than the rate we found
(26%). Around 70% of children aged I to 2 years had anti-HBs detectable but by the age of 9
to 10 years only 45% were anti-HBs positive. Wilson et al found that between 21 and 51% of
fully vaccinated children did not have detectable anti-HBs which is higher than the
proportion we found. Some possible explanations given by Wilson for the lower prevalence
of children with anti-HBs protective levels, as compared with the prevalence found in
controlled studies, included variations in vaccine storage and handling, particularly vaccine
freezing, which could be also a potential explanation for the high proportion of children
found without anti-HBs in our study. (Poovorawan et al 200 I; Wilson et al 2000).
Differences in anti-HBs levels between studies may be due to the type of vaccine used in
different studies or in the dose that children receive. The Cuban manufactured vaccine used
in the Amazon contains 20 jJg of HBsAg per vial and every vaccinated child is intended to
receive half dose of it (10 ug). It has been demonstrated that plasma derived vaccine, which
has been used in most of the studies presented here, is more immunogenic than the
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recombinant especially when anti-HBs levels are compared shortly after completing the
scheme. Del Canho et al (1992) and Stevens et al (1992) vaccinated groups of high-risk
newborns with plasma or recombinant HBV vaccines and obtained serum samples from
them at similar periods of follow up. Table 2.3 shows that in both studies children who
received plasma-derived vaccine had consistently higher levels of anti-HBs than children
who received the recombinant.
We believe that HW's poor knowledge regarding hepatitis B vaccine may be related to the
proportion of children without anti-HBs. Most health workers interviewed by us said that the
buttock was the right place to apply the hepatitis B vaccine. It had been demonstrated, in
adults that delivering hepatitis B vaccine in the buttock was related to a lower serological
response and recently it has been demonstrated in children as well. Alves et al randomly
assigned 258 infants to receive a recombinant hepatitis B vaccine either Gluteal or at the
anterolateral thigh muscle. The proportion of children who developed anti-HBs levels
greater than 10 mIV/ml was similar in both groups but anti-HBs GMT differed (1229
mIV/ml for the buttock group and 1862 mIV/ml for the anterolateral thigh muscle group)
(Fessard et al 1988; Alves A et at 200 l)
In our study. we found that the amount of anti-HBs was related to the number of days from
the child's birth to the first dose. Children who received the first dose in the first two weeks
after birth had lower antibodies levels. a higher likelihood of being anti-HBs negative, and a
lower chance of having Anti-HBs levels above 1000 IV/m!. Time between doses was not
statistically related to these outcomes though delays to receive the second dose (>5 months
from the first dose). or the third dose (>7 months from the second dose) were related to
higher anti-HBs levels. There have been few attempts before to try to relate dose timing and
response to HB vaccine, and they have been done using plasma derived vaccine. Marion S
examined the influence of time from birth to first dose in Canadian children born from
HBsAg+/HBeAg+ mothers. She found that those who received the first dose more than 2
months from birth had higher anti-HBs levels than those who received it closer to the birth
date (GMT 590 IV/ml vs. 110 IV/ml). Hadler S et al in a study among Yucpa Indians found
that the inmunologic response to HB vaccine was better among those people who received
the third dose later than recommended. This study also found that those receiving the first
dose after 20 years of age had a lower immunologic response. Hadler's study results are not
completely comparable to those in the present study because it was done on a population
with a wider range of age, and no specific analysis was done regarding time from birth to
first dose. On the other hand. our inability to find a relation between time doses and anti-HBs
titres did not seem to be an issue of low statistical power, since the sample size in the
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Hadler's study is similar to that in our study. So, it is probable that in older age groups,
young adults and adults, time between doses may be a more important predictor of the
serological response than in young children. Results from an study in Gambia seems to be in
concordance with this statement. Inskip H et al carried out a study in more than one thousand
young children vaccinated with a plasma-derived vaccine and no relation was found between
time doses and serological response. (Hadler S et al 1989; Inskip H et al 1991; Marion S
1994)
In summary our study has shown that the process of implementing a new vaccine against
hepatitis B in the Colombian Amazon has been successful. We strongly believe that our
findings are not the results of potential sources of bias but that they come from true factors in
the population where the study was done. HBY vaccine has reached a high coverage
especially among children born after the implementation of the program though adherence to
vaccine schemes should be improved. It has also been shown that following the vaccine
introduction. there has been an important reduction in the prevalence of HBY infection and
HBsAg carriers especially among children aged 0 to five years. However, new vaccination
strategies should be introduced in order to ensure an adequate and timely access of the
population to vaccination activities, especially in rural villages. Based on our
recommendations the Amazon Health Service has started a serological surveillance system
on pregnant women aimed to identify those mothers HBsAg+ and to provide their children
with more adequate HBY vaccination schemes.
III. Conclusions and Public health implications of this work:
The findings from this work have implications for the improvement of the process of the
vaccination program as well as for the impact of the hepatitis B control program in the
Amazon and. probably, other endemic areas in Colombia. First we found that while the
overall coverage of vaccination is good, the age at which children receive the vaccine is far
from being that recommended by the MOH. It is highlighted from the results that logistic
constraints and inadequate health worker knowledge are important factors associated with
delayed vaccination.
Some simple measures may lead to an improvement in the process indicators: I) Continuing
training and supervision of the health workers may reduce lost opportunities by giving them
adequate knowledge on vaccine contraindications. 2) The poorest people, especially in rural
areas, should be regularly informed about their rights under the social security scheme in
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Colombia. Vaccination has been paid for, for all children, by the MOH, so they have the
right to be vaccinated whether they hold a health insurance card or not.
Secondly and despite all the problems with the vaccine delivery, the proportion of infected
children and carriers seems to be decreasing, which demonstrates that the Cuban
manufactured hepatitis B vaccine is as effective as other recombinant hepatitis B vaccine
produced in other settings. This is important because the price offered by the Cuban
government is lower than that offered by other manufacturers. However the effectiveness of
the program could be improved if children get vaccinated with one dose soon after birth (first
15 days) and with the second dose one month after the first, especially in rural areas where
the risk is the highest.
Following recommendations from this work the Amazon department have designed a re-
training of the rural health workers which has been carried out during this year. They have
implemented serological surveillance of pregnant mothers, in order to increase the chance
that those children with the highest risk can get the vaccine soon after birth. Mothers who are
positive for Anti-HBc or HBsAg are advised that their children need hepatitis B vaccine as
soon as they can, so the interest of the parents may ensure a higher compliance with the
vaccination schedule. This surveillance did not have an important impact on the cost of the
program since less than 1000 births occur yearly in the Amazon.
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Annex 1. Univariable analysis of vaccination coverage and related factors
Table 1.1. Vaccination coverage with complete/incomplete/ missing data.
Age group Number with Number fully Number Estimates of fully
Vaccination vaccinated (% ) without vaccinated among
card (%) [95%CI] vaccination children with missing
card (%) data (worst-best %) *
I Y 158 (57) 65 (41) [31-49] 120 (43) 22-45
2/3 y 351 (52) 235 (67) [60-72] 324 (48) 49-69
4/5 Y 354 (55) 269 (76) [70-80] 289 (45) 60-78
6n y 315 (49) 236 (75) [70-80] 327 (51) 62-77
811I y 351 (43) 249 (71) [65-76] 465 (57) 50-73
Total 1529(51) 1054 (69) [64-72] 1525 (49) 50-71
The best coverage was calculated as the mid-point between the point estimate and
its upper confidence limit in the third column of the table above. The worst is
taken from the lowest limit of the coverage by age group and town. The value of
this interval is multiplied by the number of children without a vaccination card in
each age group and town in order to calculate the expected number vaccinated by
age group. This number is summed across strata and the total is divided by the
total number of children without a vaccination card in each category (fourth
column in table above) in order to estimate the overall coverage under the worst
scenario.
Example: Consider the value for children I year old without a vaccination card in
the table above with a coverage between 22 and 45%. The highest coverage
comes from the mid-point between 41%, the point estimate, and 49%, the upper
confidence limit (third column and first row),
To calculate the lowest scenario for these I year olds the lowest interval in the
first row of the table below (40%, 8%, 1%, 6%, 4%) was used. These percentages
were multiplied by the number of children without a vaccination card in that age
group and town (53 in urban Leticia, 34 in rural Leticia, II in urban P. Narifio, 13
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in rural P. Narifio, and 9 in Araracuara). This yielded an expected number of 27
children vaccinated among those without a vaccination card, given that the total
number of children in this age group was 120 it results in a worst coverage of 22%
(27/120).
Fully vaccination coverage by age group and town
Age Urban Leticia Rural Leticia Urban P. Rural P. Araracuara and
group % (95%CI) % (95% Cl) Nariiio Nariiio P. SIder
% (95% Cl) % (95% Cl) % (95%CI)
Iy 52 (40-64) 23 (8-50) 11 (1-53) 24 (6-60) 40 (4-91)
2/3 Y 70 (61-79) 66 (53-77) 38 (22-57) 64 (41-81) 60 (14-94)
4/5 Y 76 (68-83) 78 (67-86) 54 (35-72) 76 (52-90) 72 (63-79)
617 y 76 (66-83) 79 (70-86) 44 (31-57) 82 (65-92) 77 (55-90)
8/11 y 74 (67-80) 74 (57-86) 39 (18-65) 68 (46-84) 48 (23-73)
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Table 1.2. Distribution of people included in the census and vaccination coverage by
variables related with children.
Variables Number Number OR (CI95%) Number with OR (CI95%)
surveyed fully Fully vaccinated complete Hepatitis B
(%) vaccinated hepatitis B vaccination
i%2 vaccine (%2
Age P<O.OOOI P=O.OOOI
1 year 279 65 (41) 1.0 167 (79) 1.0
2/3 years 678 235 (67) 0.34 (0.2-0.5) 468 (91) 0.37 (0.24-0.57)
4/5 years 638 269 (76) 0.22 (0.1-0.3) 374 (93) 0.26 (0.14-0.48)
6/7 years 640 236 (75) 0.22 (0.1-0.3) 316 (88) 0.48 (0.26-0.87)
8/11 years 811 249 (71) 0.28 (0.2-0.4) 379 (88) 0.47 (0.27-0.80)
Sex P=0.62 P=0.66
Male 1608 554 (69) 0.95 (0.8-1.2) 896 (89) 1.0
Female 1437 500 (68) 1.0 808 (88) 1.01 (0.77-1.3)
Area P=O.02 P=O.05
Urban Leticia 1485 514 (71) 1.0 745 (89) 1.0
Rural Leticia 677 282 (69) 1.1 (0.7-1.8) 480(90) 0.98 (0.47-2.04)
Puerto Narifio 310 47 (39) 3.8 (2.4-6.1) 99 (73) 3.13 (2.06-4.75)
Rural Puerto Narifio 316 131 (68) 1.15 (0.5-2.7) 202 (84) 1.41 (0.67-2.98)
Araracuara 260 80 (64) 1.36 (0.8-2.4) 178 (96) 0.37 (0.15-0.92)
Time living in
town* P=0.84 P=0.40
All of life 2455 895 (69) 1.0 1414 (88) 1.0
Not all of life 558 171 (68) 1.03 (0.72-1.5) 292 (90) 1.18 (0.62-2.26)
Ethnic group P=O.009 P=O.025
Not Indians 1439 408(66) 1.0 616 (87) 1.0
Mestizos 341 150 (74) 0.7 (0.4-1.1) 246 (92) 0.59 (0.33-1.05)
Ticunas 781 290 (64) 1.1 (0.65-1.8) 484 (86) 0.54 (0.21-1.39)
Huitotos 150 43 (60) 1.3 (0.7-2.2) 89 (92) 1.11 (0.59-2.1)
Other groups 337 163 (83) 0.4 (0.2-0.6) 269 (95) 0.32 (0.17-0.59)
Birth order P=O.04 P=0.16
I 538 205 (74) 1.0 335 (91) 1.0
2/3 933 350 (70) 1.2 (0.8-1.8) 553 (88) 1.61 (1.0-2.61)
4/5 522 209 (65) 1.5 ( 1.0-2.2) 342 (88) 1.87 (1.12-3. 10)
6/20 312 133 (76) 0.9 (0.6-1.4) 220 (92) 1.10(0.56-2.17)
Number of
siblings P=O.16 P=0.22
I 85 27 (61) 1.0 72 (94) 1.0
2/3 930 357 (72) 0.6 (0.3-1.2) 562 (89) 1.85 (0.57-5.98)
4/5 746 283 (67) 0.8 (0.4-1.6) 442 (87) 2.36 (0.78-7.13)
6/20 525 221 (74) 0.55 (0.2-1.2) 360 (91) 1.53 (0.52-4.51 )
Born in Hospital P=O.41 P=0.82
Yes 1146 460 (74) 1.0 710 (91) 1.0
No 885 384 (71) 1.2 (0.8-1.8) 638 (90) 1.07 (0 ..54- 2.12)
Health security P=O.OO8 P=0.30
Affiliated 1638 602 (72) 1.0 1020 (90) 1.0
Not affiliated 393 109 (58) 1.8 (1.2-2.2) 216(86) 1.67 (0.71-3.97)
+ Time that the person has been living in the same place where he (she) was interviewed.
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Table 1.3. Distribution of people included in the census and vaccination coverage by
variables related to parental characteristics.
Variable Number Number fully OR (CI95%) Number OR (CI95%)
surveyed vaccinated Fully with Hepatitis B
(%) (%) vaccinated complete vaccine
hepatitis B
vaccine (%)
Living with rather P=0.69 P=0.38
Yes 1913 (58) 773 (70) 1.0 1240 (89) 1.0
No 329 (10) 120 (73) 0.9 (0.5-1.5) 201 (92) 0.73 (0.36-1.47)
Mothers age at child's birth P=0.42 P=0.51
13-19 Y 469 165 (71) 1.0 306 (90) 1.0
20-29 Y 1233 499 (71) 1.0 (0.7-1.4) 821 (89) 1.09 (0.65-1.81)
30/45 Y 546 215 (68) 1.21 (0.8-1.8) 363 (88) 1.33 (0.78-2.29)
Mother's age at survey P=O.04 P=O.43
16/20 105 32 (55) 1.0 86 (91) 1.0
21/25 468 200 (75) 0.4 (0.2-0.8) 313 (89) 1.19 (0.54-2.61 )
26/30 621 246 (73) 0.45 (0.2-0.9) 388 (91) 0.96 (0.37-2.44)
31/35 493 191 (66) 0.6 (0.3-1.27) 323 (86) 1.52 (0.59-3.92)
36/57 542 219 (73) 0.4 <0.2-0.8) 339 (91) 1.0 (0.43-2.37)
Father's age at survey P= 0.18 P =0.65
16-25 Y 171 57 (60) 1.0 115 (87) 1.0
26-30 Y 348 135 (71) 0.59 (0.33-1.03) 228 (89) 0.83 (0.45-1.51)
31-35 Y 389 164 (72) 0.56 (0.3-1.05) 243 (89) D.SO(0.37-1.73)
36-57 Y 884 361 (72) 0.56 (0.3-0.92) 568 (90) 0.71 (0.42-1.17)
58-76 Y 50 17 (61) 0.92 (0.3-2.7) 30 (81) 1.54 (0.50-4.76)
Mothers education level
(number of years in school) P=0.22 P=0.69
0/4 768 298 (70) I.D 534 (9D) 1.0
5 518 222 (73) D.8 (0.6-1.3) 356 (90) 1.0 (D.62-1.62)
6/8 281 102 (75) 0.8 (0.4-1.3) 184(94) 0.60 (0.28-1.25)
9110 114 51 (81) 0.5 (0.2-1.4) 68 (92) 0.82 (0.26-2.63)
11117 320 135(74) 0.8 (0.5-1.4) 204 (90) 1.0 (0.51-2.10)
Fathers education level (number
of years in school) P=0.34 P=0.31
0/4 1049 416 (68) 1.0 685 (88) 1.0
5 65 18 (62) 1.3 (0.6-2.8) 35 (82) 1.58 (0.61-4.09)
6/8 345 140 (75) 0.7 (0.4-1.1) 220 (91) 0.67 (0.37-1.22)
9110 364 157 (73) 0.8 (0.5-1.2) 234 (91) 0.73 (0.40-1.33)
11117 49 21 (76 0.7 (0.3-1.5) 31 (94) D.49 (0.11-2.12)
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Table 1.4 Distribution of people included in the census and vaccination coverage by
variables related to socio-economic characteristics.
Variables Number of Number OR (CI95%) Number OR (CI95%)
surveyed fully Fully with Hepatitis B
(%) vaccinated vaccinated complete vaccine
(%) hepatitis B
vaccine
(%)
Roof made with: P=O.OO3 P=O.Ol
Tile 2574 899 (70) 1.0 1488 (89) 1.0
Palm tree leaf 383 67 (52) 2.0 (1.4-2.96) 183 (82) 1.91 (1.14-3.18)
Unknown
Floor made with: P=O.07 P=0.58
Cement 1050 389 (72) 1.0 551 (90) 1.0
Wood 1829 622 (64) 1.4 (1.0-2.0) 1085(88) 1.20 (0.80-1.81)
Soil 99 32 (74) 0.9 (0.4-1.9) 51 (89) 1.02 (0.40-2.58)
Unknown 27& (8)
Walls made with: P=0.19 P=0.54
Bricks 657 228 (72) 1.0 341 (90) 1.0
Wood 2271 791 (65) 1.3 (0.9-1.8) 1316 (88) 1.16 (0.71-1.91)
Crowding: # of people P=O.ll P=0.78
by room
1/3 1416 495(71 ) 1.0 736 (89) 1.0
4/6 896 305(63) 1.4 ( 1.05-1.9) 540 (88) 1.03 (0.68-1.56)
7/9 339 134 (68) 1.1 (0.7-1.8) 223 (89) 0.95 (0.62-1.45)
lOllS 242 74 (67) 1.2 (0.8-1.8) 141 (91) 0.76 (0.35-1.60)
Freezer in house P=O.OO13 P=O.09
Yes 684 266 (77) 1.0 424 (0.92) 1.0
No 1515 513 (65) 1.&(1.2-2.6) 913 (88%) 1.55 (0.92-2.62)
Unknown
TV in house P=O.06 P=0.36
Yes 1018 360 (73) 1.0 586(91) 1.0
No 1195 421 (65) 1.45(0.97-2.15) 756 (88) 1.27 (0.75-2.17)
Unknown
Radio at home P=O.05 P=0.22
Yes 1044 374 (73) 1.0 628(81) 1.0
No 1169 407 (66) 1.39 (1.0-1.96) 714 (88) 1.34 (0.83-2.15)
Unknown
Outboard Motor P=O.II P=O.06
Yes 214 73 (76) 1.0 132 (94) 1.0
No 1999 704 (69) 1.48 (0.9-2.4) 1210 (89) 1.78 (0.97-3.27)
Unknown
Piped water P=0.98 P=0.65
Yes 1468 487 (68) 1.0 742 (88) 1.0
No 1481 536 (68) 1.0 929 (89) 0.90 (0.57-1.42)
Excretal disposal P=O.89 P=0.73
Toilet 1104 419 (67) 1.0 705 (89) 1.0
Pit 1074 331 (68) 0.96 (0.65-1.4) 500 (&8) 1.14 (0.70-1.90)
None 837 (26) 246 (66) 1.1 (0.7-1.5) 429 (87) 1.20 (0.77-1.88)
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Table 1.5 Relationship between ecological variables and individual vaccination
status against all vaccines. Health worker perceptions.
Variable OR (CI95%)Total Complete
number schedule
N N(%)
OR (CI95%) Hepatitis B
Incomplete vaccination Incomplete HB
sche~.!Il.!:_..__._ _ ~_L!c.L_..__.__..va~_c:ina!!.on._
Are there children in your
community that do not come
to the health center for
vaccination?
Yes
No
Are there children in your
community who have right
to be vaccinated by another
health provider?
Yes
No
Do you believe that in your
community there are
parents who do not agree
with vaccination?
Yes
No
Why do you believe that
hepatitis B is an important
disease in your area?
Infectiousness
Severity
What do you believe is an
important reason for
children not being
vaccinated in your area?
Parent education! Parent fear
of vaccine side effects
Logistic reasons/ Poverty
Do you believe that there is
not enough time in the
health center for
vaccination activities?
Yes
No
Do you believe that in your
community parents do not
spare enough time to take
children to health center?
Yes
No
1421
136
778
692
1230
112
1226
275
1112
158
1145
412
1458
99
P=O.002
892 (64)
104 (77)
P=0.18
515 (66)
411 (60)
P=0.19
768 (64)
78 (71)
P=O.OOI
756 (63)
207 (77)
P=O.007
747 (63)
120 (76)
P=O.02
701 (63)
295 (72)
P=O.OO8
952 (66)
44 (47)
1.90.3-2.9)
1.0
0.8 (O.S-I.I)
1.0
1.4 (0.8-2.3)
1.0
1.9 (1.3-2.8)
1.0
1.8 (1.2-2.8)
1.0
1.5 (1.1-2.2)
1.0
0.46 (0.3--0.8)
1.0
P=O.OOO
14S I (88)
179 (96)
P=0.17
747 (89)
763 (85)
P=0.88
1210 (87)
123 (88)
P=O.0003
1190 (87)
366 (95)
P=O.OOO
1162 (86)
210 (96)
P=O.03
1128 (87)
502(93)
P=O.ooo
1549 (89)
81 (71)
3.2 (2.4-4.2)
1.0
0.7 (0.4-1.2)
1.0
1.1(0.4-3.4)
1.0
3.2 (1.7-6.0)
1.0
4.1 (3.1-5.3)
1.0
1.9(1.04-3.4)
1.0
0.3 (0.16-0.48)
1.0
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Annex 2. Questionnaire for vaccination coverage for field work.
COLOMBIAN MINISTRY OF HEALTH
NATIONAL INSTITUTE OF HEALTH
AMAZON SECETARY OF HEALTH
Household Census. ( This form will be used for a census in all the households
selected in the random cluster sampling. It will provide a reference for the
main demographic characteristics of the children under study)
I) Interview Date: mm_1 dd_ I yy_
village: _
2)Town or
3) Interviewer name: _
House# _
4) Cluster # _ 5)
People who answer the questionnaire: Children's mother _Children's father _
Other_
Household characteristics:
5) How many people live in this household?: __
rooms:
6) Number of sleeping
7) Roofs made with: 8) Walls made with: _
10) Floor made with: _
Y_N_
II) Is there a water tap in the house?:
If not, how do you manage to obtain drink water?: Rain_ River_ Well_
12) Is there a toilet at home?: Y_ N_ 13) If not is there any other form of
excretal disposal? Y_N_
If yes, Please describe:
13) Are you or your children affiliated to the social security system? Y_N __
14) You or your husband owned a: Motorcycle_ Refrigerator __ TV__
Radio __
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The following form will only be filled for children less than 10 years. If you do not
find a vaccination card at home for a child, please ask the mother if it may be at the
school. If yes, please ask the school's name and child's grade. These data can be
written beside the name of the child on the external area of the table. After finishing
the interview at this household, please go to the school and ask there if the
vaccination card can be searched by the school's head-teacher.
1 2 3 4 5 6 7 8 9
Child number
Birth date
Time living in
town (years)
Relation with the
family head
Vaccination card
YIN
Does the child
have the
vaccination card
in the school? YIN
Hep B Number of
doses
151 dose date
2nd. dose date
3rd dose date
DPT Number of
doses
151 dose date
2nddose date
3rd dose date
Booster date
Measles Number
of doses
151 dose date
Booster date
Yellow fever.
First dose date
BCG first dose
date
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Annex 3. Questionnaire for risk factors
1) Child ID: 2) Cluster # _
3) Town or village: 4) Area: Urban
Rural
5)1nterviewer Name: 6)Code: _
7) Date of interview: mm_/ dd_ /yy_
8) Name of the child: 9) Sex: M_ F_
10) Date of birth: mm/dd/yy
11)Age: Years __ Months __ (record age just if date of birth IS
unknown)
12) Birth order: __ ( please ask the number of siblings older than the
child under interview. Ask even about those deceased)
13) What was the age of the mother when the child was born Years
14) Place of birth of the child: 15)Area:
Rural/Urban
16) Born in: Hospital_ Local Health Centre _ At home __
17) Birth attended by: Doctor_ Nurse_ Relative __ Other _
Specify None_
18) How long has the children been living here?: Years Months __
(please specify the number of years and months)
General information:
19) Was the child breastfed?: Y_N_
number of months)
20) For how long?: ( put the
21) Has the child had hepatitis?: Y_N_ 22) If yes, what age ?: _
23) Was he/she taken to the doctor?: Y_N_ 24) If yes, where?:
Local health centre _
Hospital_
Private _
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Mother's information:
25) Mother's Name: _
birth: _
26) Date of
27) Age:__ ( put age just if date of birth is unknown)
28) Place ofbirth: _
29) Town of birth: _
30) Time living in town where they are living now: Years__ Months __
31) Have you ever been told about having hepatitis? Y _N_
32) If yes, when? _
33) What was the last level that you reached in school?:
Primary _ Number of years _
Secondary _ Number of years_
University _ Number of years_
34) How old is the father? _
35) What was the last level that the father reached in school?
Primary _ Number of years
Secondary _ Number of years_
University _ Number of years_
36) Are you or your husband from an aboriginal family? Y _N_
If yes, could you please tell me the name of your aboriginal family?
37) Has anybody in the household had hepatitis before? Y_ N_
If yes, how many people in the household have had hepatitis before?: __
Name of the first person having hepatitis Date of
starting symptoms: Relationship with the child
DiedY_N_
Name of the second person with hepatitis, Date of
starting of symptoms Relationship with the
children Died Y_N_
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Have anybody in the household had before any of the following diseases?:
38) Cirrhosis Y_N_ If yes, how many people have had
this? How many died from this disease? __
Name Relationship with the children
__________ Died Y_ N_
Relationship
_________ Died Y_N_
Name with the children
39) Fulminant Hepatitis: Y_N_ If yes, how many
this? How many died from this disease? __
Name Relationship with
_________ Died YIN
people have had
the children
Relationship
_________ Died YIN
Name _ with the children
40) Hepatocarcinoma: Y_N_ If yes, how many people have had this?
________ How many died from this disease? __
Name Relationship with the children
________ Died Y_N _
________________ Relationship
________ Died Y_N_
Name with the children
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Annex 4. Questionnaire for health workers (To be answered by the people in
charge of the EPI programme if it is run in the health centre)
I) Name of the health centre?: _
2) Town or village: 3) Area: Rural
(Rural areas are those where population is under 5000)
Urban
4) How long have you been in this health centre? _
5) Name of the interviewer _
6) Profession:
nurse _
MD Nurse__ Health promoter Auxiliary
7) Date of the interview: mm_1 dd_ I yy _
8) Does the centre provide EP! vaccination? Y _ N _ (If not please interrupt the
interview and thanks to the director for his time)
If not, 9) Has it ever provided EPI vaccines? Y _ N_ If yes, 10) Why was it
stopped?
If answer to question number 6 was yes, please continue to the following
questions.
II) How does the health centre provide vaccination?: Just inside _
Using outreach teams __
12) Size of population covered by the health centre: _
13) Number of daily external medical consults in the last month: __
14) Does the centre have medical service every day? YIN
15) If yes, does the centre provide medical attention 24 hours a day? Y_N_
16) If not, How frequent is the medical service in the centre by week? (Please
record the week days when medical service is provided in the centre) Monday _
Tuesday_ Wednesday_ Thursday_ Friday _ Saturday_
18) How many health workers does the centre have under contract?_
19) How many doctors work in the centre? _
20) How many nurses? _
21) How many technicians? _
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22) Which vaccines are available in this moment at the centre?
Measles # of doses
Polio_ # of doses
DPT_ # of doses
HepB_
BCG_
# of doses
# of doses
23) Where are the vaccines stored? _
24) Do you have a record of temperature? Y_N_
25) If yes, may I see the temperature records in the last week?: 1 day __ 2 day
_ 3 day__ 4 day __ 5 day __ 6 day __ 7 day __
26) What days does the centre provide EPI vaccination inside? Monday_
Tuesday_ Wednesday_ Thursday_ Friday_ Saturday_
27) What days does the centre provide EPI vaccination outreach? Monday_
Tuesday_ Wednesday_ Thursday_ Friday_ Saturday_ (please tick each day
given by the interviewed)
28) What time in a day does the centre provide EPI vaccination? All day_ in the
morning __ in the afternoon_
29) In the last month, have you rejected any children coming here for vaccination
because there were no supplies of the vaccine? Y_N_
30) If yes, could you remember how many times it happened? _
31) How many workers are in charge of EPI vaccination? __
32) How long have you been working in your profession? _
33) How long have you been working in this health centre? _
34) Do you know what the diseases preventable by vaccination are? Y_N_
35) If yes, could you please tell me their names?
36) By what age should a child be completely vaccinated? _
37) Have you ever heard about hepatitis B vaccine? Y_N_
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38) If yes, how many doses are needed to immunise completely a person? __
39) Do you know in what part of the body should be the hepatitis B vaccine
administered? Y_ N
40) Do you think that there is any contraindication for administration of hepatitis
Bvaccine? Y_N_
41 ) If yes, could
contraindications?: _
you please tell me what are these
42) Do you know how hepatitis B vaccme should be stored?: YIN
43) What are the most important diseases in your area?
44) Is hepatitis B an important disease in your area? YIN
45) If yes, why? _
46) If not, why? _
47) A two year old child comes for vaccination today (1999) and his hepatitis B
vaccination history is:
la. Dose: 01/01/97 2a. Dose: 01/02/97. What would you do now?
- Start the schedule again _
- Apply the third dose_
48) Are health education materials about immunisation against hep B clearly
displayed in the clinic?
Yes_NO__
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49) What materials about immunization are present in the clinic that you can see?
Pamphlets _
Posters. _
Audiovisual material. _
Others ___
50) This table shows same conditions that children may have, as well as the
commonly administered vaccines. Please indicate whether a child with anyone of
these conditions may receive each vaccine. Please mark" + "if yes or "-" if not
Conditions DPT OPV HPB
Fever <101 'F
Fever >101 'F
Prematuri!y
Febrile convulsions
Non-febrile
convulsions
Relative with
convulsion
Prior vaccine
reaction
Cough
Leukaemia
AIDS
Diarrhoea
51) What are the 3 most important childhood diseases In this area?
I. 2. 3. _
Was hepatitis B mentioned above? Y_ N_
52) Are there children in this community who do not have access to the
vaccination services in this clinic? Y_ N_
53) If not, Why do you think those children do not have access to
vaccination? _
54) Why do you think those children don't have access to vaccination?
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55) Do you keep immunisation records from children vaccinated in the area?
y--
N
56) Dou you charge any fee for vaccination service? Yes __ No__
If yes; how much do you charge for vaccination services?
57) What do you think are some of the difficulties or problems In getting
children immunised?
Inadequate supplies _
Insufficient instruction on vaccine administration_
Not enough time in clinic session_
Not enough staff working at clinic _
Need for doctor's order delays immunization_
Other Specify _
58) Do you have written guidelines on hepatitis B vaccine issues? Yes
_No __
59) If yes, may I see them? _
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